Bicyclic azaheterocyclobenzylamines as pi3k inhibitors

ABSTRACT

wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.

This application is a divisional of U.S. application Ser. No. 13/854,789, filed Apr. 1, 2013, which claims the benefit of priority of U.S. Provisional Application No. 61/619,210, filed Apr. 2, 2012, and U.S. Provisional Application No. 61/776,608, filed Mar. 11, 2013, the disclosures of each of which are incorporated herein by reference in their entireties.

FIELD OF THE INVENTION

The present invention provides bicyclic azaheterocyclobenzylamine derivatives, for example, pyrazolopyrimidines, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.

BACKGROUND OF THE INVENTION

The phosphoinositide 3-kinases (PI3Ks) belong to a large family of lipid signaling kinases that phosphorylate phosphoinositides at the D3 position of the inositol ring (Cantley, Science, 2002, 296(5573):1655-7). PI3Ks are divided into three classes (class I, II, and III) according to their structure, regulation and substrate specificity. Class I PI3Ks, which include PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ, are a family of dual specificity lipid and protein kinases that catalyze the phosphorylation of phosphatidylinosito-4,5-bisphosphate (PIP₂) giving rise to phosphatidylinosito-3,4,5-trisphosphate (PIP₃). PIP₃ functions as a second messenger that controls a number of cellular processes, including growth, survival, adhesion and migration. All four class I PI3K isoforms exist as heterodimers composed of a catalytic subunit (p110) and a tightly associated regulatory subunit that controls their expression, activation, and subcellular localization. PI3Kα, PI3Kβ, and PI3Kδ associate with a regulatory subunit known as p85 and are activated by growth factors and cytokines through a tyrosine kinase-dependent mechanism (Jimenez, et al., J Biol Chem., 2002, 277(44):41556-62) whereas PI3Kγ associates with two regulatory subunits (p101 and p84) and its activation is driven by the activation of G-protein-coupled receptors (Brock, et al., J Cell Biol., 2003, 160(1):89-99). PI3Kα and PI3Kβ are ubiquitously expressed. In contrast, PI3Kγ and PI3Kδ are predominantly expressed in leukocytes (Vanhaesebroeck, et al., Trends Biochem Sci., 2005, 30(4):194-204).

The differential tissue distribution of the PI3K isoforms factors in their distinct biological functions. Genetic ablation of either PI3Kα or PI3Kβ results in embryonic lethality, indicating that PI3Kα and PI3Kβ have essential and non-redundant functions, at least during development (Vanhaesebroeck, et al., 2005). In contrast, mice which lack PI3Kγ and PI3Kδ are viable, fertile and have a normal life span although they show an altered immune system. PI3Kγ deficiency leads to impaired recruitment of macrophages and neutrophils to sites of inflammation as well as impaired T cell activation (Sasaki, et al., Science, 2000, 287(5455):1040-6). PI3Kδ-mutant mice have specific defects in B cell signaling that lead to impaired B cell development and reduced antibody responses after antigen stimulation (Clayton, et al., J Exp Med. 2002, 196(6):753-63; Jou, et al., Mol Cell Biol. 2002, 22(24):8580-91; Okkenhaug, et al., Science, 2002, 297(5583): 1031-4).

The phenotypes of the PI3Kγ and PI3Kδ-mutant mice suggest that these enzymes may play a role in inflammation and other immune-based diseases and this is borne out in preclinical models. PI3Kγ-mutant mice are largely protected from disease in mouse models of rheumatoid arthritis (RA) and asthma (Camps, et al., Nat Med. 2005, 11(9):936-43; Thomas, et al., Eur J Immunol. 2005, 35(4):1283-91). In addition, treatment of wild-type mice with a selective inhibitor of PI3Kγ was shown to reduce glomerulonephritis and prolong survival in the MRL-lpr model of systemic lupus nephritis (SLE) and to suppress joint inflammation and damage in models of RA (Barber, et al., Nat Med. 2005, 11(9):933-5; Camps, et al., 2005). Similarly, both PI3Kδ-mutant mice and wild-type mice treated with a selective inhibitor of PI3Kδ have been shown to have attenuated allergic airway inflammation and hyper-responsiveness in a mouse model of asthma (Ali, et al., Nature. 2004, 431(7011):1007-11; Lee, et al., FASEB J. 2006, 20(3):455-65) and to have attenuated disease in a model of RA (Randis, et al., Eur. J. Immunol., 2008, 38(5):1215-24).

B cell proliferation has shown to play a major role in the development of inflammatory autoimmune diseases (Puri, Frontiers in Immunology (2012), 3(256), 1-16; Walsh, Kidney International (2007) 72, 676-682). For example, B cells support T-cell autoreactivity, an important component of inflammatory autoimmune diseases. Once activated and matured, B cells can traffic to sites of inflammation and recruit inflammatory cells or differentiate to plasmablasts. Thus, activity of B-cells can be affected by targeting B-cell stimulatory cytokines, B-cell surface receptors, or via B-cell depletion. Rituximaban—IgG1 κ mouse/human chimeric monoclonal antibody directed against the B-cell surface receptor CD20—has been shown to deplete CD20+ B cells. Use of rituximab has been shown to have efficacy in treating idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, or vasculitis. For example, treatment with rituximab resulted in remission of the disease in patients suffering from anti-neutrophil cytoplasm antibody associated (ANCA) systemic vasculitis (AASV) with demonstrated peripheral B-cell depletion (Walsh, 2007; Lovric, Nephrol Dial Transplant (2009) 24: 179-185). Similarly, a complete response was reported in one-third to two-thirds of patients having mixed cryoglobulinemia vasculitis after treatment with rituximab, including patients who presented with a severe form of vasculitis that was resistant or intolerant to other treatments (Cacoub, Ann Rheum Dis 2008; 67:283-287). Similarly, rituximab has been shown to have efficacy in treating patients with idiopathic thrombocytopenic purpura (or immune thrombocytopenic purpura) (Garvey, British Journal of Haematology, (2008) 141, 149-169; Godeau, Blood (2008), 112(4), 999-1004; Medeo, European Journal of Haematology, (2008) 81, 165-169) and autoimmune hemolytic anemia (Garvey, British Journal of Haematology, (2008) 141, 149-169).

PI3Kδ signaling has been tied to B cell survival, migration, and activation (Puri, Frontiers in Immunology, 2012, 3(256), 1-16, at pages 1-5; and Clayton, J Exp Med, 2002, 196(6):753-63). For example, PI3Kδ is required for antigen-dependent B-cell activation driven by B cell receptor. By blocking B-cell adhesion, survival, activation, and proliferation, PI3Kδ inhibition can impair the ability of B cells to activate T cells, preventing their activation and reducing secreation of autoantibodies and pro-inflammatory cytokines. Hence, by their ability to inhibit B cell activation, PI3Kδ inhibitors would be expected to treat B cell mediated diseases that were treatable by similar methods such as B cell depletion by rituximab. Indeed, PI3Kδ inhibitors have been shown to be useful mouse models of various autoimmune diseases that are also treatable by rituximab such as arthritis (Puri (2012)). Further, innate-like B cells, which are linked to autoimmunity are sensitive to PI3Kδ activity, as MZ and B-1 cells are nearly absent in mice lacking the p110δ gene (Puri (2012). PI3Kδ inhibitors can reduce trafficking of and activation of MZ and B-1 cells, which are implicated in autoimmune diseases.

In addition to their potential role in inflammatory diseases, all four class I PI3K isoforms may play a role in cancer. The gene encoding p110a is mutated frequently in common cancers, including breast, prostate, colon and endometrial (Samuels, et al., Science, 2004, 304(5670):554; Samuels, et al., Curr Opin Oncol. 2006, 18(1):77-82). Eighty percent of these mutations are represented by one of three amino acid substitutions in the helical or kinase domains of the enzyme and lead to a significant upregulation of kinase activity resulting in oncogenic transformation in cell culture and in animal models (Kang, et al., Proc Natl Acad Sci USA, 2005, 102(3):802-7; Bader, et al., Proc Natl Acad Sci USA. 2006, 103(5):1475-9). No such mutations have been identified in the other PI3K isoforms although there is evidence that they can contribute to the development and progression of malignancies. Consistent overexpression of PI3Kδ is observed in acute myeloblastic leukemia (Sujobert, et al., Blood, 2005, 106(3):1063-6) and inhibitors of PI3Kδ can prevent the growth of leukemic cells (Billottet, et al., Oncogene, 2006, 25(50):6648-59). Elevated expression of PI3Kγ is seen in chronic myeloid leukemia (Hickey, et al., J Biol Chem. 2006, 281(5):2441-50). Alterations in expression of PI3Kβ, PI3Kγ and P1310 have also been observed in cancers of the brain, colon and bladder (Benistant, et al., Oncogene, 2000, 19(44):5083-90; Mizoguchi, et al., Brain Pathol. 2004, 14(4):372-7; Knobbe, et al., Neuropathol Appl Neurobiol. 2005, 31(5):486-90). Further, these isoforms have all been shown to be oncogenic in cell culture (Kang, et al., 2006).

Thus, new or improved agents which inhibit kinases such as PI3K are continually needed for developing new and more effective pharmaceuticals that are aimed at augmentation or suppression of the immune and inflammatory pathways (such as immunosuppressive agents for organ transplants), as well as agents for the prevention and treatment of autoimmune diseases (e.g., multiple sclerosis, rheumatoid arthritis, asthma, type I diabetes, inflammatory bowel disease, Crohn's disease, autoimmune thyroid disorders, Alzheimer's disease, nephritis), diseases involving a hyperactive inflammatory response (e.g., eczema), allergies, lung diseases, cancer (e.g., prostate, breast, leukemia, multiple myeloma), and some immune reactions (e.g., skin rash or contact dermatitis or diarrhea) caused by other therapeutics. The compounds, compositions, and methods described herein are directed toward these needs and others.

SUMMARY

The present invention provides, inter alia, a compound of Formula I:

or a pharmaceutically acceptable salt thereof, wherein the variables are defined infra.

The present invention further provides compositions comprising a compound of the invention, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

The present invention also provides methods of modulating an activity of a PI3K kinase, comprising contacting the kinase with a compound of the invention, or a pharmaceutically acceptable salt thereof.

The present invention further provides methods of treating a disease in a patient, wherein said disease is associated with abnormal expression or activity of a PI3K kinase, comprising administering to said patient a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof.

The present invention further provides methods of treating an immune-based disease in a patient, comprising administering to said patient a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof.

The present invention also provides methods of treating a cancer in a patient, comprising administering to said patient a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof.

The present invention further provides methods of treating a lung disease in a patient, comprising administering to said patient a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof.

The present invention also provides a compound of the invention, or a pharmaceutically acceptable salt thereof, for use in any of the methods described herein.

The present invention further provides use of a compound, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for use in any of the methods described herein.

DETAILED DESCRIPTION

The present invention provides, inter alia, a compound of Formula I:

or a pharmaceutically acceptable salt thereof, wherein:

V is C(═O), S(═O)₂, CH₂, CHR^(3c), and CR^(3c)R^(3c);

T is C(═O), S(═O)₂, CH₂, CHR^(3a), and CR^(3a)R^(3a);

Q is C(═O), S(═O)₂, (CH₂)_(n), (CHR^(3a))_(n), and (CR^(3a)R^(3a))_(n); wherein n is 0, 1, or 2;

U is O or NR^(3d);

provided that when T is C(═O) or S(═O)₂, then Q is (CH₂)_(n), (CHR^(3a))_(n), or (CR^(3a)R^(3a))_(n);

further provided that when Q is C(═O) or S(═O)₂, then T is CH₂, CHR^(3a), or CR^(3a)R^(3a), and U is NR^(3d);

R^(A) is H or C₁₋₃ alkyl;

Ar is

X¹ is CH or N;

Y¹ is CH or N;

or alternatively, R^(A) and Ar, together with the N to which they are attached, combine to form a moiety of formula:

X is CR⁹ or N;

W is CR⁷ or N;

Y is CR⁸, CR^(8a), or N;

Z is a bond or C(═O);

provided that —W═Y—Z— is —CR⁷═CR⁸—, —N═CR⁸—, —CR⁷═CR^(8a)—C(═O)—, —N═CR^(8a)—C(═O)—, or —CR⁷═N—C(═O)—;

R¹ is C₁₋₃ alkyl;

each R^(3a) is independently selected from C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, and Cy¹; wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl are each optionally substituted with 1, 2, or 3 independently selected R¹¹ groups;

R^(3b) is H, Cy, —(C₁₋₃ alkylene)-Cy, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C(═O)R^(b), C(═O)NR^(c)R^(d), C(═O)OR^(a), C(═NR^(e))R^(b), C(═NR^(e))NR^(c)R^(d), S(═O)₂R^(b), or S(═O)₂NR^(c)R^(d); wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl are each optionally substituted by 1, 2, 3, or 4 independently selected R^(13b) groups;

each R^(3c) is independently selected from C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₁₋₄ alkoxy-C₁₋₄ alkyl, and C₁₋₄ haloalkoxy-C₁₋₄ alkyl;

R^(3d) is H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₁₋₄ alkoxy-C₁₋₄ alkyl, or C₁₋₄ haloalkoxy-C₁₋₄ alkyl;

R⁴ is H, halo, OH, CN, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₁₋₄ alkoxy, or C₁₋₄ haloalkoxy;

R⁵ is halo, OH, CN, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₁₋₄ alkoxy, C₁₋₄ haloalkoxy, or cyclopropyl;

R⁶ is H, halo, OH, CN, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₁₋₄ alkoxy, or C₁₋₄ haloalkoxy;

R⁷ is H or C₁₋₄ alkyl;

R⁸ is H, halo, —OH, —CN, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, Cy², —(C₁₋₃ alkylene)-Cy², OR^(a2), SR^(a2), C(═O)R^(b2), C(═O)NR^(c2)R^(d2), C(═O)OR^(a2), OC(═O)R^(b2), OC(═O)NR^(c2)R^(d2), NR^(c2)R^(d2), NR^(c2)C(═O)R^(b2), NR^(c2)C(═O)OR^(b2), NR^(c2)C(═O)NR^(c2)R^(d2), C(═NR^(e))R^(b2), C(═NR^(e))NR^(c2)R^(d2), NR^(c2)C(═NR^(e))NR^(c2)R^(d2), NR^(c2)S(═O)R^(b2), NR^(c2)S(═O)₂NR^(c2)R^(d2), S(═O)R^(b2), S(═O)₂R^(b2), or S(═O)₂NR^(c2)R^(d2); wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl are each optionally substituted by 1, 2, 3, or 4 independently selected R¹¹ groups;

R^(8a) is H, halo, —CN, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, Cy², —(C₁₋₃ alkylene)-Cy², C(═O)R^(b2), C(═O)NR^(c2)R^(d2), C(═O)OR^(a2), NR^(c2)R^(d2), NR^(c2)C(═O)R^(b2), NR^(c2)C(═O)OR^(b2), NR^(c2)C(═O)NR^(c2)R^(d2), NR^(c2)S(═O)R^(b2), NR^(c2)S(═O)₂NR^(c2)R^(d2), S(═O)R^(b2), S(═O)₂R^(b2), or S(═O)₂NR^(c2)R^(d2); wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl are each optionally substituted by 1, 2, 3, or 4 independently selected R¹¹ groups;

R⁹ is H, halo, OH, CN, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₁₋₄ alkoxy, or C₁₋₄ haloalkoxy;

R¹⁰ is H or C₁₋₄ alkyl;

each R¹¹ is independently selected from halo, OH, NO₂, CN, C₁₋₃ alkyl, C₂₋₃ alkenyl, C₂₋₃ alkynyl, C₁₋₃ haloalkyl, cyano-C₁₋₃ alkyl, HO—C₁₋₃ alkyl, C₁₋₃ alkoxy-C₁₋₃ alkyl, C₃₋₇ cycloalkyl, C₁₋₃ alkoxy, C₁₋₃ haloalkoxy, amino, C₁₋₃ alkylamino, di(C₁₋₃ alkyl)amino, thio, C₁₋₃ alkylthio, C₁₋₃ alkylsulfinyl, C₁₋₃ alkylsulfonyl, carbamyl, C₁₋₃ alkylcarbamyl, di(C₁₋₃ alkyl)carbamyl, carboxy, C₁₋₃ alkylcarbonyl, C₁₋₄ alkoxycarbonyl, C₁₋₃ alkylcarbonylamino, C₁₋₃ alkylsulfonylamino, aminosulfonyl, C₁₋₃ alkylaminosulfonyl, di(C₁₋₃ alkyl)aminosulfonyl, aminosulfonylamino, C₁₋₃ alkylaminosulfonylamino, di(C₁₋₃ alkyl)aminosulfonylamino, aminocarbonylamino, C₁₋₃ alkylaminocarbonylamino, and di(C₁₋₃ alkyl)aminocarbonylamino;

each R^(13b) is independently selected from Cy¹, —(C₁₋₃ alkylene)-Cy¹, halo, CN, NO₂, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, OR^(a1), SR^(a1), C(═O)R^(b1), C(═O)NR^(c1)R^(c1), C(═O)OR^(a1), OC(═O)R^(b1), OC(═O)NR^(c1)R^(d1), NR^(c1)R^(d1), NR^(c1)C(═O)R^(b1), NR^(c1)C(═O)OR^(b1), NR^(c1)C(═O)NR^(c1)R^(d1), C(═NR^(e))R^(b1), C(═NR^(e))NR^(c1)R^(d1), NR^(c1)C(═NR^(e))NR^(c1)R^(d1), NR^(c1)S(═O)R^(b1), NR^(c1)S(═O)₂NR^(c1)R^(d1), S(═O)R^(b1), S(═O)₂R^(b1), and S(═O)₂NR^(c1)R^(d1); wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl are each optionally substituted with 1, 2, or 3 independently selected R¹¹ groups;

each Cy is independently selected from C₃₋₇ cycloalkyl, 4-10 membered heterocycloalkyl, phenyl, naphthyl, and 5-10 membered heteroaryl, wherein said C₃₋₇ cycloalkyl, 4-10 membered heterocycloalkyl, phenyl, naphthyl, and 5-10 membered heteroaryl are optionally substituted with 1, 2, 3, or 4 independently selected R^(13b) groups;

each R^(a), R^(c), and R^(d) is independently selected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, and Cy; wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl are each optionally substituted with 1, 2, or 3 independently selected R^(13b) groups;

each R^(b) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, and Cy; wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl are each optionally substituted with 1, 2, or 3 independently selected R^(13b) groups; or

alternatively, R^(c) and R^(d) together with the N atom to which they are attached form a 4-, 5-, 6-, or 7 membered heterocycloalkyl group, which is optionally substituted with 1, 2, or 3 independently selected R^(13b) groups;

each R^(e) is independently selected from H, CN, OH, C₁₋₄ alkyl, and C₁₋₄ alkoxy;

each Cy¹ is independently selected from C₃₋₇ cycloalkyl, 4-7 membered heterocycloalkyl, phenyl, and 5-6 membered heteroaryl, wherein said C₃₋₇ cycloalkyl, 4-7 membered heterocycloalkyl, phenyl, and 5-6 membered heteroaryl are optionally substituted with 1, 2, 3, or 4 independently selected R¹¹ groups;

each R^(a1), R^(c1), and R^(d1) is independently selected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, 4-7 membered heterocycloalkyl, phenyl, and 5-6 membered heteroaryl; wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, 4-7 membered heterocycloalkyl, phenyl and 5-6 membered heteroaryl are each optionally substituted with 1, 2, or 3 independently selected R¹¹ groups;

each R^(b1) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, 4-7 membered heterocycloalkyl, phenyl, and 5-6 membered heteroaryl; wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, 4-7 membered heterocycloalkyl, phenyl and 5-6 membered heteroaryl are each optionally substituted with 1, 2, or 3 independently selected R¹¹ groups; or

alternatively, R^(c1) and R^(d1) together with the N atom to which they are attached form a 4-, 5-, 6-, or 7 membered heterocycloalkyl group, which is optionally substituted with —OH or C₁₋₃ alkyl;

each Cy² is independently selected from C₃₋₇ cycloalkyl, 4-7 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, and 9-10-membered bicyclic heteroaryl, each of which is optionally substituted with 1, 2, 3, or 4 independently selected R¹¹ groups;

each R^(a2), R^(c2), and R^(d2) is independently selected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, 4-7 membered heterocycloalkyl, phenyl, and 5-6 membered heteroaryl; wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, 4-7 membered heterocycloalkyl, phenyl and 5-6 membered heteroaryl are each optionally substituted with 1, 2, or 3 independently selected R¹¹ groups; and

each R^(b2) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, 4-7 membered heterocycloalkyl, phenyl, and 5-6 membered heteroaryl; wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, 4-7 membered heterocycloalkyl, phenyl and 5-6 membered heteroaryl are each optionally substituted with 1, 2, or 3 independently selected R¹¹ groups; or

alternatively, R^(c2) and R^(d2) together with the N atom to which they are attached form a 4-, 5-, 6-, or 7 membered heterocycloalkyl group, which is optionally substituted with —OH or C₁₋₃ alkyl.

The present invention further provides a compound of Formula I:

or a pharmaceutically acceptable salt thereof, wherein:

V is C(═O), S(═O)₂, CH₂, CHR^(3c), and CR^(3c)R^(3c);

T is C(═O), S(═O)₂, CH₂, CHR^(3a), and CR^(3a)R^(3a);

Q is C(═O), S(═O)₂, (CH₂)_(n), (CHR^(3a))_(n), and (CR^(3a)R^(3a))_(n); wherein n is 0, 1, or 2;

U is O or NR^(3d);

provided that when T is C(═O) or S(═O)₂, then Q is (CH₂)_(n), (CHR^(3a))_(n), or (CR^(3a)R^(3a))_(n);

further provided that when Q is C(═O) or S(═O)₂, then T is CH₂, CHR^(3a), or CR^(3a)R^(3a), and U is NR^(3d);

R^(A) is H or C₁₋₃ alkyl;

Ar is

X¹ is CH or N;

Y¹ is CH or N;

or alternatively, R^(A) and Ar, together with the N to which they are attached, combine to form a moiety of formula:

X is CR⁹ or N;

W is CR⁷ or N;

Y is CR⁸, CR^(8a), or N;

Z is a bond or C(═O);

provided that —W═Y—Z— is —CR⁷═CR⁸—, —N═CR⁸—, —CR⁷═CR^(8a)—C(═O)—, —N═CR^(8a)—C(═O)—, or —CR⁷═N—C(═O)—;

R¹ is C₁₋₃ alkyl;

each R^(3a) is independently selected from C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, and Cy¹; wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl are each optionally substituted with 1, 2, or 3 independently selected R¹¹ groups;

R^(3b) is H, Cy, —(C₁₋₃ alkylene)-Cy, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C(═O)R^(b), C(═O)NR^(c)R^(d), C(═O)OR^(a), C(═NR^(e))R^(b), C(═NR^(e))NR^(c)R^(d), S(═O)₂R^(b), or S(═O)₂NR^(c)R^(d); wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl are each optionally substituted by 1, 2, 3, or 4 independently selected R^(13b) groups;

each R^(3c) is independently selected from C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₁₋₄ alkoxy-C₁₋₄ alkyl, and C₁₋₄ haloalkoxy-C₁₋₄ alkyl;

R^(3d) is H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₁₋₄ alkoxy-C₁₋₄ alkyl, or C₁₋₄ haloalkoxy-C₁₋₄ alkyl;

R⁴ is H, halo, OH, CN, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₁₋₄ alkoxy, or C₁₋₄ haloalkoxy;

R⁵ is halo, OH, CN, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₁₋₄ alkoxy, C₁₋₄ haloalkoxy, or cyclopropyl;

R⁶ is H, halo, OH, CN, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₁₋₄ alkoxy, or C₁₋₄ haloalkoxy;

R⁷ is H or C₁₋₄ alkyl;

R⁸ is H, halo, —OH, —CN, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, Cy², —(C₁₋₃ alkylene)-Cy², OR^(a2), SR^(a2), C(═O)R^(b2), C(═O)NR^(c2)R^(d2), C(═O)OR^(a2), OC(═O)R^(b2), OC(═O)NR^(c2)R^(d2), NR^(c2)R^(d2), NR^(c2)C(═O)R^(b2), NR^(c2)C(═O)OR^(b2), NR^(c2)C(═O)NR^(c2)R^(d2), C(═NR^(e))R^(b2), C(═NR^(e))NR^(c2)R^(d2), NR^(c2)C(═NR^(e))NR^(c2)R^(d2) NR^(c2)S(═O)R^(b2), NR^(c2)S(═O)₂NR^(c2)R^(d2), S(═O)R^(b2), S(═O)₂R^(b2), or S(═O)₂NR^(c2)R^(d2); wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl are each optionally substituted by 1, 2, 3, or 4 independently selected R¹¹ groups;

R^(8a) is H, halo, —CN, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, Cy², —(C₁₋₃ alkylene)-Cy², C(═O)R^(b2), C(═O)NR^(c2)R^(d2), C(═O)OR^(a2), NR^(c2)R^(d2) NR^(c2)C(═O)R^(b2) NR^(c2)C(═O)OR^(b2) NR^(c2)C(═O)NR^(c2)R^(d2), NR^(c2)S(═O)R^(b2), NR^(c2)S(═O)₂NR^(c2)R^(d2), S(═O)R^(b2), S(═O)₂R^(b2), or S(═O)₂NR^(c2)R^(d2); wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl are each optionally substituted by 1, 2, 3, or 4 independently selected R¹¹ groups;

R⁹ is H, halo, OH, CN, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₁₋₄ alkoxy, or C₁₋₄ haloalkoxy;

R¹⁰ is H or C₁₋₄ alkyl;

each R¹¹ is independently selected from halo, OH, NO₂, CN, C₁₋₃ alkyl, C₂₋₃ alkenyl, C₂₋₃ alkynyl, C₁₋₃ haloalkyl, cyano-C₁₋₃ alkyl, HO—C₁₋₃ alkyl, C₁₋₃ alkoxy-C₁₋₃ alkyl, C₃₋₇ cycloalkyl, C₁₋₃ alkoxy, C₁₋₃ haloalkoxy, amino, C₁₋₃ alkylamino, di(C₁₋₃ alkyl)amino, thio, C₁₋₃ alkylthio, C₁₋₃ alkylsulfinyl, C₁₋₃ alkylsulfonyl, carbamyl, C₁₋₃ alkylcarbamyl, di(C₁₋₃ alkyl)carbamyl, carboxy, C₁₋₃ alkylcarbonyl, C₁₋₄ alkoxycarbonyl, C₁₋₃ alkylcarbonylamino, C₁₋₃ alkylsulfonylamino, aminosulfonyl, C₁₋₃ alkylaminosulfonyl, di(C₁₋₃ alkyl)aminosulfonyl, aminosulfonylamino, C₁₋₃ alkylaminosulfonylamino, di(C₁₋₃ alkyl)aminosulfonylamino, aminocarbonylamino, C₁₋₃ alkylaminocarbonylamino, and di(C₁₋₃ alkyl)aminocarbonylamino;

each R^(13b) is independently selected from Cy¹, —(C₁₋₃ alkylene)-Cy¹, halo, CN, NO₂, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, OR^(a1), SR^(a1), C(═O)R^(b1), C(═O)NR^(c1)R^(d1), C(═O)OR^(a1), OC(═O)R^(b1), OC(═O)NR^(c1)R^(d1), NR^(c1)R^(d1), NR^(c1)C(═O)R^(b1), NR^(c1)C(═O)OR^(b1), NR^(c1)C(═O)NR^(c1)R^(d1), C(═NR^(e))R^(b1), C(═NR^(e))NR^(c1)R^(d1), NR^(c1)C(═NR^(e))NR^(c1)R^(d1), NR^(c1)S(═O)R^(b1), NR^(c1)S(═O)₂NR^(c1)R^(d1), S(═O)R^(b1), S(═O)₂R^(b1), and S(═O)₂NR^(c1)R^(d1); wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl are each optionally substituted with 1, 2, or 3 independently selected R¹¹ groups;

each Cy is independently selected from C₃₋₇ cycloalkyl, 4-10 membered heterocycloalkyl, phenyl, naphthyl, and 5-10 membered heteroaryl, wherein said C₃₋₇ cycloalkyl, 4-10 membered heterocycloalkyl, phenyl, naphthyl, and 5-10 membered heteroaryl are optionally substituted with 1, 2, 3, or 4 independently selected R^(13b) groups;

each R^(a), R^(c), and R^(d) is independently selected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, and Cy; wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl are each optionally substituted with 1, 2, or 3 independently selected R^(13b) groups;

each R^(b) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, and Cy; wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl are each optionally substituted with 1, 2, or 3 independently selected R^(13b) groups; or alternatively, R^(c) and R^(d) together with the N atom to which they are attached form a 4-, 5-, 6-, or 7 membered heterocycloalkyl group, which is optionally substituted with 1, 2, or 3 independently selected R^(13b) groups;

each R^(e) is independently selected from H, CN, OH, C₁₋₄ alkyl, and C₁₋₄ alkoxy; each Cy¹ is independently selected from C₃₋₇ cycloalkyl, 4-7 membered heterocycloalkyl, phenyl, and 5-6 membered heteroaryl, wherein said C₃₋₇ cycloalkyl, 4-7 membered heterocycloalkyl, phenyl, and 5-6 membered heteroaryl are optionally substituted with 1, 2, 3, or 4 independently selected R¹¹ groups;

each R^(a1), R^(c1), and R^(d1) is independently selected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, 4-7 membered heterocycloalkyl, phenyl, and 5-6 membered heteroaryl; wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, 4-7 membered heterocycloalkyl, phenyl and 5-6 membered heteroaryl are each optionally substituted with 1, 2, or 3 independently selected R¹¹ groups;

each R^(b1) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, 4-7 membered heterocycloalkyl, phenyl, and 5-6 membered heteroaryl; wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, 4-7 membered heterocycloalkyl, phenyl and 5-6 membered heteroaryl are each optionally substituted with 1, 2, or 3 independently selected R¹¹ groups; or

alternatively, R^(c1) and R^(d1) together with the N atom to which they are attached form a 4-, 5-, 6-, or 7 membered heterocycloalkyl group, which is optionally substituted with —OH or C₁₋₃ alkyl;

each Cy² is independently selected from C₃₋₇ cycloalkyl, 4-7 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, and 9-10-membered bicyclic heteroaryl, each of which is optionally substituted with 1, 2, 3, or 4 independently selected R¹¹ groups;

each R^(a2), R^(c2), and R^(d2) is independently selected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, 4-7 membered heterocycloalkyl, phenyl, and 5-6 membered heteroaryl; wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, 4-7 membered heterocycloalkyl, phenyl and 5-6 membered heteroaryl are each optionally substituted with 1, 2, or 3 independently selected R¹¹ groups; and

each R^(b2) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, 4-7 membered heterocycloalkyl, phenyl, and 5-6 membered heteroaryl; wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, 4-7 membered heterocycloalkyl, phenyl and 5-6 membered heteroaryl are each optionally substituted with 1, 2, or 3 independently selected R¹¹ groups; or

alternatively, R^(c2) and R^(d2) together with the N atom to which they are attached form a 4-, 5-, 6-, or 7 membered heterocycloalkyl group, which is optionally substituted with —OH or C₁₋₃ alkyl.

In some embodiments, V is C(═O) or CH₂.

In some embodiments, V is C(═O).

In some embodiments, V is S(═O)₂.

In some embodiments, V is CHR^(3c).

In some embodiments, V is CH₂.

In some embodiments, T is CH₂.

In some embodiments, T is C(═O).

In some embodiments, T is S(═O)₂.

In some embodiments, T is CHR^(3a).

In some embodiments, T is CH(CH₃).

In some embodiments, Q is S(═O)₂.

In some embodiments, Q is (CHR^(3a))_(n); wherein n is 0, 1, or 2.

In some embodiments, Q is (CH₂)_(n); wherein n is 0, 1, or 2.

In some embodiments, Q is CH₂, CH(CH₃), CH(CH₂CH₃), or CH₂CH₂.

In some embodiments, n is 1.

In some embodiments, n is 0.

In some embodiments, Q is CHR^(3a).

In some embodiments, Q is CH₂.

In some embodiments, Q is CH(CH₃).

In some embodiments, Q is CH(CH₂CH₃).

In some embodiments, Q is CH₂CH₂.

In some embodiments, U is O.

In some embodiments, U is NR^(3d).

In some embodiments, U is NH.

In some embodiments, U is NCH₃.

In some embodiments, R^(A) is H; and Ar

In some embodiments, R^(A) is H; and Ar is

In some embodiments, R^(A) is H; and Ar is

In some embodiments, R^(A) and Ar, together with the N to which they are attached, combine to form a moiety of formula:

In some embodiments, R^(A) and Ar, together with the N to which they are attached, combine to form a moiety of formula:

In some embodiments, R^(A) and Ar, together with the N to which they are attached, combine to form a moiety of formula:

In some embodiments, R^(A) and Ar, together with the N to which they are attached, combine to form a moiety of formula:

In some embodiments, R^(A) and Ar, together with the N to which they are attached, combine to form a moiety of formula:

In some embodiments, R^(A) and Ar, together with the N to which they are attached, combine to form a moiety of formula:

In some embodiments, R¹ is methyl.

In some embodiments, R¹ is methyl or ethyl.

In some embodiments, R⁴ is C₁₋₄ alkyl, halo, or CN.

In some embodiments, R⁴ is C₁₋₄ alkyl.

In some embodiments, R⁴ is methyl.

In some embodiments, R⁴ is halo.

In some embodiments, R⁴ is F.

In some embodiments, R⁴ is CN.

In some embodiments, R⁵ is halo.

In some embodiments, R⁵ is chloro.

In some embodiments, R⁶ is H.

In some embodiments, R^(3b) is H, Cy, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C(═O)R^(b), C(═O)NR^(c)R^(d), C(═O)OR^(a), or S(═O)₂R^(b), wherein said C₁₋₆ alkyl is optionally substituted by 1, 2, 3, or 4 independently selected R^(13b) groups.

In some embodiments, R^(3b) is H, Cy, C₁₋₆ alkyl, C(═O)R^(b), C(═O)NR^(c)R^(d), C(═O)OR^(a), or S(═O)₂R^(b), wherein said C₁₋₆ alkyl is optionally substituted by 1, 2, 3, or 4 independently selected R^(13b) groups;

each R^(a), R^(b), R^(c), and R^(d) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, and Cy; wherein said C₁₋₆ alkyl are each optionally substituted with 1, 2, or 3 independently selected R^(13b) groups.

In some embodiments, R^(3b) is H, Cy, —(C₁₋₃ alkylene)-Cy, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C(═O)R^(b), C(═O)NR^(c)R^(d), C(═O)OR^(a), or S(═O)₂R^(b), wherein said C₁₋₆ alkyl is optionally substituted by 1, 2, 3, or 4 independently selected R^(13b) groups.

In some embodiments, R^(3b) is H, Cy, —(C₁₋₃ alkylene)-Cy, C₁₋₆ alkyl, C(═O)R^(b), C(═O)NR^(c)R^(d), C(═O)OR^(a), or S(═O)₂R^(b), wherein said C₁₋₆ alkyl is optionally substituted by 1, 2, 3, or 4 independently selected R^(13b) groups;

each R^(a), R^(b), R^(c), and R^(d) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, and Cy; wherein said C₁₋₆ alkyl are each optionally substituted with 1, 2, or 3 independently selected R^(13b) groups.

In some embodiments, each Cy is independently selected from C₃₋₇ cycloalkyl, 4-8 membered heterocycloalkyl, phenyl, and 5-10 membered heteroaryl, wherein said C₃₋₇ cycloalkyl, 4-8 membered heterocycloalkyl, phenyl, and 5-10 membered heteroaryl are optionally substituted with 1, 2, 3, or 4 independently selected R^(13b) groups.

In some embodiments, each Cy is independently selected from monocyclic C₃₋₇ cycloalkyl, monocyclic 4-7 membered heterocycloalkyl, phenyl, and monocyclic 5-6 membered heteroaryl, wherein said monocyclic C₃₋₇ cycloalkyl, monocyclic 4-7 membered heterocycloalkyl, phenyl, and monocyclic 5-6 membered heteroaryl are optionally substituted with 1, 2, 3, or 4 independently selected R^(13b) groups.

In some embodiments, each R^(13b) is independently selected from CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl, OR^(a1), C(═O)R^(b1), or C(═O)OR^(a1).

In some embodiments, each R^(13b) is independently selected from CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl, OR^(a1), C(═O)R^(b1), C(═O)NR^(c1)R^(d1), C(═O)OR^(a1), NR^(c1)C(═O)R^(b1), S(═O)₂R^(b1), and S(═O)₂NR^(c1)R^(d1), wherein said C₁₋₆ alkyl is optionally substituted with 1, 2, or 3 independently selected R¹¹ groups.

In some embodiments, each R^(a1), R^(c1), and R^(d1) is independently selected from H, C₁₋₆ alkyl, and C₁₋₆ haloalkyl; and each R^(b1) is independently selected from C₁₋₆ alkyl and C₁₋₆ haloalkyl.

In some embodiments, each R¹¹ is independently selected from OH, CN, C₁₋₃ alkoxy, amino, C₁₋₃ alkylamino, di(C₁₋₃ alkyl)amino, carbamyl, C₁₋₃ alkylcarbamyl, and di(C₁₋₃ alkyl)carbamyl.

In some embodiments, each R¹¹ is independently selected from OH and carbamyl.

In some embodiments, the compound is a compound of Formula II:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound is a compound of Formula III:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound is a compound of Formula IV:

or a pharmaceutically acceptable salt thereof.

In some embodiments of the compound of Formula IV, V is C(═O) or CH₂.

In some embodiments, the compound is a compound of Formula IVa:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound is a compound of Formula IVb:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound is a compound of Formula V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, XVI, XVII, XVIII, XIX, or XX:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound is a compound of Formula XXI, XXII or XXIII:

or a pharmaceutically acceptable salt thereof.

In some embodiments, R^(a) is methyl or ethyl for the compound of Formula XXI, XXII, or XIII, or pharmaceutically acceptable salt thereof.

In some embodiments, the compound is a compound of Formula XXIa, XXIb, or XXIIa:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound is a compound of Formula XXIV:

or a pharmaceutically acceptable salt thereof.

In some embodiments, R^(a) is methyl for the compound of Formula XXIV, or pharmaceutically acceptable salt thereof.

In some embodiments, the compound is a compound of Formula II:

or a pharmaceutically acceptable salt thereof, wherein:

V is C(═O), S(═O)₂, or CH₂;

T is C(═O), S(═O)₂, or CH₂;

Q is C(═O), S(═O)₂, or CH₂;

U is O or NR^(3d);

provided that when T is C(═O) or S(═O)₂, then Q is CH₂;

further provided that when Q is C(═O) or S(═O)₂, then T is CH₂, and U is NR^(3d);

R¹ is C₁₋₃ alkyl;

R^(3b) is H, Cy, —(C₁₋₃ alkylene)-Cy, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C(═O)R^(b), C(═O)NR^(c)R^(d), C(═O)OR^(a), S(═O)₂R^(b), or S(═O)₂NR^(c)R^(d); wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl are optionally substituted by 1, 2, 3, or 4 independently selected R^(13b) groups;

R^(3d) is H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₁₋₄ alkoxy-C₁₋₄ alkyl, or C₁₋₄ haloalkoxy-C₁₋₄ alkyl;

R⁴ is H, halo, OH, CN, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₁₋₄ alkoxy, or C₁₋₄ haloalkoxy;

R⁵ is halo, OH, CN, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₁₋₄ alkoxy, C₁₋₄ haloalkoxy, or cyclopropyl;

R⁶ is H;

R⁸ is H, halo, —OH, —CN, C₁₋₆ alkyl, or C₁₋₆ haloalkyl;

R¹⁰ is H or C₁₋₄ alkyl;

each R¹¹ is independently selected from halo, OH, NO₂, CN, C₁₋₃ alkyl, C₁₋₃ haloalkyl, C₁₋₃ alkoxy, C₁₋₃ haloalkoxy, amino, C₁₋₃ alkylamino, and di(C₁₋₃ alkyl)amino;

each R^(13b) is independently selected from halo, CN, NO₂, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, OR^(a1), SR^(a1), C(═O)R^(b1), C(═O)NR^(c1)R^(d1), C(═O)OR^(a1), OC(═O)R^(b1), OC(═O)NR^(c1)R^(d1), NR^(c1)R^(d1), NR^(c1)C(═O)R^(b1), NR^(c1)S(═O)R^(b1), NR^(c1)S(═O)₂NR^(c1)R^(d1), S(═O)R^(b1), S(═O)₂R^(b1), and S(═O)₂NR^(c1)R^(d1); wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl are each optionally substituted with 1, 2, or 3 independently selected R¹¹ groups;

each Cy is independently selected from C₃₋₇ cycloalkyl, 4-10 membered heterocycloalkyl, phenyl, and 5-10 membered heteroaryl, wherein said C₃₋₇ cycloalkyl, 4-10 membered heterocycloalkyl, phenyl, and 5-10 membered heteroaryl are optionally substituted with 1, 2, 3, or 4 independently selected R^(13b) groups;

each R^(a), R^(c), and R^(d) is independently selected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, and Cy; wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl are each optionally substituted with 1, 2, or 3 independently selected R^(13b) groups;

each R^(b) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, and Cy; wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl are each optionally substituted with 1, 2, or 3 independently selected R^(13b) groups; or

each R^(a1), R^(c1), and R^(dl) is independently selected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, 4-7 membered heterocycloalkyl, phenyl, and 5-6 membered heteroaryl; wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, 4-7 membered heterocycloalkyl, phenyl and 5-6 membered heteroaryl are each optionally substituted with 1, 2, or 3 independently selected R¹¹ groups; and

each R^(b1) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, 4-7 membered heterocycloalkyl, phenyl, and 5-6 membered heteroaryl; wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, 4-7 membered heterocycloalkyl, phenyl and 5-6 membered heteroaryl are each optionally substituted with 1, 2, or 3 independently selected R¹¹ groups; or

each Cy² is independently selected from C₃₋₇ cycloalkyl, 4-7 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, and 9-10-membered bicyclic heteroaryl, each of which is optionally substituted with 1, 2, 3, or 4 independently selected R¹¹ groups.

In some embodiments, the compound is a compound of Formula II:

or a pharmaceutically acceptable salt thereof, wherein:

V is C(═O), S(═O)₂, or CH₂;

T is C(═O), S(═O)₂, CH₂, or CH(CH₃);

Q is C(═O), S(═O)₂, CH₂, CH(CH₃), CH(CH₂CH₃), or CH₂CH₂;

U is O or NR^(3d);

provided that when T is C(═O) or S(═O)₂, then Q is CH₂ or CH(CH₃);

further provided that when Q is C(═O) or S(═O)₂, then T is CH₂, and U is NR^(3d);

R¹ is C₁₋₃ alkyl;

R^(3b) is H, Cy, —(C₁₋₃ alkylene)-Cy, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C(═O)R^(b), C(═O)NR^(c)R^(d), C(═O)OR^(a), S(═O)₂R^(b), or S(═O)₂NR^(c)R^(d); wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl are optionally substituted by 1, 2, 3, or 4 independently selected R^(13b) groups;

R^(3d) is H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₁₋₄ alkoxy-C₁₋₄ alkyl, or C₁₋₄ haloalkoxy-C₁₋₄ alkyl;

R⁴ is H, halo, OH, CN, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₁₋₄ alkoxy, or C₁₋₄ haloalkoxy;

R⁵ is halo, OH, CN, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₁₋₄ alkoxy, C₁₋₄ haloalkoxy, or cyclopropyl;

R⁶ is H;

R⁸ is H, halo, —OH, —CN, C₁₋₆ alkyl, or C₁₋₆ haloalkyl;

R¹⁰ is H or C₁₋₄ alkyl;

each R¹¹ is independently selected from halo, OH, NO₂, CN, C₁₋₃ alkyl, C₁₋₃ haloalkyl, C₁₋₃ alkoxy, C₁₋₃ haloalkoxy, amino, C₁₋₃ alkylamino, di(C₁₋₃ alkyl)amino, carbamyl, C₁₋₃ alkylcarbamyl, and di(C₁₋₃ alkyl)carbamyl;

each R^(13b) is independently selected from halo, CN, NO₂, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, OR^(a1), SR^(a1), C(═O)R^(b1), C(═O)NR^(c1)R^(d1), C(═O)OR^(a1), OC(═O)R^(b1), OC(═O)NR^(c1)R^(d1), NR^(c1)R^(d1), NR^(c1)C(═O)R^(b1), NR^(c1)S(═O)R^(b1), NR^(c1)S(═O)₂NR^(c1)R^(d1), S(═O)R^(b1), S(═O)₂R^(b1), and S(═O)₂NR^(c1)R^(d1); wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl are each optionally substituted with 1, 2, or 3 independently selected R¹¹ groups;

each Cy is independently selected from C₃₋₇ cycloalkyl, 4-10 membered heterocycloalkyl, phenyl, and 5-10 membered heteroaryl, wherein said C₃₋₇ cycloalkyl, 4-10 membered heterocycloalkyl, phenyl, and 5-10 membered heteroaryl are optionally substituted with 1, 2, 3, or 4 independently selected R^(13b) groups;

-   -   each R^(a), R^(c), and R^(d) is independently selected from H,         C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, and Cy;         wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl are each         optionally substituted with 1, 2, or 3 independently selected         R^(13b) groups;

each R^(b) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, and Cy; wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl are each optionally substituted with 1, 2, or 3 independently selected R^(13b) groups; or

each R^(a1), R^(c1), and R^(d1) is independently selected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, 4-7 membered heterocycloalkyl, phenyl, and 5-6 membered heteroaryl; wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, 4-7 membered heterocycloalkyl, phenyl and 5-6 membered heteroaryl are each optionally substituted with 1, 2, or 3 independently selected R¹¹ groups; and

each R^(b1) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, 4-7 membered heterocycloalkyl, phenyl, and 5-6 membered heteroaryl; wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, 4-7 membered heterocycloalkyl, phenyl and 5-6 membered heteroaryl are each optionally substituted with 1, 2, or 3 independently selected R¹¹ groups; or

each Cy² is independently selected from C₃₋₇ cycloalkyl, 4-7 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, and 9-10-membered bicyclic heteroaryl, each of which is optionally substituted with 1, 2, 3, or 4 independently selected R¹¹ groups.

In some embodiments:

R⁴ is C₁₋₄ alkyl;

R⁵ is halo;

R⁶ is H;

R^(3b) is H, Cy, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C(═O)R^(b), C(═O)NR^(c)R^(d), C(═O)OR^(a), or S(═O)₂R^(b), wherein said C₁₋₆ alkyl is optionally substituted by 1, 2, 3, or 4 independently selected R^(13b) groups;

each R^(a), R^(b), R^(c), and R^(d) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, and Cy; wherein said C₁₋₆ alkyl are each optionally substituted with 1, 2, or 3 independently selected R^(13b) groups;

each Cy is independently selected from monocyclic C₃₋₇ cycloalkyl, monocyclic 4-7 membered heterocycloalkyl, phenyl, and monocyclic 5-6 membered heteroaryl, wherein said monocyclic C₃₋₇ cycloalkyl, monocyclic 4-7 membered heterocycloalkyl, phenyl, and monocyclic 5-6 membered heteroaryl are optionally substituted with 1, 2, 3, or 4 independently selected R^(13b) groups;

each R^(13b) is independently selected from CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl, OR^(a1), C(═O)R^(b1), and C(═O)OR^(a1);

each R^(a1) is independently selected from H, C₁₋₆ alkyl, and C₁₋₆ haloalkyl; and

each R^(b1) is independently selected from C₁₋₆ alkyl and C₁₋₆ haloalkyl.

In some embodiments:

R¹ is methyl;

R⁴ is methyl, F or CN;

R⁵ is Cl;

R⁶ is H;

R^(3b) is H, Cy, —(C₁₋₃ alkylene)-Cy, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C(═O)R^(b), C(═O)NR^(c)R^(d), C(═O)OR^(a), or S(═O)₂R^(b), wherein said C₁₋₆ alkyl is optionally substituted by 1, 2, 3, or 4 independently selected R^(13b) groups;

each R^(a), R^(b), R^(c), and R^(d) is independently selected from C₁₋₆ alkyl and Cy; wherein said C₁₋₆ alkyl is optionally substituted with 1, 2, or 3 independently selected R^(13b) groups;

each Cy is independently selected from monocyclic C₃₋₇ cycloalkyl, monocyclic 4-7 membered heterocycloalkyl, phenyl, and monocyclic 5-6 membered heteroaryl, wherein said monocyclic C₃₋₇ cycloalkyl, monocyclic 4-7 membered heterocycloalkyl, phenyl, and monocyclic 5-6 membered heteroaryl are optionally substituted with 1, 2, 3, or 4 independently selected R^(13b) groups;

each R^(13b) is independently selected from CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl, OR^(a1), C(═O)R^(b1), C(═O)NR^(c1)R^(d1), C(═O)OR^(a1), NR^(c1)C(═O)R^(b1), S(═O)₂R^(b1), and S(═O)₂NR^(c1)R^(d1), wherein said C₁₋₆ alkyl is optionally substituted with 1 or 2 independently selected R¹¹ groups;

each R¹¹ is independently selected from OH and carbamyl;

each R^(a1), R^(c1), and R^(dl) is independently selected from H, C₁₋₆ alkyl, and C₁₋₆ haloalkyl; and

each R^(b1) is independently selected from C₁₋₆ alkyl and C₁₋₆ haloalkyl.

In some embodiments, the compound is a compound of Formula II:

or a pharmaceutically acceptable salt thereof, wherein:

R⁴ is C₁₋₄ alkyl;

R⁵ is halo;

R⁶ is H;

R¹⁰ is H or C₁₋₄ alkyl;

R^(3b) is H, Cy, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C(═O)R^(b), C(═O)NR^(c)R^(d), C(═O)OR^(a), or S(═O)₂R^(b), wherein said C₁₋₆ alkyl is optionally substituted by 1, 2, 3, or 4 independently selected R^(13b) groups;

each R^(a), R^(b), R^(c), and R^(d) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, and Cy; wherein said C₁₋₆ alkyl are each optionally substituted with 1, 2, or 3 independently selected R^(13b) groups;

each Cy is independently selected from monocyclic C₃₋₇ cycloalkyl, monocyclic 4-7 membered heterocycloalkyl, phenyl, and monocyclic 5-6 membered heteroaryl, wherein said monocyclic C₃₋₇ cycloalkyl, monocyclic 4-7 membered heterocycloalkyl, phenyl, and monocyclic 5-6 membered heteroaryl are optionally substituted with 1, 2, 3, or 4 independently selected R^(13b) groups;

each R^(13b) is independently selected from CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl, OR^(a1), C(═O)R^(b1), and C(═O)OR^(a1);

each R^(a1) is independently selected from H, C₁₋₆ alkyl, and C₁₋₆ haloalkyl; and

each R^(b1) is independently selected from C₁₋₆ alkyl and C₁₋₆ haloalkyl.

In some embodiments, the compound is a compound of Formula IV:

or a pharmaceutically acceptable salt thereof, wherein:

V is C(═O) or CH₂;

R⁴ is C₁₋₄ alkyl;

R⁵ is halo;

R⁶ is H;

R⁸ is C₁₋₆ alkyl;

R¹⁰ is H or C₁₋₄ alkyl;

R^(3b) is H, Cy, C₁₋₆ alkyl, C(═O)R^(b), C(═O)NR^(c)R^(d), C(═O)OR^(a), or S(═O)₂R^(b), wherein said C₁₋₆ alkyl is optionally substituted by 1, 2, 3, or 4 independently selected R^(13b) groups;

each R^(a), R^(b), R^(c), and R^(d) is independently selected from C₁₋₆ alkyl and Cy; wherein said C₁₋₆ alkyl are each optionally substituted with 1, 2, or 3 independently selected R^(13b) groups;

each Cy is independently selected from monocyclic C₃₋₇ cycloalkyl, monocyclic 4-7 membered heterocycloalkyl, phenyl, and monocyclic 5-6 membered heteroaryl, wherein said monocyclic C₃₋₇ cycloalkyl, monocyclic 4-7 membered heterocycloalkyl, phenyl, and monocyclic 5-6 membered heteroaryl are optionally substituted with 1, 2, 3, or 4 independently selected R^(13b) groups;

each R^(13b) is independently selected from CN, C₁₋₆ alkyl, OR^(a1), C(═O)R^(b1), and C(═O)OR^(a1);

each R^(a1) is independently selected from H, C₁₋₆ alkyl, and C₁₋₆ haloalkyl; and

each R^(b1) is independently selected from C₁₋₆ alkyl and C₁₋₆ haloalkyl.

In some embodiments, the compound is a compound of Formula IV:

or a pharmaceutically acceptable salt thereof, wherein:

V is C(═O) or CH₂;

R¹ is methyl;

R⁴ is methyl, F or CN;

R⁵ is Cl;

R⁶ is H;

R^(3b) is H, Cy, —(C₁₋₃ alkylene)-Cy, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C(═O)R^(b), C(═O)NR^(c)R^(d), C(═O)OR^(a), or S(═O)₂R^(b), wherein said C₁₋₆ alkyl is optionally substituted by 1, 2, 3, or 4 independently selected R^(13b) groups;

each R^(a), R^(b), R^(c), and R^(d) is independently selected from C₁₋₆ alkyl and Cy; wherein said C₁₋₆ alkyl is optionally substituted with 1, 2, or 3 independently selected R^(13b) groups;

each Cy is independently selected from monocyclic C₃₋₇ cycloalkyl, monocyclic 4-7 membered heterocycloalkyl, phenyl, and monocyclic 5-6 membered heteroaryl, wherein said monocyclic C₃₋₇ cycloalkyl, monocyclic 4-7 membered heterocycloalkyl, phenyl, and monocyclic 5-6 membered heteroaryl are optionally substituted with 1, 2, 3, or 4 independently selected R^(13b) groups;

each R^(13b) is independently selected from CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl, OR^(a1), C(═O)R^(b1), C(═O)NR^(c1)R^(d1), C(═O)OR^(a1), NR^(c1)C(═O)R^(b1), S(═O)₂R^(b1), and S(═O)₂NR^(c1)R^(d1), wherein said C₁₋₆ alkyl is optionally substituted with 1 or 2 independently selected R¹¹ groups;

each R¹¹ is independently selected from OH and carbamyl;

each R^(a1), R^(c1), and R^(dl) is independently selected from H, C₁₋₆ alkyl, and C₁₋₆ haloalkyl; and

each R^(b1) is independently selected from C₁₋₆ alkyl and C₁₋₆ haloalkyl.

In some embodiments, the compound is a compound of Formula XXI, XXII, or XXXIII:

or a pharmaceutically acceptable salt thereof, wherein:

R¹ is methyl;

R^(3a) is methyl or ethyl;

R⁴ is methyl, F or CN;

R⁵ is Cl;

R⁶ is H;

R^(3b) is H, Cy, —(C₁₋₃ alkylene)-Cy, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C(═O)R^(b), C(═O)NR^(c)R^(d), C(═O)OR^(a), or S(═O)₂R^(b), wherein said C₁₋₆ alkyl is optionally substituted by 1, 2, 3, or 4 independently selected R^(13b) groups;

each R^(a), R^(b), R^(c), and R^(d) is independently selected from C₁₋₆ alkyl and Cy; wherein said C₁₋₆ alkyl is optionally substituted with 1, 2, or 3 independently selected R^(13b) groups;

each Cy is independently selected from monocyclic C₃₋₇ cycloalkyl, monocyclic 4-7 membered heterocycloalkyl, phenyl, and monocyclic 5-6 membered heteroaryl, wherein said monocyclic C₃₋₇ cycloalkyl, monocyclic 4-7 membered heterocycloalkyl, phenyl, and monocyclic 5-6 membered heteroaryl are optionally substituted with 1, 2, 3, or 4 independently selected R^(13b) groups;

each R^(13b) is independently selected from CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl, OR^(a1), C(═O)R^(b1), C(═O)NR^(c1)R^(d1), C(═O)OR^(a1), NR^(c1)C(═O)R^(b1), S(═O)₂R^(b1), and S(═O)₂NR^(c1)R^(d1), wherein said C₁₋₆ alkyl is optionally substituted with 1 or 2 independently selected R¹¹ groups;

each R¹¹ is independently selected from OH and carbamyl;

each R^(a1), R^(c1), and R^(dl) is independently selected from H, C₁₋₆ alkyl, and C₁₋₆ haloalkyl; and

each R^(b1) is independently selected from C₁₋₆ alkyl and C₁₋₆ haloalkyl.

In some embodiments, the compound is a compound of Formula XXIV:

or a pharmaceutically acceptable salt thereof, wherein:

R¹ is methyl;

R^(3a) is methyl;

R⁴ is methyl, F or CN;

R⁵ is Cl;

R⁶ is H;

R^(3b) is H, Cy, —(C₁₋₃ alkylene)-Cy, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C(═O)R^(b), C(═O)NR^(c)R^(d), C(═O)OR^(a), or S(═O)₂R^(b), wherein said C₁₋₆ alkyl is optionally substituted by 1, 2, 3, or 4 independently selected R^(13b) groups;

each R^(a), R^(b), R^(c), and R^(d) is independently selected from C₁₋₆ alkyl and Cy; wherein said C₁₋₆ alkyl is optionally substituted with 1, 2, or 3 independently selected R^(13b) groups;

each Cy is independently selected from monocyclic C₃₋₇ cycloalkyl, monocyclic 4-7 membered heterocycloalkyl, phenyl, and monocyclic 5-6 membered heteroaryl, wherein said monocyclic C₃₋₇ cycloalkyl, monocyclic 4-7 membered heterocycloalkyl, phenyl, and monocyclic 5-6 membered heteroaryl are optionally substituted with 1, 2, 3, or 4 independently selected R^(13b) groups;

each R^(13b) is independently selected from CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl, OR^(a1), C(═O)R^(b1), C(═O)NR^(c1)R^(d1), C(═O)OR^(a), NR^(c1)C(═O)R^(b1), S(═O)₂R^(b1), and S(═O)₂NR^(c1)R^(d1), wherein said C₁₋₆ alkyl is optionally substituted with 1 or 2 independently selected R¹¹ groups;

each R¹¹ is independently selected from OH and carbamyl;

each R^(a1), R^(c1), and R^(d1) is independently selected from H, C₁₋₆ alkyl, and C₁₋₆ haloalkyl; and

each R^(b1) is independently selected from C₁₋₆ alkyl and C₁₋₆ haloalkyl.

It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, can also be provided in combination in a single embodiment (the embodiments in the specification should be construed as if they were written as claims, which are multiply dependent on each of the other embodiments). Conversely, various features of the invention which are, for brevity, described in the context of a single embodiment, can also be provided separately or in any suitable subcombination.

At various places in the present specification, divalent linking substituents are described.

It is specifically intended that each divalent linking substituent include both the forward and backward forms of the linking substituent. For example, —NR(CR′R″)_(n)— includes both —NR(CR′R″)_(n)— and —(CR′R″)_(n)NR—. Where the structure clearly requires a linking group, the Markush variables listed for that group are understood to be linking groups.

The term “n-membered” where n is an integer typically describes the number of ring-forming atoms in a moiety where the number of ring-forming atoms is n. For example, piperidinyl is an example of a 6-membered heterocycloalkyl ring, pyrazolyl is an example of a 5-membered heteroaryl ring, pyridyl is an example of a 6-membered heteroaryl ring, and 1,2,3,4-tetrahydro-naphthalene is an example of a 10-membered cycloalkyl group.

As used herein, the phrase “optionally substituted” means unsubstituted or substituted. As used herein, the term “substituted” means that a hydrogen atom is removed and replaced by a substituent. It is to be understood that substitution at a given atom is limited by valency.

Throughout the definitions, the term “C_(n-m)” indicates a range which includes the endpoints, wherein n and m are integers and indicate the number of carbons. Examples include C₁₋₄, C₁₋₆, and the like.

As used herein, the term “C_(n-m) alkyl”, employed alone or in combination with other terms, refers to a saturated hydrocarbon group that may be straight-chain or branched, having n to m carbons. In some embodiments, the alkyl group contains from 1 to 6 carbon atoms, from 1 to 4 carbon atoms, from 1 to 3 carbon atoms, or 1 to 2 carbon atoms. Examples of alkyl moieties include, but are not limited to, chemical groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, isobutyl, sec-butyl; higher homologs such as 2-methyl-1-butyl, n-pentyl, 3-pentyl, n-hexyl, 1,2,2-trimethylpropyl, and the like.

As used herein, “C_(n-m) alkenyl” refers to an alkyl group having one or more double carbon-carbon bonds and having n to m carbons. In some embodiments, the alkenyl moiety contains 2 to 6, 2 to 4, or 2 to 3 carbon atoms. Example alkenyl groups include, but are not limited to, ethenyl, n-propenyl, isopropenyl, n-butenyl, sec-butenyl, and the like.

As used herein, “C_(n-m) alkynyl” refers to an alkyl group having one or more triple carbon-carbon bonds and having n to m carbons. Example alkynyl groups include, but are not limited to, ethynyl, propyn-1-yl, propyn-2-yl, and the like. In some embodiments, the alkynyl moiety contains 2 to 6, 2 to 4, or 2 to 3 carbon atoms.

As used herein, the term “alkylene”, employed alone or in combination with other terms, refers to a divalent alkyl linking group. Examples of alkylene groups include, but are not limited to, ethan-1,2-diyl, propan-1,3-diyl, propan-1,2-diyl, butan-1,4-diyl, butan-1,3-diyl, butan-1,2-diyl, 2-methyl-propan-1,3-diyl, and the like.

As used herein, the term “C_(n-m) alkoxy”, employed alone or in combination with other terms, refers to a group of formula —O-alkyl, wherein the alkyl group has n to m carbons. Example alkoxy groups include methoxy, ethoxy, propoxy (e.g., n-propoxy and isopropoxy), t-butoxy, and the like. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.

As used herein, the term “C_(n-m) alkylamino” refers to a group of formula —NH(alkyl), wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.

As used herein, the term “C_(n-m) alkoxycarbonyl” refers to a group of formula —C(O)O— alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.

As used herein, the term “C_(n-m) alkylcarbonyl” refers to a group of formula —C(O)-alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.

As used herein, the term “C_(n-m) alkylcarbonylamino” refers to a group of formula —NHC(O)-alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.

As used herein, the term “C_(n-m) alkylsulfonylamino” refers to a group of formula —NHS(O)₂-alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.

As used herein, the term “aminosulfonyl” refers to a group of formula —S(O)₂NH₂.

As used herein, the term “C_(n-m) alkylaminosulfonyl” refers to a group of formula —S(O)₂NH(alkyl), wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.

As used herein, the term “di(C_(n-m) alkyl)aminosulfonyl” refers to a group of formula —S(O)₂N(alkyl)₂, wherein each alkyl group independently has n to m carbon atoms. In some embodiments, each alkyl group has, independently, 1 to 6, 1 to 4, or 1 to 3 carbon atoms.

As used herein, the term “aminosulfonylamino” refers to a group of formula —NHS(O)₂NH₂.

As used herein, the term “C_(n-m) alkylaminosulfonylamino” refers to a group of formula —NHS(O)₂NH(alkyl), wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.

As used herein, the term “di(C_(n-m) alkyl)aminosulfonylamino” refers to a group of formula —NHS(O)₂N(alkyl)₂, wherein each alkyl group independently has n to m carbon atoms. In some embodiments, each alkyl group has, independently, 1 to 6, 1 to 4, or 1 to 3 carbon atoms.

As used herein, the term “aminocarbonylamino”, employed alone or in combination with other terms, refers to a group of formula —NHC(O)NH₂.

As used herein, the term “C_(n-m) alkylaminocarbonylamino” refers to a group of formula —NHC(O)NH(alkyl), wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.

As used herein, the term “di(C_(n-m) alkyl)aminocarbonylamino” refers to a group of formula —NHC(O)N(alkyl)₂, wherein each alkyl group independently has n to m carbon atoms.

In some embodiments, each alkyl group has, independently, 1 to 6, 1 to 4, or 1 to 3 carbon atoms.

As used herein, the term “C_(n-m) alkylcarbamyl” refers to a group of formula —C(O)—NH(alkyl), wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.

As used herein, the term “thio” refers to a group of formula —SH.

As used herein, the term “C_(n-m) alkylthio” refers to a group of formula —S-alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.

As used herein, the term “C_(n-m) alkylsulfinyl” refers to a group of formula —S(O)-alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.

As used herein, the term “C_(n-m) alkylsulfonyl” refers to a group of formula —S(O)₂-alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.

As used herein, the term “amino” refers to a group of formula —NH₂.

As used herein, the term “carbamyl” to a group of formula —C(O)NH₂.

As used herein, the term “carbonyl”, employed alone or in combination with other terms, refers to a —C(═O)— group. Also may be written as C(O).

As used herein, the term “cyano-C₁₋₃ alkyl” refers to a group of formula —(C₁₋₃ alkylene)-CN.

As used herein, the term “HO—C₁₋₃ alkyl” refers to a group of formula —(C₁₋₃ alkylene)-OH.

As used herein, the term “C₁₋₃ alkoxy-C₁₋₃ alkyl” refers to a group of formula —(C₁₋₃ alkylene)-O(C₁₋₃ alkyl).

As used herein, the term “C₁₋₄ alkoxy-C₁₋₄ alkyl” refers to a group of formula —(C₁₋₄ alkylene)-O(C₁₋₄ alkyl).

As used herein, the term “C₁₋₄ haloalkoxy-C₁₋₄ alkyl” refers to a group of formula —(C₁₋₄ alkylene)-O(C₁₋₄ haloalkyl).

As used herein, the term “carboxy” refers to a group of formula —C(O)OH.

As used herein, the term “di(C_(n-m)-alkyl)amino” refers to a group of formula —N(alkyl)₂, wherein the two alkyl groups each has, independently, n to m carbon atoms. In some embodiments, each alkyl group independently has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.

As used herein, the term “di(C_(n-m)-alkyl)carbamyl” refers to a group of formula —C(O)N(alkyl)₂, wherein the two alkyl groups each has, independently, n to m carbon atoms. In some embodiments, each alkyl group independently has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.

As used herein, “halo” refers to F, Cl, Br, or I. In some embodiments, the halo group is F or Cl.

As used herein, “C_(n-m) haloalkoxy” refers to a group of formula —O-haloalkyl having n to m carbon atoms. An example haloalkoxy group is OCF₃. In some embodiments, the haloalkoxy group is fluorinated only. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.

As used herein, the term “C_(n-m) haloalkyl”, employed alone or in combination with other terms, refers to an alkyl group having from one halogen atom to 2s+1 halogen atoms which may be the same or different, where “s” is the number of carbon atoms in the alkyl group, wherein the alkyl group has n to m carbon atoms. In some embodiments, the haloalkyl group is fluorinated only. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.

As used herein, “cycloalkyl” refers to non-aromatic cyclic hydrocarbons including cyclized alkyl and/or alkenyl groups. Cycloalkyl groups can include mono- or polycyclic (e.g., having 2, 3 or 4 fused rings) groups and spirocycles. Cycloalkyl groups can have 3, 4, 5, 6, or 7 ring-forming carbons (C₃-7). Ring-forming carbon atoms of a cycloalkyl group can be optionally substituted by oxo or sulfido. Cycloalkyl groups also include cycloalkylidenes. Example cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinyl, norcarnyl, and the like. In some embodiments, cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. Also included in the definition of cycloalkyl are moieties that have one or more aromatic rings fused (i.e., having a bond in common with) to the cycloalkyl ring, for example, benzo or thienyl derivatives of cyclopentane, cyclohexane, and the like. A cycloalkyl group containing a fused aromatic ring can be attached through any ring-forming atom including a ring-forming atom of the fused aromatic ring.

As used herein, “heteroaryl” refers to a monocyclic or polycyclic aromatic heterocycle having at least one heteroatom ring member selected from sulfur, oxygen, and nitrogen. In some embodiments, the heteroaryl ring has 1, 2, 3, or 4 heteroatom ring members independently selected from nitrogen, sulfur and oxygen. In some embodiments, any ring-forming N in a heteroaryl moiety can be an N-oxide. In some embodiments, the heteroaryl has 5-10 ring atoms and 1, 2, 3 or 4 heteroatom ring members independently selected from nitrogen, sulfur and oxygen. In some embodiments, the heteroaryl has 5-6 ring atoms and 1 or 2 heteroatom ring members independently selected from nitrogen, sulfur and oxygen. In some embodiments, the heteroaryl is a five-membered or six-membered heteroaryl ring.

A five-membered heteroaryl ring is a heteroaryl with a ring having five ring atoms wherein one or more (e.g., 1, 2, or 3) ring atoms are independently selected from N, O, and S. Exemplary five-membered ring heteroaryls are thienyl, furyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl, 1,2,3-triazolyl, tetrazolyl, 1,2,3-thiadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-triazolyl, 1,2,4-thiadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-triazolyl, 1,3,4-thiadiazolyl, and 1,3,4-oxadiazolyl.

A six-membered heteroaryl ring is a heteroaryl with a ring having six ring atoms wherein one or more (e.g., 1, 2, or 3) ring atoms are independently selected from N, O, and S. Exemplary six-membered ring heteroaryls are pyridyl, pyrazinyl, pyrimidinyl, triazinyl and pyridazinyl.

A “bicyclic C₉₋₁₀ heteroaryl” is bicyclic fused heteroaryl having 9 to 10 ring members.

As used herein, “heterocycloalkyl” refers to non-aromatic monocyclic or polycyclic heterocycles having one or more ring-forming heteroatoms selected from O, N, or S. Included in heterocycloalkyl are monocyclic 4-, 5-, 6-, and 7-membered heterocycloalkyl groups. Heterocycloalkyl groups can also include spirocycles. Example heterocycloalkyl groups include pyrrolidin-2-one, 1,3-isoxazolidin-2-one, pyranyl, tetrahydropuran, oxetanyl, azetidinyl, morpholino, thiomorpholino, piperazinyl, tetrahydrofuranyl, tetrahydrothienyl, piperidinyl, pyrrolidinyl, isoxazolidinyl, isothiazolidinyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl, imidazolidinyl, azepanyl, benzazapene, and the like. Ring-forming carbon atoms and heteroatoms of a heterocycloalkyl group can be optionally substituted by oxo or sulfido (e.g., C(O), S(O), C(S), or S(O)₂, etc.). The heterocycloalkyl group can be attached through a ring-forming carbon atom or a ring-forming heteroatom. In some embodiments, the heterocycloalkyl group contains 0 to 3 double bonds. In some embodiments, the heterocycloalkyl group contains 0 to 2 double bonds. Also included in the definition of heterocycloalkyl are moieties that have one or more aromatic rings fused (i.e., having a bond in common with) to the cycloalkyl ring, for example, benzo or thienyl derivatives of piperidine, morpholine, azepine, etc. A heterocycloalkyl group containing a fused aromatic ring can be attached through any ring-forming atom including a ring-forming atom of the fused aromatic ring. In some embodiments, the heterocycloalkyl has 4-10, 4-7 or 4-6 ring atoms with 1 or 2 heteroatoms independently selected from nitrogen, oxygen or sulfur and having one or more oxidized ring members.

At certain places, the definitions or embodiments refer to specific rings (e.g., an azetidine ring, a pyridine ring, etc.). Unless otherwise indicated, these rings can be attached to any ring member provided that the valency of the atom is not exceeded. For example, an azetidine ring may be attached at any position of the ring, whereas an azetidin-3-yl ring is attached at the 3-position.

The compounds described herein can be asymmetric (e.g., having one or more stereocenters). All stereoisomers, such as enantiomers and diastereomers, are intended unless otherwise indicated. Compounds of the present invention that contain asymmetrically substituted carbon atoms can be isolated in optically active or racemic forms. Methods on how to prepare optically active forms from optically inactive starting materials are known in the art, such as by resolution of racemic mixtures or by stereoselective synthesis. Many geometric isomers of olefins, C═N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. Cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms.

In some embodiments, the compound has the (R)-configuration (e.g., at the carbon to which R¹ is attached). In some embodiments, the compound has the (S)-configuration (e.g., at the carbon to which R¹ is attached).

Resolution of racemic mixtures of compounds can be carried out by any of numerous methods known in the art. An example method includes fractional recrystallizaion using a chiral resolving acid which is an optically active, salt-forming organic acid. Suitable resolving agents for fractional recrystallization methods are, for example, optically active acids, such as the D and L forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid or the various optically active camphorsulfonic acids such as β-camphorsulfonic acid. Other resolving agents suitable for fractional crystallization methods include stereoisomerically pure forms of α-methylbenzylamine (e.g., S and R forms, or diastereomerically pure forms), 2-phenylglycinol, norephedrine, ephedrine, N-methylephedrine, cyclohexylethylamine, 1,2-diaminocyclohexane, and the like.

Resolution of racemic mixtures can also be carried out by elution on a column packed with an optically active resolving agent (e.g., dinitrobenzoylphenylglycine). Suitable elution solvent composition can be determined by one skilled in the art.

Compounds of the invention also include tautomeric forms. Tautomeric forms result from the swapping of a single bond with an adjacent double bond together with the concomitant migration of a proton. Tautomeric forms include prototropic tautomers which are isomeric protonation states having the same empirical formula and total charge. Example prototropic tautomers include ketone—enol pairs, amide—imidic acid pairs, lactam—lactim pairs, enamine—imine pairs, and annular forms where a proton can occupy two or more positions of a heterocyclic system, for example, 1H- and 3H-imidazole, 1H-, 2H- and 4H-1,2,4-triazole, 1H- and 2H-isoindole, and 1H- and 2H-pyrazole. Tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution.

Compounds of the invention can also include all isotopes of atoms occurring in the intermediates or final compounds. Isotopes include those atoms having the same atomic number but different mass numbers. For example, isotopes of hydrogen include tritium and deuterium.

The term, “compound,” as used herein is meant to include all stereoisomers, geometric iosomers, tautomers, and isotopes of the structures depicted. Compounds herein identified by name or structure as one particular tautomeric form are intended to include other tautomeric forms unless otherwise specified.

All compounds, and pharmaceutically acceptable salts thereof, can be found together with other substances such as water and solvents (e.g. hydrates and solvates) or can be isolated.

In some embodiments, the compounds of the invention, or salts thereof, are substantially isolated. By “substantially isolated” is meant that the compound is at least partially or substantially separated from the environment in which it was formed or detected. Partial separation can include, for example, a composition enriched in the compounds of the invention. Substantial separation can include compositions containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% by weight of the compounds of the invention, or salt thereof. Methods for isolating compounds and their salts are routine in the art.

The phrase “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

The expressions, “ambient temperature” and “room temperature” or “rt” as used herein, are understood in the art, and refer generally to a temperature, e.g. a reaction temperature, that is about the temperature of the room in which the reaction is carried out, for example, a temperature from about 20° C. to about 30° C.

The present invention also includes pharmaceutically acceptable salts of the compounds described herein. As used herein, “pharmaceutically acceptable salts” refers to derivatives of the disclosed compounds wherein the parent compound is modified by converting an existing acid or base moiety to its salt form. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts of the present invention include the conventional non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, non-aqueous media like ether, ethyl acetate, alcohols (e.g., methanol, ethanol, iso-propanol, or butanol) or acetonitrile (ACN) are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418 and Journal of Pharmaceutical Science, 66, 2 (1977), each of which is incorporated herein by reference in its entirety.

Synthesis

Compounds of the invention, including salts thereof, can be prepared using known organic synthesis techniques and can be synthesized according to any of numerous possible synthetic routes.

The reactions for preparing compounds of the invention can be carried out in suitable solvents which can be readily selected by one of skill in the art of organic synthesis. Suitable solvents can be substantially non-reactive with the starting materials (reactants), the intermediates, or products at the temperatures at which the reactions are carried out, e.g., temperatures which can range from the solvent's freezing temperature to the solvent's boiling temperature. A given reaction can be carried out in one solvent or a mixture of more than one solvent. Depending on the particular reaction step, suitable solvents for a particular reaction step can be selected by the skilled artisan.

Preparation of compounds of the invention can involve the protection and deprotection of various chemical groups. The need for protection and deprotection, and the selection of appropriate protecting groups, can be readily determined by one skilled in the art. The chemistry of protecting groups can be found, for example, in T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 3^(rd) Ed., Wiley & Sons, Inc., New York (1999), which is incorporated herein by reference in its entirety.

Reactions can be monitored according to any suitable method known in the art. For example, product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.g., ¹H or ¹³C), infrared spectroscopy, spectrophotometry (e.g., UV-visible), mass spectrometry, or by chromatographic methods such as high performance liquid chromatography (HPLC), liquid chromatography-mass spectroscopy (LCMS), or thin layer chromatography (TLC). Compounds can be purified by those skilled in the art by a variety of methods, including high performance liquid chromatography (HPLC) (“Preparative LC-MS Purification: Improved Compound Specific Method Optimization” Karl F. Blom, Brian Glass, Richard Sparks, Andrew P. Combs J. Combi. Chem. 2004, 6(6), 874-883, which is incorporated herein by reference in its entirety) and normal phase silica chromatography.

In the Schemes below, the enantiomers of the compounds of Formula (I) (e.g., the carbon to which R¹ is attached is a chiral carbon) can be separated by chiral chromatography to afford a single enantiomer. Alternatively, a chiral intermediate may be separate by chiral chromatography and then used in the remaining steps of the Scheme to form a compound of Formula (I).

Compounds of Formula I can be formed as shown in Scheme I. Compound (i) can be acylated with a suitable acylating reagent (e.g., R¹—COCl) to form an ester which can be rearranged under Lewis acid conditions (e.g., BF₃/HOAc complex) to afford ketone (ii). Halogenation of ketone (ii) using NX²S (e.g., NX²S=N-chlorosuccinamide, N-bromosuccinamide or N-iodosuccinamide) can give compound (iii) where X²=Cl, Br, or I. The phenol can be converted to the ether (v) using standard Mitsunobu conditions (e.g., R″OH, where R″OH=HO-Q-T-NR^(3b), for example HOCH₂CH₂NR^(3b)P, where P is a protecting group, such as Boc or Cbz, and activating agents, such as DEAD, Ph₃P;) or standard alkylating conditions (base and R″-Lg, where Lg=leaving group; for example Na₂CO₃ and BrCH₂CH₂NHP, where P is a protecting group, such as Boc or Cbz). The halo group of (v) can be coupled to a vinyl boronic acid or vinyl boronic ester (vi) (R^(3c)-M, where M is a boronic acid, boronic ester or an appropriately substituted metal (e.g., R^(3c)—M is R^(3c)—B(OH)₂, R^(3c)—Sn(Bu)₄, or Zn—R^(3c)), under standard Suzuki conditions or standard Stille conditions (e.g., in the presence of a palladium(0) catalyst, such as tetrakis(triphenylphosphine)palladium(0) and a base (e.g., a bicarbonate or carbonate base) or standard Negishi conditions (e.g., in the presence of a palladium(0) catalyst, such as tetrakis(triphenylphosphine)palladium(0), to give a vinyl derivative (vii). Oxidation of the vinyl group of compound (vii) under standard conditions (e.g., OsO₄ and then NaIO₄ or ozone and then a reducing agent, such as triphenylphosphine or DMS, can provide compound (viii). Deprotection of the nitrogen protecting group can give the amine that can cyclize to form the imine and be reduced with a suitable reagent, such as NaBH₄, to give an alcohol which can be converted to an intermediate (ix) bearing a leaving group, (e.g., Lg is chloride via reaction with SO₂Cl₂ or cyanuric chloride or mesylate via reaction with methanesulfonic anhydride). The intermediate (ix) can be reacted with a heterocycle (x) in the presence of a base (e.g., CsCO₃ or NaH) to give a heterocyclic derivative (xi). Alternatively, the intermediate (ix) can be converted to an azide derivative which can be reduced to an amine (xii) under appropriate reducing conditions, such as trimethylphosphine or TMSI. The amine (xii) can be optionally reacted with an appropriate alkylating agent R^(A)X (e.g., MeI) or reacted under reductive amination conditions to give a secondary amine which can be reacted with a heteroaryl halide compound (e.g., Ar—X, such as 6-chloro-9H-purine) to give a compound of Formula I (xiii). The reaction of amine (xii) with R^(A)—X³ can be skipped to give compounds of Formula I (xiii), wherein R^(A) is H.

Compounds of Formula I can be formed as shown in Scheme II. Carbonyl derivative (i) (compound viii from Scheme I where R^(3b)=H) can be N-deprotected to give an amine that can cyclize to form an imine and then be reduced with a suitable reagent, such as NaBH₄, to give a bicyclic alcohol containing compound (ii). The alcohol (ii) which can be converted to a derivative bearing a leaving group, (e.g., Lg is chloride via reaction with SO₂Cl₂ or cyanuric chloride or mesylate via reaction with methanesulfonic anhydride) and then reacted with a heterocycle (iii) in the presence of a base (e.g., CsCO₃ or NaH) to give a heterocyclic derivative (iv). N-deprotection and reaction with a variety of acylating or alkylating or arylating agents can provide compounds (v). Alternatively, ketone (i) (compound (viii) from Scheme I where R^(3b)=H) can be N-deprotected to give an amine that can cyclize to form an imine and then be reduced with a suitable reagent, such as NaCNBH₃ to give a bicyclic amine (vi). Reaction of the amine (vi) with a variety of acylating or alkylating or arylating agents and then reduction of the ketone and conversion of the alcohol to a derivative bearing a leaving group, (e.g., Lg is chloride via reaction with SO₂Cl₂ or cyanuric chloride or mesylate via reaction with methanesulfonic anhydride) can provide compounds (vii). Reaction with a heterocycle (iii) in the presence of a base (e.g., CsCO₃ or NaH) can give a bicyclic derivative (v). Alternatively, intermediate (vii) can be converted to an azide and reduced with a suitable agent, such as trimethylphosphine or TMSI. The amine (viii) can be optionally reacted with an appropriate alkylating agent R^(A)X³ (e.g., MeI) or reacted under reductive amination conditions to give a secondary amine which can be reacted with a heteroaryl halide compound (e.g., Ar—X⁴, such as 6-chloro-9H-purine) to give a compound of Formula I (ix). The reaction of amine (viii) with R^(A)—X³ can be skipped to give compounds of Formula I (ix), wherein R^(A) is H.

Compounds of Formula I can be formed as shown in Scheme III. Aldehyde (i) (compound viii from Scheme I) can be oxidized to the corresponding carboxylic acid and then N-deprotected to give an amine that can cyclize under standard peptide coupling conditions (e.g., HATU with DIEA) to provide an amide (ii). Alternatively, when R^(3b)=H, the amine of the carboxylic acid can be N-deprotected and converted to a secondary amine under reductive amination conditions or alkylation (e.g., NaCNBH₃ and R^(3b)CHO or R^(3b)-halo and base) and then cyclized under standard peptide coupling conditions (e.g., HATU with DIEA) to provide an amide (ii). The ketone of compound (ii) can be converted to compounds of Formula I (iv and vi) by similar methods as described in Schemes I and II.

Compounds of Formula I can be formed as shown in Scheme IV. Phenol (i) can be converted to the corresponding triflate (ii) using triflic anhydride and base and then coupled to an amine (iv) by heating in base or under Buchwald conditions (e.g., in the presence of a palladium(0) catalyst, such as tetrakis(triphenylphosphine)palladium(0) and a base (e.g., an alkoxide base)) to afford diamine (iii). Halogenation of diamine (iii) using NX²S (e.g., NX²S=N-chlorosuccinamide, N-bromosuccinamide or N-iodosuccinamide) can give compound (v) where X²=Cl, Br, or I. The halo group of (v) can be coupled to a vinyl boronic acid or vinyl boronic ester (vi) (R^(3c)-M, where M is a boronic acid, boronic ester or an appropriately substituted metal (e.g., R^(3c)-M is R^(3c)—B(OH)₂, R^(3c)—Sn(Bu)₄, or Zn—R^(3c)), under standard Suzuki conditions or standard Stille conditions (e.g., in the presence of a palladium(0) catalyst, such as tetrakis(triphenylphosphine)palladium(0) and a base (e.g., a bicarbonate or carbonate base) or standard Negishi conditions (e.g., in the presence of a palladium(0) catalyst, such as tetrakis(triphenylphosphine)palladium(0), to give a vinyl derivative (vii). Oxidation of the vinyl group of compound (vii) under standard conditions (e.g., OsO₄ and then NaIO₄ or ozone and then a reducing agent, such as triphenylphosphine or DMS) can provide compound (viii). Deprotection of the nitrogen protecting group can give the amine that can cyclize to form the imine and be reduced with a suitable reagent, such as NaBH₄, to give an alcohol that can be converted to a intermediate (ix) bearing a leaving group, (e.g., Lg is chloride via reaction with SO₂Cl₂ or cyanuric chloride or mesylate via reaction with methanesulfonic anhydride). Intermediate (ix) can be converted to compounds of Formula I (xi and xiii) by similar methods as described in Schemes I and II.

Compounds of Formula I can be formed as shown in Scheme V. Aldehyde (i) (compound viii where R^(3c)=H in Scheme IV) can be oxidized to the corresponding carboxylic acid and then N-deprotected to give an amine that can cyclize under standard peptide coupling conditions (e.g., HATU with DIEA) to provide an amide and then be reduced with a suitable reagent, such as NaBH₄, and the resulting alcohol can be converted to a intermediate (ii) bearing a leaving group, (e.g., Lg is chloride via reaction of the alcohol with SO₂Cl₂ or cyanuric chloride or mesylate via reaction with methanesulfonic anhydride). The intermediate compound (ii) can be converted to compounds of Formula I (iv and vi) by similar methods as shown for intermediates bearing leaving groups in Schemes I and II.

Compounds of Formula I can be formed as shown in Scheme VI. Phenol (i) can be converted to the corresponding triflate (ii) using triflic anhydride and base and then coupled to an amino-ester (e.g., R² is alkyl) (iv) by heating in base or under Buchwald conditions (e.g., in the presence of a palladium(0) catalyst, such as tetrakis(triphenylphosphine)palladium(0) and a base (e.g., an alkoxide base)) to afford ester (iii). Halogenation of ketone (iii) using NX²S (e.g., NX²S=N-chlorosuccinamide, N-bromosuccinamide or N-iodosuccinamide) can give compound (v) where X²=Cl, Br, or I. The halo group of (v) can be coupled to a vinyl boronic acid or vinyl boronic ester (vi) (R^(3c)-M, where M is a boronic acid, boronic ester or an appropriately substituted metal (e.g., R^(3c)-M is R^(3c)—B(OH)₂, R^(3c)—Sn(Bu)₄, or Zn—R^(3c)), under standard Suzuki conditions or standard Stille conditions (e.g., in the presence of a palladium(0) catalyst, such as tetrakis(triphenylphosphine)palladium(0) and a base (e.g., a bicarbonate or carbonate base) or standard Negishi conditions (e.g., in the presence of a palladium(0) catalyst, such as tetrakis(triphenylphosphine)palladium(0), to give a vinyl derivative (vii). Oxidation of the vinyl group of compound (vii) under standard conditions (e.g., OsO₄ and then NaIO₄ or ozone and then a reducing agent, such as triphenylphosphine or DMS, can provide compound (viii). Reductive amination with a suitable amine (R^(3b)NH₂) and appropriate reducing agent (e.g., NaCHBH₃) can give the corresponding amine product that can intramolecularly cyclize to form the amide and then be reduced with a suitable reagent, such as NaBH₄, and the resulting alcohol can be converted to a intermediate (ix) bearing a leaving group, (e.g., Lg is chloride via reaction with SO₂Cl₂ or cyanuric chloride or mesylate via reaction with methanesulfonic anhydride). Intermediate (ix) can be converted to compounds of Formula I (xi and xiii) by similar methods as described in Schemes I and II.

Compounds of Formula I can be formed as shown in Scheme VII. Phenol (i) can be converted to the corresponding triflate (ii) using triflic anhydride and base and then coupled to a primary amine (R^(3d)NH₂) by heating in base or under Buchwald conditions (e.g., in the presence of a palladium(0) catalyst, such as tetrakis(triphenylphosphine)palladium(0) and a base (e.g., an alkoxide base)), and then peptide coupling to an amino-acid (iv) can afford amide (iii). Halogenation of amide (iii) using NX²S (e.g., NX²S=N-chlorosuccinamide, N-bromosuccinamide or N-iodosuccinamide) can give compound (v) where X²=Cl, Br, or I. The halo group of (v) can be coupled to a vinyl boronic acid or vinyl boronic ester (vi) (R^(3c)-M, where M is a boronic acid, boronic ester or an appropriately substituted metal (e.g., R^(3c)-M is R^(3c)—B(OH)₂, R^(3c)—Sn(Bu)₄, or Zn—R^(3c)), under standard Suzuki conditions or standard Stille conditions (e.g., in the presence of a palladium(0) catalyst, such as tetrakis(triphenylphosphine)palladium(0) and a base (e.g., a bicarbonate or carbonate base) or standard Negishi conditions (e.g., in the presence of a palladium(0) catalyst, such as tetrakis(triphenylphosphine)palladium(0), to give a vinyl derivative (vii). Oxidation of the vinyl group of compound (vii) under standard conditions (e.g., OsO₄ and then NaIO₄ or ozone and then a reducing agent, such as triphenylphosphine or DMS, can provide compound (viii). Deprotection of the nitrogen protecting group can give the amine that can cyclize to form the imine and be reduced with a suitable reagent, such as NaBH₄, to give bicyclic alcohol which can be converted to a derivative (ix) bearing a leaving group, (e.g., Lg is chloride via reaction with SO₂Cl₂ or cyanuric chloride or mesylate via reaction with methanesulfonic anhydride). Intermediate (ix) can be converted to compounds of Formula I (xi and xiii) by similar methods as described in Schemes I, II and III.

Compounds of Formula I can be formed as shown in Scheme VIII. Halogenation of ketone (i) using NX¹S (e.g., NX¹S═N-chlorosuccinamide, N-bromosuccinamide or N-iodosuccinamide) can give compound (ii) where X¹=Cl, Br, or I. The phenol can be reacted with a halo-ester (iii) to give the ether (iv) using standard alkylating conditions (Base and R′-Lg, where Lg=leaving group (e.g., NaH and BrCR^(3a)CO₂Me). The halo group of (iv) can be coupled to a vinyl boronic acid or vinyl boronic ester (v) (R^(3c)-M, where M is a boronic acid, boronic ester or an appropriately substituted metal (e.g., R^(3c)-M is R^(3c)—B(OH)₂, R^(3c)—Sn(Bu)₄, or Zn—R^(3c)), under standard Suzuki conditions or standard Stille conditions (e.g., in the presence of a palladium(0) catalyst, such as tetrakis(triphenylphosphine)palladium(0) and a base (e.g., a bicarbonate or carbonate base) or standard Negishi conditions (e.g., in the presence of a palladium(0) catalyst, such as tetrakis(triphenylphosphine)palladium(0), to give a vinyl derivative (vi). Oxidation of the vinyl group of compound (vi) under standard conditions (e.g., OsO₄ and then NaIO₄ or ozone and then a reducing agent, such as triphenylphosphine or DMS, can provide compound (vii). Reductive amination with a suitable amine (R^(3b)NH₂) and appropriate reducing agent (e.g., NaCNBH₃) can give the corresponding amine product that can intramolecularly cyclize to form the amide and then be reduced with a suitable reagent, such as NaBH₄, and the resulting alcohol can be converted to a derivative (viii) bearing a leaving group, (e.g., Lg is chloride via reaction with SO₂Cl₂ or cyanuric chloride or mesylate via reaction with methanesulfonic anhydride). Intermediate (viii) can be converted to compounds of Formula I (x and xii) by similar methods as described in Schemes I and II.

Compounds of Formula I can be formed as shown in Scheme IX. Aldehyde (i) (compound vii where R^(3c)=H in Scheme VIII) can be oxidized to the corresponding carboxylic acid and then N-deprotected to give an amine that can cyclize under standard peptide coupling conditions (e.g., HATU with DIEA) to provide an amide and then be reduced with a suitable reagent, such as NaBH₄, and the resulting alcohol can be converted to an intermediate (ii) bearing a leaving group, (e.g., Lg is chloride via reaction of the alcohol with SO₂Cl₂ or cyanuric chloride or mesylate via reaction with methanesulfonic anhydride). The intermediate compound (ii) can be converted to compounds of Formula I (iv and vi) by similar methods as shown for intermediates bearing leaving groups in Schemes I and II.

Compounds of Formula I can be formed as shown in Scheme X. Phenol (i) can be converted to the corresponding triflate (ii) using triflic anhydride and base and then coupled to a primary amine (e.g., R^(3b)NH₂) by heating in base or under Buchwald conditions (e.g., in the presence of a palladium(0) catalyst, such as tetrakis(triphenylphosphine)palladium(0) and a base (e.g., an alkoxide base)) and further protection (e.g., Boc or Cbz using (Boc)₂O or Cbz-Cl, respectively) of the resulting amine can give compound (iii). Halogenation of compound (iii) using NX²S (e.g., NX²S═N-chlorosuccinamide, N-bromosuccinamide or N-iodosuccinamide) can give compound (v) where X²=Cl, Br, or I. The halo group of (v) can be coupled to a vinyl boronic acid or vinyl boronic ester (vi) (R^(3c)-M, where M is a boronic acid, boronic ester or an appropriately substituted metal (e.g., R^(3c)-M is R^(3c)—B(OH)₂, R^(3c)—Sn(Bu)₄, or Zn—R^(3c)), under standard Suzuki conditions or standard Stille conditions (e.g., in the presence of a palladium(0) catalyst, such as tetrakis(triphenylphosphine)palladium(0) and a base (e.g., a bicarbonate or carbonate base) or standard Negishi conditions (e.g., in the presence of a palladium(0) catalyst, such as tetrakis(triphenylphosphine)palladium(0), to give a vinyl derivative (vii). Oxidation of the vinyl group of compound (vii) under standard conditions (e.g., OsO₄ and then NaIO₄ or ozone and then a reducing agent, such as triphenylphosphine or DMS, can provide compound (viii). Reductive amination of carbonyl derivative (viii) with a suitable amine (iv) (e.g., R^(3b)NH₂) and appropriate reducing agent (e.g., NaCHBH₃) can give the corresponding amine product. Deprotection of the nitrogen protecting group can give a diamine that can be cyclized to form a urea (e.g., Q=CO by reaction with phosgene) or sulfamide (e.g., Q=SO₂ by reaction with SO₂Cl₂ or NH₂SO₂NH₂) and then reduction with a suitable reagent, such as NaBH₄, can give an alcohol which can be further converted to an intermediate (ix) bearing a leaving group, (e.g., Lg is chloride via reaction with SO₂Cl₂ or cyanuric chloride or mesylate via reaction with methanesulfonic anhydride). The intermediate compound (ix) can be converted to compounds of Formula I (xi and xiii) by similar methods as shown for intermediates bearing leaving groups in Schemes I and II.

Compounds of Formula I can be formed as shown in Scheme XI. Phenol (i) can reacted with a suitable reagent (e.g., H₂SO₄) to form a sulfate which can be chlorinated using standard conditions (e.g., SOCl₂) to afford a sulfonylchloride (ii). Reaction of the sulfonylchoride with an amine (iv) can give a sulfonamide (iii). When the amine (iv) contains a second amino group (U=NPR^(2d)) the sulfonamide (ii) can be reacted with triflic anhydride to give a triflate and then the amine deprotected and cyclized by heating in the presence of base or under Buchwald conditions (e.g., in the presence of a palladium(0) catalyst, such as tetrakis(triphenylphosphine)palladium(0) and a base (e.g., an alkoxide base)) to give the bicyclic compound (vi). The carbonyl of compound (vi) can be reduced with a suitable reagent, such as NaBH₄, to give an alcohol which can be further converted to an intermediate (vii) bearing a leaving group, (e.g., Lg is chloride via reaction with SO₂Cl₂ or cyanuric chloride or mesylate via reaction with methanesulfonic anhydride). The intermediate compound (vii) can be converted to compounds of Formula I by similar methods as shown for intermediates bearing leaving groups in Schemes I and II. Alternatively, when the amine (iv) contains an alcohol group (U=OH) the sulfonamide (viii) can be intramolecularly cyclized to an ether (ix) using standard Mitsunobu conditions (e.g., DEAD, Ph₃P). The ketone of compound (ix) can be reduced with a suitable reagent, such as NaBH₄, to give an alcohol which can be further converted to an intermediate (x) bearing a leaving group, (e.g., Lg is chloride via reaction with SO₂Cl₂ or cyanuric chloride or mesylate via reaction with methanesulfonic anhydride). The intermediate compound (x) can be converted to compounds of Formula I by similar methods as shown for intermediates bearing leaving groups in Schemes I and II.

Compounds of Formula I can be formed as shown in Scheme XII. Carbonyl derivative (i) can be reductively aminated with an amine (e.g., NH₂R^(3b) in the presence of NaCNBH₃) and then reacted with a sulfonylchloride (e.g., ClSO₂QCl, where Q=(CR^(3a)R^(3a))_(n)) to give the corresponding sulfonamide (ii). Deprotection of the nitrogen and subsequent cyclization followed by reduction of the carbonyl with a suitable reagent, such as NaBH₄, can give an alcohol which can be further converted to an intermediate (iii) bearing a leaving group, (e.g., Lg is chloride via reaction with SO₂Cl₂ or cyanuric chloride or mesylate via reaction with methanesulfonic anhydride). The intermediate compound (iii) can be converted to compounds of Formula I by similar methods as shown for intermediates bearing leaving groups in Schemes I and II. Alternatively, the amine of compound (i) can be deprotected and reacted with a sulfonylchloride (e.g., ClSO₂QCl, where Q=(CR^(3a)R^(3a))_(n)) to give the corresponding sulfonamide (iv). Reductive amination of the sulfonamide (iv) with an amine (e.g., NH₂R^(3b) in the presence of a reducing agent, such as NaCNBH₃) followed by intramolecular cyclization and subsequent reduction with a suitable reagent, such as NaBH₄, to give an alcohol which can be further converted to an intermediate (v) bearing a leaving group, (e.g., Lg is chloride via reaction with SO₂Cl₂ or cyanuric chloride or mesylate via reaction with methanesulfonic anhydride). The intermediate compound (v) can be converted to compounds of Formula I by similar methods as shown for intermediates bearing leaving groups in Schemes I and II.

Compound of Formula I can be synthesized from an acid chloride compound (i) as illustrated in Scheme XIII. Condensation of an acid chloride (i) with malononitrile in the presence of a base, such as sodium hydride, can give a dicyanoenol intermediate, which can be O-methylated with an appropriate reagent, such as dimethyl sulfate in the presence of an appropriate base, such as sodium bicarbonate, to yield an enol ether (ii). Reaction of enol ether (ii) with hydrazine dihydrochloride in the presence of a suitable base, such as triethylamine, can give a pyrazole compound (iii). Pyrazole compound (iii) can then be reacted with formamide to give pyrazolopyrimidine (iv). Finally, compound (iv) can be reacted with appropriate compound bearing a leaving group (v) under basic conditions to give a compound of Formula I (vi).

Compounds of Formula I can also be formed as shown in Scheme XIV. The compound (i) can be reacted with a halo-substituted heterocycle (ii) (e.g., 3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine or 4-amino-6-iodopyrido[2,3-d]pyrimidin-5 (8H)-one) under basic conditions (e.g., NaH or CsCO₃ or K₂CO₃) to give compound (iii) where X²=Cl, Br, or I. The halo group of (iii) can be coupled to R³-M, where M is a boronic acid, boronic ester or an appropriately substituted metal (e.g., R⁸-M is R⁸—B(OH)₂, R⁸—Sn(Bu)₄, or Zn—R⁸), under standard Suzuki conditions or standard Stille conditions (e.g., in the presence of a palladium(0) catalyst, such as tetrakis(triphenylphosphine)palladium(0) and a base (e.g., a bicarbonate or carbonate base) or standard Negishi conditions (e.g., in the presence of a palladium(0) catalyst, such as tetrakis(triphenylphosphine)palladium(0), to give a derivative of formula (iii). Alternatively, R⁸-M can be a cyclic amine (where M is H and attached to the amine nitrogen) with coupling to compound (iii) being performed by heating in base or under Buchwald conditions (e.g., in the presence of a palladium(0) catalyst, such as tetrakis(triphenylphosphine)palladium(0) and a base (e.g., an alkoxide base)) to afford compounds of Formula I (iv).

Compounds of Formula I can be synthesized from commercially available 4-aminopyrido[2,3-d]pyrimidine-5(8H)-one (i) as shown in Scheme XV. Halogenation of compound (i) with suitable reagents, such as N-halo succinamide (NX²S, where X²=Cl, Br or I) can give the corresponding halo compound (ii). Reaction of the halo derivative (ii) with a compound (iii) bearing a leaving group in the presence of a suitable base (e.g. diisopropylethylamine) can give compound (iv). The halo compound (iv) can be coupled to R^(8a)-M, where M is a boronic acid, boronic ester or an appropriately substituted metal (e.g., R^(8a)-M is R^(8a)—B(OH)₂, R^(8a)—Sn(Bu)₄, or Zn—R^(8a)), under standard Suzuki conditions or standard Stille conditions (e.g., in the presence of a palladium(0) catalyst, such as tetrakis(triphenylphosphine)palladium(0) and a base (e.g., a bicarbonate or carbonate base) or standard Negishi conditions (e.g., in the presence of a palladium(0) catalyst, such as tetrakis(triphenylphosphine)palladium(0), to give a derivative of formula (iii). Alternatively, R^(8a)-M can be a cyclic amine (where M is H and attached to the amine nitrogen) with coupling to compound (iii) being performed by heating in base or under Buchwald conditions (e.g., in the presence of a palladium(0) catalyst, such as tetrakis(triphenylphosphine)palladium(0) and a base (e.g., an alkoxide base)) to afford compounds of Formula I (v).

Compounds of Formula I can also be formed as shown in Scheme XVI. The compound (i) can be reacted with a halo-substituted heterocycle (ii) (e.g., 6-chloro-9H-purine) under basic conditions (e.g., NaH or CsCO₃ or K₂CO₃) to give a compound of Formula I (ii).

Ketones which can be used in the processes of Scheme I, II and III, can also be formed as shown in Scheme XVII. The carboxylic acid (i) can be activated with a coupling agent (e.g. HBTU or HATU) and then reacted with N, O-dimethylhydroxylamine to give a N-methoxy-N-methylcarboxamide. Reaction of compound (ii) with a Grignard reagent of formula R¹—MgX² (X²=halo) can give ketone (iii). The ketone (iii) can be transformed using similar methods as shown in Scheme I, II and III to afford compounds of Formula I.

Compounds of Formula I can also be formed as shown in Scheme XVIII. The compound (i) can be reacted with a halo-substituted heterocycle (ii) (e.g., 4-chloropyrido[3,2-d]pyrimidine [Anichem, cat #: N10204] and 7-chlorothiazolo[5,4-d]pyrimidine) [Combi-Blocks, cat #: QA2711] under basic conditions (e.g., NaH or CsCO₃ or K₂CO₃) to give a compound of Formula I (ii).

Methods

The compounds of the invention can modulate activity of one or more of various kinases including, for example, phosphoinositide 3-kinases (PI3Ks). The term “modulate” is meant to refer to an ability to increase or decrease the activity of one or more members of the PI3K family. Accordingly, the compounds of the invention can be used in methods of modulating a PI3K by contacting the PI3K with any one or more of the compounds or compositions described herein. In some embodiments, compounds of the present invention can act as inhibitors of one or more PI3Ks. In further embodiments, the compounds of the invention can be used to modulate activity of a PI3K in an individual in need of modulation of the receptor by administering a modulating amount of a compound of the invention, or a pharmaceutically acceptable salt thereof. In some embodiments, modulating is inhibiting.

Given that cancer cell growth and survival is impacted by multiple signaling pathways, the present invention is useful for treating disease states characterized by drug resistant kinase mutants. In addition, different kinase inhibitors, exhibiting different preferences in the kinases which they modulate the activities of, may be used in combination. This approach could prove highly efficient in treating disease states by targeting multiple signaling pathways, reduce the likelihood of drug-resistance arising in a cell, and reduce the toxicity of treatments for disease.

Kinases to which the present compounds bind and/or modulate (e.g., inhibit) include any member of the PI3K family. In some embodiments, the PI3K is PI3Kα, PI3Kβ, PI3Kγ, or PI3Kδ. In some embodiments, the PI3K is PI3Kγ or PI3Kδ. In some embodiments, the PI3K is PI3Kγ. In some embodiments, the PI3K is PI3Kδ. In some embodiments, the PI3K includes a mutation. A mutation can be a replacement of one amino acid for another, or a deletion of one or more amino acids. In such embodiments, the mutation can be present in the kinase domain of the PI3K.

In some embodiments, more than one compound of the invention is used to inhibit the activity of one kinase (e.g., PI3Kγ or PI3Kδ).

In some embodiments, more than one compound of the invention is used to inhibit more than one kinase, such as at least two kinases (e.g., PI3Kγ and PI3Kδ).

In some embodiments, one or more of the compounds is used in combination with another kinase inhibitor to inhibit the activity of one kinase (e.g., PI3Kγ or PI3Kδ).

In some embodiments, one or more of the compounds is used in combination with another kinase inhibitor to inhibit the activities of more than one kinase (e.g., PI3Kγ or PI3Kδ), such as at least two kinases.

The compounds of the invention can be selective. By “selective” is meant that the compound binds to or inhibits a kinase with greater affinity or potency, respectively, compared to at least one other kinase. In some embodiments, the compounds of the invention are selective inhibitors of PI3Kγ or PI3Kδ over PI3Kα and/or PI3Kβ. In some embodiments, the compounds of the invention are selective inhibitors of PI3Kδ (e.g., over PI3Kα, PI3Kβ and PI3Kγ). In some embodiments, the compounds of the invention are selective inhibitors of PI3Kγ (e.g., over PI3Kα, PI3Kβ and PI3Kδ). In some embodiments, selectivity can be at least about 2-fold, 5-fold, 10-fold, at least about 20-fold, at least about 50-fold, at least about 100-fold, at least about 200-fold, at least about 500-fold or at least about 1000-fold. Selectivity can be measured by methods routine in the art. In some embodiments, selectivity can be tested at the K_(m) ATP concentration of each enzyme. In some embodiments, the selectivity of compounds of the invention can be determined by cellular assays associated with particular PI3K kinase activity.

Another aspect of the present invention pertains to methods of treating a kinase (such as PI3K)-associated disease or disorder in an individual (e.g., patient) by administering to the individual in need of such treatment a therapeutically effective amount or dose of one or more compounds of the present invention or a pharmaceutical composition thereof. A PI3K-associated disease can include any disease, disorder or condition that is directly or indirectly linked to expression or activity of the PI3K, including overexpression and/or abnormal activity levels. In some embodiments, the disease can be linked to Akt (protein kinase B), mammalian target of rapamycin (mTOR), or phosphoinositide-dependent kinase 1 (PDK1). In some embodiments, the mTOR-related disease can be inflammation, atherosclerosis, psoriasis, restenosis, benign prostatic hypertrophy, bone disorders, pancreatitis, angiogenesis, diabetic retinopathy, atherosclerosis, arthritis, immunological disorders, kidney disease, or cancer. A PI3K-associated disease can also include any disease, disorder or condition that can be prevented, ameliorated, or cured by modulating PI3K activity. In some embodiments, the disease is characterized by the abnormal activity of PI3K. In some embodiments, the disease is characterized by mutant PI3K. In such embodiments, the mutation can be present in the kinase domain of the PI3K.

Examples of PI3K-associated diseases include immune-based diseases involving the system including, for example, rheumatoid arthritis, allergy, asthma, glomerulonephritis, lupus, or inflammation related to any of the above.

Further examples of PI3K-associated diseases include cancers such as breast, prostate, colon, endometrial, brain, bladder, skin, uterus, ovary, lung, pancreatic, renal, gastric, or hematological cancer.

In some embodiments, the hematological cancer is acute myeloblastic leukemia (AML) or chronic myeloid leukemia (CML), or B cell lymphoma.

Further examples of PI3K-associated diseases include lung diseases such as acute lung injury (ALI) and adult respiratory distress syndrome (ARDS).

Further examples of PI3K-associated diseases include osteoarthritis, restenosis, atherosclerosis, bone disorders, arthritis, diabetic retinopathy, psoriasis, benign prostatic hypertrophy, inflammation, angiogenesis, pancreatitis, kidney disease, inflammatory bowel disease, myasthenia gravis, multiple sclerosis, or Sjögren's syndrome, and the like.

Further examples of PI3K-associated diseases include idiopathic thrombocytopenic purpura (ITP), autoimmune hemolytic anemia (AIHA), vasculitis, systemic lupus erythematosus, lupus nephritis, pemphigus, membranous nephropathy, chronic lymphocytic leukemia (CLL), Non-Hodgkin lymphoma, hairy cell leukemia, Mantle cell lymphoma, Burkitt lymphoma, small lymphocytic lymphoma, follicular lymphoma, lymphoplasmacytic lymphoma, extranodal marginal zone lymphoma, activated B-cell like (ABC) diffuse large B cell lymphoma, or germinal center B cell (GCB) diffuse large B cell lymphoma.

In some embodiments, the ITP is relapsed ITP. In some embodiments, the ITP is refractory ITP.

In some embodiments, the method is a method of treating autoimmune hemolytic anemia (AIHA).

In some embodiments, the method is a method of treating vasculitis. In some embodiments, the vasculitis is Behçet's disease, Cogan's syndrome, giant cell arteritis, polymyalgia rheumatica (PMR), Takayasu's arteritis, Buerger's disease (thromboangiitis obliterans), central nervous system vasculitis, Kawasaki disease, polyarteritis nodosa, Churg-Strauss syndrome, mixed cryoglobulinemia vasculitis (essential or hepatitis C virus (HCV)-induced), Henoch-Schonlein purpura (HSP), hypersensitivity vasculitis, microscopic polyangiitis, Wegener's granulomatosis, or anti-neutrophil cytoplasm antibody associated (ANCA) systemic vasculitis (AASV). In some embodiments, the method is a method of treating nephritis.

In some embodiments, the method of treating non-Hodgkin lymphoma (NHL) is relapsed or refractory NHL or recucurrent follicular NHL.

In some embodiments, the present application provides a method of treating an aggressive lymphoma (e.g., germinal center B cell-like (GCB) or activated B cell-like (ABC)) in a patient, comprising administering a therapeutic amount of any of the compounds described herein to said patient, or a pharmaceutically acceptable salt thereof.

In some embodiments, the present application provides a method of treating acute myloid leukemia in a patient, comprising administering a therapeutic amount of any of the compounds described herein to said patient, or a pharmaceutically acceptable salt thereof.

As used herein, the term “contacting” refers to the bringing together of indicated moieties in an in vitro system or an in vivo system. For example, “contacting” a PI3K with a compound of the invention includes the administration of a compound of the present invention to an individual or patient, such as a human, having a PI3K, as well as, for example, introducing a compound of the invention into a sample containing a cellular or purified preparation containing the PI3K.

As used herein, the term “individual” or “patient,” used interchangeably, refers to any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and most preferably humans.

As used herein, the phrase “therapeutically effective amount” refers to the amount of active compound or pharmaceutical agent that elicits the biological or medicinal response that is being sought in a tissue, system, animal, individual or human by a researcher, veterinarian, medical doctor or other clinician. In some embodiments, the dosage of the compound, or a pharmaceutically acceptable salt thereof, administered to a patient or individual is about 1 mg to about 2 g, about 1 mg to about 1000 mg, about 1 mg to about 500 mg, about 1 mg to about 100 mg, about 1 mg to 50 mg, or about 50 mg to about 500 mg.

As used herein, the term “treating” or “treatment” refers to one or more of (1) preventing the disease; for example, preventing a disease, condition or disorder in an individual who may be predisposed to the disease, condition or disorder but does not yet experience or display the pathology or symptomotology of the disease; (2) inhibiting the disease; for example, inhibiting a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomotology of the disease, condition or disorder (i.e., arresting further development of the pathology and/or symptomotology); and (3) ameliorating the disease; for example, ameliorating a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomotology of the disease, condition or disorder (i.e., reversing the pathology and/or symptomotology) such as decreasing the severity of disease.

Combination Therapies

One or more additional pharmaceutical agents such as, for example, chemotherapeutics, anti-inflammatory agents, steroids, immunosuppressants, as well as Bcr-Abl, Flt-3, EGFR, HER2, JAK (e.g., JAK1 or JAK2), c-MET, VEGFR, PDGFR, cKit, IGF-1R, RAF, FAK, Akt mTOR, PIM, and AKT (e.g., AKT1, AKT2, or AKT3) kinase inhibitors such as, for example, those described in WO 2006/056399, or other agents such as, therapeutic antibodies can be used in combination with the compounds of the present invention for treatment of PI3K-associated diseases, disorders or conditions. The one or more additional pharmaceutical agents can be administered to a patient simultaneously or sequentially.

Example antibodies for use in combination therapy include but are not limited to Trastuzumab (e.g. anti-HER2), Ranibizumab (e.g. anti-VEGF-A), Bevacizumab (trade name Avastin, e.g. anti-VEGF, Panitumumab (e.g. anti-EGFR), Cetuximab (e.g. anti-EGFR), Rituxan (anti-CD20) and antibodies directed to c-MET.

One or more of the following agents may be used in combination with the compounds of the present invention and are presented as a non limiting list: a cytostatic agent, cisplatin, doxorubicin, taxotere, taxol, etoposide, irinotecan, camptostar, topotecan, paclitaxel, docetaxel, epothilones, tamoxifen, 5-fluorouracil, methoxtrexate, temozolomide, cyclophosphamide, SCH 66336, R115777, L778,123, BMS 214662, Iressa, Tarceva, antibodies to EGFR, Gleevec™, intron, ara-C, adriamycin, cytoxan, gemcitabine, Uracil mustard, Chlormethine, Ifosfamide, Melphalan, Chlorambucil, Pipobroman, Triethylenemelamine, Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine, Streptozocin, Dacarbazine, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, oxaliplatin, leucovirin, ELOXATIN™, Pentostatine, Vinblastine, Vincristine, Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Teniposide 17.alpha.-Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrolacetate, Methylprednisolone, Methyltestosterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, goserelin, Cisplatin, Carboplatin, Hydroxyurea, Amsacrine, Procarbazine, Mitotane, Mitoxantrone, Levamisole, Navelbene, Anastrazole, Letrazole, Capecitabine, Reloxafine, Droloxafine, Hexamethylmelamine, Avastin, herceptin, Bexxar, Velcade, Zevalin, Trisenox, Xeloda, Vinorelbine, Porfimer, Erbitux, Liposomal, Thiotepa, Altretamine, Melphalan, Trastuzumab, Lerozole, Fulvestrant, Exemestane, Fulvestrant, Ifosfomide, Rituximab, C225, Campath, Clofarabine, cladribine, aphidicolon, rituxan, sunitinib, dasatinib, tezacitabine, Sml1, fludarabine, pentostatin, triapine, didox, trimidox, amidox, 3-AP, MDL-101,731, bendamustine (Treanda), ofatumumab, and GS-1101 (also known as CAL-101).

Example chemotherapeutics include proteosome inhibitors (e.g., bortezomib), thalidomide, revlimid, and DNA-damaging agents such as melphalan, doxorubicin, cyclophosphamide, vincristine, etoposide, carmustine, and the like.

Example steroids include coriticosteroids such as dexamethasone or prednisone.

Example Bcr-Abl inhibitors include the compounds, and pharmaceutically acceptable salts thereof, of the genera and species disclosed in U.S. Pat. No. 5,521,184, WO 04/005281, and U.S. Ser. No. 60/578,491.

Example suitable Flt-3 inhibitors include compounds, and their pharmaceutically acceptable salts, as disclosed in WO 03/037347, WO 03/099771, and WO 04/046120.

Example suitable RAF inhibitors include compounds, and their pharmaceutically acceptable salts, as disclosed in WO 00/09495 and WO 05/028444.

Example suitable FAK inhibitors include compounds, and their pharmaceutically acceptable salts, as disclosed in WO 04/080980, WO 04/056786, WO 03/024967, WO 01/064655, WO 00/053595, and WO 01/014402.

Example suitable mTOR inhibitors include compounds, and their pharmaceutically acceptable salts, as disclosed in WO 2011/025889.

In some embodiments, the compounds of the invention can be used in combination with one or more other kinase inhibitors including imatinib, particularly for treating patients resistant to imatinib or other kinase inhibitors.

In some embodiments, the compounds of the invention can be used in combination with a chemotherapeutic in the treatment of cancer, such as multiple myeloma, and may improve the treatment response as compared to the response to the chemotherapeutic agent alone, without exacerbation of its toxic effects. Examples of additional pharmaceutical agents used in the treatment of multiple myeloma, for example, can include, without limitation, melphalan, melphalan plus prednisone [MP], doxorubicin, dexamethasone, and Velcade (bortezomib).

Further additional agents used in the treatment of multiple myeloma include Bcr-Abl, Flt-3, RAF and FAK kinase inhibitors. Additive or synergistic effects are desirable outcomes of combining a PI3K inhibitor of the present invention with an additional agent. Furthermore, resistance of multiple myeloma cells to agents such as dexamethasone may be reversible upon treatment with the PI3K inhibitor of the present invention. The agents can be combined with the present compound in a single or continuous dosage form, or the agents can be administered simultaneously or sequentially as separate dosage forms.

In some embodiments, a corticosteroid such as dexamethasone is administered to a patient in combination with the compounds of the invention where the dexamethasone is administered intermittently as opposed to continuously.

In some further embodiments, combinations of the compounds of the invention with other therapeutic agents can be administered to a patient prior to, during, and/or after a bone marrow transplant or stem cell transplant.

Pharmaceutical Formulations and Dosage Forms

When employed as pharmaceuticals, the compounds of the invention can be administered in the form of pharmaceutical compositions. These compositions can be prepared in a manner well known in the pharmaceutical art, and can be administered by a variety of routes, depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including transdermal, epidermal, ophthalmic and to mucous membranes including intranasal, vaginal and rectal delivery), pulmonary (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal or intranasal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal intramuscular or injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Parenteral administration can be in the form of a single bolus dose, or may be, for example, by a continuous perfusion pump. Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.

This invention also includes pharmaceutical compositions which contain, as the active ingredient, the compound of the invention or a pharmaceutically acceptable salt thereof, in combination with one or more pharmaceutically acceptable carriers (excipients). In some embodiments, the composition is suitable for topical administration. In making the compositions of the invention, the active ingredient is typically mixed with an excipient, diluted by an excipient or enclosed within such a carrier in the form of, for example, a capsule, sachet, paper, or other container. When the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.

In preparing a formulation, the active compound can be milled to provide the appropriate particle size prior to combining with the other ingredients. If the active compound is substantially insoluble, it can be milled to a particle size of less than 200 mesh. If the active compound is substantially water soluble, the particle size can be adjusted by milling to provide a substantially uniform distribution in the formulation, e.g. about 40 mesh.

The compounds of the invention may be milled using known milling procedures such as wet milling to obtain a particle size appropriate for tablet formation and for other formulation types. Finely divided (nanoparticulate) preparations of the compounds of the invention can be prepared by processes known in the art, e.g., see International App. No. WO 2002/000196.

Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, and methyl cellulose. The formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates; sweetening agents; and flavoring agents. The compositions of the invention can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.

The compositions can be formulated in a unit dosage form, each dosage containing from about 5 to about 1000 mg (1 g), more usually about 100 to about 500 mg, of the active ingredient. The term “unit dosage forms” refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.

In some embodiments, the compositions of the invention contain from about 5 to about 50 mg of the active ingredient. One having ordinary skill in the art will appreciate that this embodies compositions containing about 5 to about 10, about 10 to about 15, about 15 to about 20, about 20 to about 25, about 25 to about 30, about 30 to about 35, about 35 to about 40, about 40 to about 45, or about 45 to about 50 mg of the active ingredient.

In some embodiments, the compositions of the invention contain from about 50 to about 500 mg of the active ingredient. One having ordinary skill in the art will appreciate that this embodies compositions containing about 50 to about 100, about 100 to about 150, about 150 to about 200, about 200 to about 250, about 250 to about 300, about 350 to about 400, or about 450 to about 500 mg of the active ingredient.

In some embodiments, the compositions of the invention contain from about 500 to about 1000 mg of the active ingredient. One having ordinary skill in the art will appreciate that this embodies compositions containing about 500 to about 550, about 550 to about 600, about 600 to about 650, about 650 to about 700, about 700 to about 750, about 750 to about 800, about 800 to about 850, about 850 to about 900, about 900 to about 950, or about 950 to about 1000 mg of the active ingredient.

Similar dosages may be used of the compounds described herein in the methods and uses of the invention.

The active compound can be effective over a wide dosage range and is generally administered in a pharmaceutically effective amount. It will be understood, however, that the amount of the compound actually administered will usually be determined by a physician, according to the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.

For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention. When referring to these preformulation compositions as homogeneous, the active ingredient is typically dispersed evenly throughout the composition so that the composition can be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation is then subdivided into unit dosage forms of the type described above containing from, for example, about 0.1 to about 1000 mg of the active ingredient of the present invention.

The tablets or pills of the present invention can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.

The liquid forms in which the compounds and compositions of the present invention can be incorporated for administration orally or by injection include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical vehicles.

Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra. In some embodiments, the compositions are administered by the oral or nasal respiratory route for local or systemic effect. Compositions can be nebulized by use of inert gases. Nebulized solutions may be breathed directly from the nebulizing device or the nebulizing device can be attached to a face mask, tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions can be administered orally or nasally from devices which deliver the formulation in an appropriate manner.

Topical formulations can contain one or more conventional carriers. In some embodiments, ointments can contain water and one or more hydrophobic carriers selected from, for example, liquid paraffin, polyoxyethylene alkyl ether, propylene glycol, white Vaseline, and the like. Carrier compositions of creams can be based on water in combination with glycerol and one or more other components, e.g. glycerinemonostearate, PEG-glycerinemonostearate and cetylstearyl alcohol. Gels can be formulated using isopropyl alcohol and water, suitably in combination with other components such as, for example, glycerol, hydroxyethyl cellulose, and the like. In some embodiments, topical formulations contain at least about 0.1, at least about 0.25, at least about 0.5, at least about 1, at least about 2, or at least about 5 wt % of the compound of the invention. The topical formulations can be suitably packaged in tubes of, for example, 100 g which are optionally associated with instructions for the treatment of the select indication, e.g., psoriasis or other skin condition.

The amount of compound or composition administered to a patient will vary depending upon what is being administered, the purpose of the administration, such as prophylaxis or therapy, the state of the patient, the manner of administration, and the like. In therapeutic applications, compositions can be administered to a patient already suffering from a disease in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications. Effective doses will depend on the disease condition being treated as well as by the judgment of the attending clinician depending upon factors such as the severity of the disease, the age, weight and general condition of the patient, and the like.

The compositions administered to a patient can be in the form of pharmaceutical compositions described above. These compositions can be sterilized by conventional sterilization techniques, or may be sterile filtered. Aqueous solutions can be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration. The pH of the compound preparations typically will be between 3 and 11, more preferably from 5 to 9 and most preferably from 7 to 8. It will be understood that use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of pharmaceutical salts.

The therapeutic dosage of a compound of the present invention can vary according to, for example, the particular use for which the treatment is made, the manner of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician. The proportion or concentration of a compound of the invention in a pharmaceutical composition can vary depending upon a number of factors including dosage, chemical characteristics (e.g., hydrophobicity), and the route of administration. For example, the compounds of the invention can be provided in an aqueous physiological buffer solution containing about 0.1 to about 10% w/v of the compound for parenteral administration. Some typical dose ranges are from about 1 μg/kg to about 1 g/kg of body weight per day. In some embodiments, the dose range is from about 0.01 mg/kg to about 100 mg/kg of body weight per day. The dosage is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, formulation of the excipient, and its route of administration. Effective doses can be extrapolated from dose-response curves derived from in vitro or animal model test systems.

The compositions of the invention can further include one or more additional pharmaceutical agents such as a chemotherapeutic, steroid, anti-inflammatory compound, or immunosuppressant, examples of which are listed herein.

Labeled Compounds and Assay Methods

Another aspect of the present invention relates to labeled compounds of the invention (radio-labeled, fluorescent-labeled, etc.) that would be useful not only in imaging techniques but also in assays, both in vitro and in vivo, for localizing and quantitating PI3K in tissue samples, including human, and for identifying PI3K ligands by inhibition binding of a labeled compound. Accordingly, the present invention includes PI3K assays that contain such labeled compounds.

The present invention further includes isotopically-labeled compounds of the invention. An “isotopically” or “radio-labeled” compound is a compound of the invention where one or more atoms are replaced or substituted by an atom having an atomic mass or mass number different from the atomic mass or mass number typically found in nature (i.e., naturally occurring). Suitable radionuclides that may be incorporated in compounds of the present invention include but are not limited to ³H (also written as T for tritium), ¹¹C, ¹³C, ¹⁴C, ¹³N, ¹⁵N, ¹⁵O, ¹⁷O, ¹⁸O, ¹⁸F, ³⁵S, ³⁶Cl, ⁸²Br, ⁷⁵Br, ⁷⁶Br, ⁷⁷Br, ¹²³I, ¹²⁴I, ¹²⁵I and ¹³¹I. The radionuclide that is incorporated in the instant radio-labeled compounds will depend on the specific application of that radio-labeled compound. For example, for in vitro PI3K labeling and competition assays, compounds that incorporate ³H, ¹⁴C, ⁸²Br, ¹²⁵I, ¹³¹I, ³⁵S or will generally be most useful. For radio-imaging applications ¹¹C, ¹⁸F, ¹²⁵I, ¹²³I, ¹²⁴I, ¹³¹I, ⁷⁵Br, ⁷⁶Br or ⁷⁷Br will generally be most useful.

It is understood that a “radio-labeled” or “labeled compound” is a compound that has incorporated at least one radionuclide. In some embodiments the radionuclide is selected from the group consisting of ³H, ¹⁴C, ¹²⁵I, ³⁵S and ⁸²Br. In some embodiments, one or more H atoms for any compound described herein is each replaced by a deuterium atom.

The present invention can further include synthetic methods for incorporating radio-isotopes into compounds of the invention. Synthetic methods for incorporating radio-isotopes into organic compounds are well known in the art, and an ordinary skill in the art will readily recognize the methods applicable for the compounds of invention.

A labeled compound of the invention can be used in a screening assay to identify/evaluate compounds. For example, a newly synthesized or identified compound (i.e., test compound) which is labeled can be evaluated for its ability to bind a PI3K by monitoring its concentration variation when contacting with the PI3K, through tracking of the labeling. For example, a test compound (labeled) can be evaluated for its ability to reduce binding of another compound which is known to bind to a PI3K (i.e., standard compound). Accordingly, the ability of a test compound to compete with the standard compound for binding to the PI3K directly correlates to its binding affinity. Conversely, in some other screening assays, the standard compound is labeled and test compounds are unlabeled. Accordingly, the concentration of the labeled standard compound is monitored in order to evaluate the competition between the standard compound and the test compound, and the relative binding affinity of the test compound is thus ascertained.

Kits

The present invention also includes pharmaceutical kits useful, for example, in the treatment or prevention of PI3K-associated diseases or disorders, such as cancer, which include one or more containers containing a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention. Such kits can further include, if desired, one or more of various conventional pharmaceutical kit components, such as, for example, containers with one or more pharmaceutically acceptable carriers, additional containers, etc., as will be readily apparent to those skilled in the art. Instructions, either as inserts or as labels, indicating quantities of the components to be administered, guidelines for administration, and/or guidelines for mixing the components, can also be included in the kit.

The invention will be described in greater detail by way of specific examples. The following examples are offered for illustrative purposes, and are not intended to limit the invention in any manner. Those of skill in the art will readily recognize a variety of non-critical parameters which can be changed or modified to yield essentially the same results. The compounds of the Examples have been found to be PI3K inhibitors according to at least one assay described herein.

EXAMPLES

The example compounds below containing one or more chiral centers were obtained in racemate form or as isomeric mixtures, unless otherwise specified. Salt stoichiometry which is indicated in any of the products below is meant only to indicate a probable stoichiometry, and should not be construed to exclude the possible formation of salts in other stoichiometries.

Example 1. tert-Butyl 9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-6-methyl-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate

Step 1. tert-Butyl [2-(6-acetyl-2-bromo-4-chloro-3-methylphenoxy)ethyl]carbamate

A suspension of 1-(3-bromo-5-chloro-2-hydroxy-4-methylphenyl)ethanone (8.0 g, 30 mmol) in methylene chloride (304 mL) was heated with a heat gun to dissolve the solids and cooled to 0° C. To the mixture was added triphenylphosphine (11 g, 43 mmol) and tert-butyl (2-hydroxyethyl)carbamate (9.4 mL, 61 mmol). Diisopropyl azodicarboxylate (8.4 mL, 43 mmol) was added dropwise. The mixture was stirred for 23 hours at room temperature. The reaction mixture was poured into water and extracted with methylene chloride. The organic layer was separated, washed with brine, dried with sodium sulfate, filtered, and concentrated. The oil was dissolved in methylene chloride and was purified on silica using ethyl acetate in hexanes (0-25%) to give the desired compound (7.3 g, 59%). LCMS calculated for C₁₆H₂₁BrClNO₄Na (M+Na)⁺: m/z=428.0, 430.0; found: 428.0, 430.0.

Step 2. tert-Butyl [2-(6-acetyl-4-chloro-3-methyl-2-vinylphenoxy)ethyl]carbamate

A mixture of tert-butyl [2-(6-acetyl-2-bromo-4-chloro-3-methylphenoxy)ethyl]carbamate (6.5 g, 16 mmol), 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane (3.3 mL, 19 mmol), [1,1′-bis(diphenylphosphino)ferrocene]-dichloropalladium(II), complex with dichloromethane (1:1) (600 mg, 0.8 mmol) and potassium carbonate (6.6 g, 48 mmol) in 1,4-dioxane (100 mL), and water (50 mL) was heated at 80° C. for 3 hours and 50° C. overnight. The reaction mixture was cooled to room temperature and extracted with ethyl acetate (3×10 mL). The organic layers were combined and washed with brine, dried over magnesium sulfate, filtered and concentrated under reduced pressure. The residue was purified on a silica gel with ethyl acetate in hexanes (0-25%) to afford the desired compound (4.1 g, 72%). LCMS calculated for C₁₈H₂₄ClNO₄Na (M+Na)+: m/z=376.1; found: 376.0.

Step 3. tert-Butyl [2-(6-acetyl-4-chloro-2-formyl-3-methylphenoxy)ethyl]carbamate

tert-Butyl [2-(6-acetyl-4-chloro-3-methyl-2-vinylphenoxy)ethyl]carbamate (4.1 g, 12 mmol) was dissolved in tetrahydrofuran (300 mL) and 0.157 M osmium tetraoxide in water (10 mL) was added followed by a solution of sodium metaperiodate (7.4 g, 35 mmol) in water (20 mL). The reaction was stirred at 60° C. for 2 hours. Additional 0.157 M osmium tetraoxide in water (10 mL) and a solution of sodium metaperiodate (7.4 g, 35 mmol) in water (20 mL) were added and the mixture was heated at 60° C. for 2 more hours. The mixture was poured into ethyl acetate and washed with water, brine, dried over sodium sulfate, filtered and evaporated. Purification on silica gel using ethyl acetate in hexanes (0-12%) gave the desired compound (3.0 g, 73%) (note: elutes as 2 separate peaks in both normal and reversed phase chromatography). LCMS calculated for C₁₇H₂₂ClNO₅Na (M+Na)⁺: m/z=378.1; found: 378.0.

Step 4. 1-(7-Chloro-6-methyl-2,3-dihydro-1,4-benzoxazepin-9-yl)ethanone

tert-Butyl [2-(6-acetyl-4-chloro-2-formyl-3-methylphenoxy)ethyl]carbamate (270 mg, 0.76 mmol) was stirred in 4.0 M hydrogen chloride in dioxane (5.0 mL) at room temperature for 1 hour and evaporated. Tetrahydrofuran was added and the mixture was evaporated to give the desired compound (180 mg, 100%). LCMS calculated for C₁₂H₁₃ClNO₂ (M+H)⁺: m/z=238.1; found: 238.0.

Step 5. 1-(7-Chloro-6-methyl-2,3,4,5-tetrahydro-1,4-benzoxazepin-9-yl)ethanol

1-(7-Chloro-6-methyl-2,3-dihydro-1,4-benzoxazepin-9-yl)ethanone (630 mg, 2.6 mmol) was stirred in methanol (20 mL) and cooled to 0° C. Sodium tetrahydroborate (150 mg, 4.0 mmol) was added. The mixture was stirred for 1 hour at room temperature and evaporated. The mixture was extracted with ethyl acetate, washed with saturated sodium bicarbonate, brine, dried over sodium sulfate, filtered and evaporated gave the desired compound (580 mg, 90%). LCMS calculated for C₁₂H₁₇ClNO₂ (M+H)⁺: m/z=242.1; found: 242.0.

Step 6. tert-Butyl 7-chloro-9-(1-hydroxyethyl)-6-methyl-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate

1-(7-Chloro-6-methyl-2,3,4,5-tetrahydro-1,4-benzoxazepin-9-yl)ethanol (250 mg, 1.0 mmol) and di-tert-butyldicarbonate (220 mg, 1.0 mmol) were stirred in tetrahydrofuran (12 mL) and N,N-diisopropylethylamine (1.3 mL, 7.2 mmol) was added. The mixture was stirred at room temperature for 1 hour. The mixture was diluted with saturated bicarbonate and extracted with ethyl acetate. The extracts were washed with brine, dried over sodium sulfate, filtered and evaporated to give the crude. Purification on silica gel using ethyl acetate in hexanes 0-35% gave the desired compound (89%). LCMS calculated for C₁₇H₂₄ClNO₄Na (M+Na)⁺: m/z=364.1; found: 364.0.

Step 7. tert-Butyl 7-chloro-9-(1-chloroethyl)-6-methyl-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate

A mixture of tert-butyl 7-chloro-9-(1-hydroxyethyl)-6-methyl-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (280 mg, 0.82 mmol) and N,N-dimethylformamide (30 μL) in methylene chloride (6 mL) was stirred and thionyl chloride (120 μL, 1.7 mmol) was added dropwise. The mixture was stirred at room temperature for 20 minutes. The mixture was diluted with methylene chloride, washed with saturated sodium bicarbonate, water, brine, dried over sodium sulfate, filtered and concentrated to give the desired product (295 mg, 100%).

Step 8. tert-Butyl 9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-6-methyl-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate

Cesium carbonate (500 mg, 2 mmol) was added to a mixture of 3-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (150 mg, 0.98 mmol) in N,N-dimethylformamide (30 mL) and stirred for 10 minutes. To this was added tert-butyl 7-chloro-9-(1-chloroethyl)-6-methyl-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (290 mg, 0.82 mmol) in N,N-dimethylformamide (1 mL) and the reaction was stirred at 80° C. for 1 hour. The mixture was diluted with ethyl acetate and washed with water and brine. The extracts were dried over sodium sulfate, filtered and evaporated. The crude was dissolved in methylene chloride and filtered to remove insoluble material (unwanted regioisomer). Purification on silica gel using ethyl acetate in hexanes (0-100%) followed by methanol in ethyl acetate (0-15%) gave the desired compound (240 mg, 62%). LCMS calculated for C₂₃H₃₀ClN₆O₃(M+H)⁺: m/z=473.2; found: 473.2. ¹H NMR (300 MHz, CD₃OD): δ 8.14 (s, 1H), 7.29 (m, 1H), 6.32 (m, 1H), 4.70 (m, 1H), 4.40 (m, 1H), 3.83 (m, 2H), 3.57 (m, 2H), 2.58 (s, 3H), 2.48 (m, 3H), 1.78 (m, 3H), 1.39 (m, 9H).

Example 2. 1-[1-(7-Chloro-6-methyl-2,3,4,5-tetrahydro-1,4-benzoxazepin-9-yl)ethyl]-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine bis(trifluoroacetate)

tert-Butyl 9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-6-methyl-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (10 mg, 0.02 mmol) was stirred in 4 N HCl in dioxane (1 mL), and then the solvent was evaporated. Purification by preparative LCMS (pH 2) gave the desired compound (1.8 mg, 7%). LCMS calculated for C₁₈H₂₂ClN₆₀ (M+H)⁺: m/z=373.2; found: 373.1.

Example 3. tert-Butyl 3-[9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-6-methyl-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]azetidine-1-carboxylate

tert-Butyl 9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-6-methyl-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (100 mg, 0.2 mmol) was treated with 4 N HCl in dioxane (1 mL), and then the solvent was evaporated. The residue was stirred in methanol (5 mL) and tert-butyl 3-oxoazetidine-1-carboxylate (140 mg, 0.84 mmol) was added. Sodium cyanoborohydride (120 mg, 1.9 mmol) was added and the mixture was warmed to 60° C. for 1.5 hours. Purification by preparative LCMS (pH 10) gave the desired compound (3.3 mg, 10%). LCMS calculated for C₂₆H₃₅ClN₇O₃(M+H)⁺: m/z=528.2; found: 528.3. ¹H NMR (300 MHz, CD₃OD): δ 8.14 (s, 1H), 7.33 (s, 1H), 6.33 (m, 1H), 4.00 (m, 2H), 3.82 (m, 1H), 3.74 (m, 2H), 3.63 (m, 3H), 3.41 (m, 1H), 2.76 (m, 2H), 2.58 (s, 3H), 2.37 (s, 3H), 1.79 (m, 3H), 1.42 (s, 9H).

Example 4. 1-{1-[4-(1-Acetylazetidin-3-yl)-7-chloro-6-methyl-2,3,4,5-tetrahydro-1,4-benzoxazepin-9-yl]ethyl}-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

tert-Butyl 3-[9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-6-methyl-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]azetidine-1-carboxylate (15 mg, 0.035 mmol) was treated with 4 N HCl in dioxane (1 mL), and then the solvent was evaporated. The residue was stirred in N,N-dimethylformamide (0.5 mL) with N,N-diisopropylethylamine (10 μL, 0.06 mmol) and acetic anhydride (20 μL, 0.2 mmol) was added. The mixture was stirred for 5 minutes and diluted with methanol. Purification by preparative LCMS (pH 10) gave the desired compound (2.2 mg, 13%). LCMS calculated for C₂₃H₂₉ClN₇O₂(M+H)⁺: m/z=470.2; found: 470.2. ¹H NMR (300 MHz, CD₃OD): δ 8.14 (s, 1H), 7.33 (s, 1H), 6.33 (m, 1H), 4.27 (m, 1H), 4.02 (m, 2H), 3.80 (m, 1H), 3.72 (m, 1H), 3.69 (m, 3H), 3.48 (m, 1H), 2.79 (m, 2H), 2.58 (s, 3H), 2.38 (s, 3H), 1.82 (m, 3H), 1.77 (m, 3H).

Example 5. 1-[1-(7-Chloro-4-cyclobutyl-6-methyl-2,3,4,5-tetrahydro-1,4-benzoxazepin-9-yl)ethyl]-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine bis(trifluoroacetate)

The desired compound was prepared according to the procedure of Example 3, using cyclobutanone instead of tert-butyl 3-oxoazetidine-1-carboxylate as the starting material in 50% yield. LCMS calculated for C₂₂H₂₈ClN₆O (M+H)⁺: m/z=427.2; found: 427.0. ¹H NMR (300 MHz, CD₃OD): δ 8.31 (s, 1H), 7.61 (s, 1H), 6.47 (m, 1H), 4.37 (s, 2H), 3.89 (m, 1H), 3.48 (m, 2H), 2.64 (s, 3H), 2.45 (m, 4H), 2.28 (m, 1H), 1.86 (m, 3H).

Example 6. 1-[1-(7-Chloro-4-cyclopentyl-6-methyl-2,3,4,5-tetrahydro-1,4-benzoxazepin-9-yl)ethyl]-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine bis(trifluoroacetate)

The desired compound was prepared according to the procedure of Example 3, using cyclopentanone instead of tert-butyl 3-oxoazetidine-1-carboxylate as the starting material in 50% yield. LCMS calculated for C₂₃H₃₀ClN₆₀ (M+H)⁺: m/z=441.2; found: 441.0. ¹H NMR (300 MHz, CD₃OD): δ 8.31 (s, 1H), 7.60 (s, 1H), 6.47 (m, 1H), 4.52 (br s, 2H), 3.79 (m, 1H), 3.62 (m, 2H), 2.63 (s, 3H), 2.47 (s, 3H), 2.03 (m, 3H), 1.81 (m, 10H).

Example 7. 1-[1-(7-Chloro-4-cyclohexyl-6-methyl-2,3,4,5-tetrahydro-1,4-benzoxazepin-9-yl)ethyl]-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine bis(trifluoroacetate)

The desired compound was prepared according to the procedure of Example 3, using cyclohexanone instead of tert-butyl 3-oxoazetidine-1-carboxylate as the starting material in 20% yield. LCMS calculated for C₂₄H₃₂ClN₆O (M+H)⁺: m/z=455.2; found: 455.2. ¹H NMR (300 MHz, CD₃OD): δ 8.30 (s, 1H), 7.59 (s, 1H), 6.48 (m, 1H), 4.60 (m, 2H), 4.48 (m, 2H), 3.75 (m, 1H), 3.47 (m, 2H), 2.63 (s, 3H), 2.48 (s, 3H), 2.18 (m, 2H), 2.03 (m, 2H), 1.85 (m, 3H), 1.73 (m, 3H), 1.47 (m, 2H), 1.29 (m, 1H).

Example 8. 1-{1-[7-Chloro-4-(4-methoxycyclohexyl)-6-methyl-2,3,4,5-tetrahydro-1,4-benzoxazepin-9-yl]ethyl}-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine bis(trifluoroacetate)

The desired compound was prepared according to the procedure of Example 3, using 4-methoxycyclohexanone instead of tert-butyl 3-oxoazetidine-1-carboxylate as the starting material in 10% yield. LCMS calculated for C₂₅H₃₄ClN₆O₂(M+H)⁺: m/z=485.2; found: 485.3. ¹H NMR (300 MHz, CD₃OD): δ 8.51 (s, 1H), 7.56 (s, 1H), 6.48 (m, 1H), 4.60 (m, 2H), 4.48 (m, 2H), 3.75 (m, 1H), 3.47 (m, 2H), 3.30 (m, 4H), 2.62 (s, 3H), 2.48 (s, 3H), 2.20 (m, 2H), 1.85 (m, 6H), 1.60 (m, 2H), 1.29 (m, 1H).

Example 9. 1-[1-(7-Chloro-4,6-dimethyl-2,3,4,5-tetrahydro-1,4-benzoxazepin-9-yl)ethyl]-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine bis(trifluoroacetate)

tert-Butyl 9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-6-methyl-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (10 mg, 0.02 mmol) (treated with 4 N HCl in dioxane, and then the solvent was evaporated) was stirred in 3.0 M formaldehyde in water (0.5 mL, 2 mmol) and formic acid (0.5 mL, 10 mmol) was added. The mixture was heated to 90° C. for 10 minutes. Purification by preparative LCMS (pH 2) gave the desired compound (3.0 mg, 20%). LCMS calculated for C₁₉H₂₄ClN₆O (M+H)⁺: m/z=387.2; found: 387.1. ¹H NMR (300 MHz, CD₃OD): δ 8.30 (s, 1H), 7.60 (s, 1H), 6.47 (m, 1H), 4.55 (m, 2H), 4.25 (m, 1H), 3.60 (m, 3H), 3.03 (s, 3H), 2.64 (s, 3H), 2.47 (s, 3H), 1.85 (m, 3H).

Example 10. 1-[1-(7-Chloro-4-isopropyl-6-methyl-2,3,4,5-tetrahydro-1,4-benzoxazepin-9-yl)ethyl]-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine bis(trifluoroacetate)

tert-Butyl 9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-6-methyl-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (15 mg, 0.032 mmol) (treated with 4 N HCl in dioxane, and then the solvent was evaporated) was stirred in acetone (1.0 mL, 14 mmol) and sodium cyanoborohydride (6.0 mg, 0.095 mmol) was added. The mixture was stirred overnight. Purification by preparative LCMS (pH 2) gave the desired compound (7.0 mg, 34%). LCMS calculated for C₂₁H₂₈ClN₆O (M+H)⁻: m/z=415.2; found: 415.1. ¹H NMR (300 MHz, CD₃OD): δ 8.31 (s, 1H), 7.59 (s, 1H), 6.47 (br s, 1H), 4.49 (m, 4H), 3.80 (m, 2H), 3.50 (m, 1H), 2.64 (s, 3H), 2.48 (s, 3H), 1.86 (m, 3H), 1.46 (m, 6H).

Example 11. [9-[1-(4-Amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-6-methyl-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]acetonitrile bis(trifluoroacetate)

tert-Butyl 9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-6-methyl-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (10 mg, 0.02 mmol) (treated with 4 N HCl in dioxane, and then the solvent was evaporated) was stirred in N-methylpyrrolidinone (1.0 mL) and N,N-diisopropylethylamine (0.0082 g, 0.063 mmol) was added. Bromoacetonitrile (5.1 mg, 0.042 mmol) was added and the mixture was warmed to 80° C. for 1 hour. Purification by preparative LCMS (pH 2) gave the desired compound (4.9 mg, 40%). LCMS calculated for C₂₀H₂₃ClN₇O (M+H)⁺: m/z=412.2; found: 412.1. ¹H NMR (300 MHz, CD₃OD): δ 8.30 (s, 1H), 7.38 (s, 1H), 6.46 (m, 1H), 4.03 (m, 1H), 3.91 (s, 2H), 3.81 (m, 3H), 3.05 (m, 2H), 2.65 (s, 3H), 2.41 (s, 3H), 1.83 (m, 3H).

Example 12. 3-[9-[1-(4-Amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-6-methyl-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-3-oxopropanenitrile Trifluoroacetate

tert-Butyl 9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-6-methyl-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (10 mg, 0.02 mmol) (treated with 4 N HCl in dioxane, and then the solvent was evaporated) was stirred in N-methylpyrrolidinone (1.0 mL) and N,N-diisopropylethylamine (0.0082 g, 0.063 mmol) was added. 3-[(2,5-Dioxopyrrolidin-1-yl)oxy]-3-oxopropanenitrile (0.008 g, 0.042 mmol) was added and the mixture was warmed to 80° C. for 1 hour. Purification by preparative LCMS (pH 2) gave the desired compound (1.8 mg, 20%). LCMS calculated for C₂₁H₂₃ClN₇O₂ (M+H)⁺: m/z=440.2; found: 440.3. ¹H NMR (300 MHz, CD₃OD): δ 8.28 (s, 1H), 7.38 (s, 1H), 6.45 (m, 1H), 4.88 (m, 1H), 4.54 (m, 1H), 3.82 (m, 5H), 2.65 (s, 3H), 2.56 (s, 3H), 1.83 (m, 3H).

Example 13. 1-{1-[7-Chloro-6-methyl-4-(methylsulfonyl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-9-yl]ethyl}-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine Trifluoroacetate

tert-Butyl 9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-6-methyl-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (10 mg, 0.02 mmol) (treated with 4 N HCl in dioxane, and then the solvent was evaporated) was stirred in tetrahydrofuran (0.5 mL) with N,N-diisopropylethylamine (18 μL, 0.10 mmol) and methanesulfonyl chloride (1.6 μL, 0.021 mmol) was added. The mixture was stirred at room temperature for 20 minutes. Purification by preparative LCMS (pH 2) gave the desired compound (6.3 mg, 53%). LCMS calculated for C₁₉H₂₄ClN₆O₃S (M+H)⁺: m/z=451.1; found: 451.0. ¹H NMR (300 MHz, CD₃OD): δ 8.29 (s, 1H), 7.41 (s, 1H), 6.47 (m, 1H), 4.62 (m, 1H), 4.43 (m, 1H), 4.12 (m, 1H), 3.74 (m, 3H), 2.81 (s, 3H), 2.65 (s, 3H), 2.44 (s, 3H), 1.83 (m, 3H).

Example 14. 1-{1-[7-Chloro-6-methyl-4-(phenylsulfonyl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-9-yl]ethyl}-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine Trifluoroacetate

The desired compound was prepared according to the procedure of Example 13, using bezenesulfonyl chloride instead of methanesulfonyl chloride in 53% yield. LCMS calculated for C₂₄H₂₆ClN₆O₃S (M+H)⁺: m/z=513.1; found: 513.0. ¹H NMR (300 MHz, CD₃OD): δ 8.26 (s, 1H), 7.70 (m, 2H), 7.49 (m, 4H), 6.36 (m, 1H), 4.60 (m, 1H), 4.33 (m, 1H), 3.97 (m, 1H), 3.62 (m, 3H), 2.65 (s, 3H), 2.51 (s, 3H), 1.77 (m, 3H).

Example 15. 9-[1-(4-Amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-6-methyl-N-(2-methylphenyl)-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxamide Trifluoroacetate

The desired compound was prepared according to the procedure of Example 13, using 1-isocyanato-2-methylbenzene instead of methanesulfonyl chloride in 27% yield. LCMS calculated for C₂₆H₂₉ClN₇O₂(M+H)⁺: m/z=506.2; found: 506.0. ¹H NMR (300 MHz, CD₃OD): δ 8.29 (s, 1H), 7.36 (s, 1H), 7.08 (m, 4H), 6.49 (m, 1H), 4.80 (m, 1H), 4.60 (m, 1H), 4.12 (m, 1H), 3.88 (m, 3H), 2.65 (s, 3H), 2.47 (s, 3H), 1.95 (s, 3H), 1.84 (m, 3H).

Example 16. 1-[1-(4-Benzoyl-7-chloro-6-methyl-2,3,4,5-tetrahydro-1,4-benzoxazepin-9-yl)ethyl]-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine Trifluoroacetate

The desired compound was prepared according to the procedure of Example 13, using benzoyl chloride instead of methanesulfonyl chloride, Purification by preparative LCMS (pH 2) gave the desired compound (2.1 mg, 17%). LCMS calculated for C₂₅H₂₆ClN₆O₂(M+H)⁺: m/z=477.2; found: 477.0. ¹H NMR (300 MHz, CD₃OD): δ 8.27 (s, 1H), 7.42 (s, 6H), 6.46 (m, 1H), 4.89 (m, 1H), 4.79 (m, 1H), 4.00 (m, 1H), 3.77 (m, 3H), 2.64 (m, 6H), 1.83 (m, 3H).

Example 17. 1-(1-{7-Chloro-4-[(3,5-dimethylisoxazol-4-yl)sulfonyl]-6-methyl-2,3,4,5-tetrahydro-1,4-benzoxazepin-9-yl}yl)ethyl)-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine Trifluoroacetate

tert-Butyl 9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-6-methyl-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (10 mg, 0.02 mmol) (treated with 4 N HCl in dioxane, and then the solvent was evaporated) was stirred in methylene chloride (1.0 mL) with N,N-diisopropylethylamine (11 μL, 0.063 mmol) and 3,5-dimethylisoxazole-4-sulfonyl chloride (8.3 mg, 0.042 mmol) was added. The mixture was stirred at room temperature for 20 minutes. Purification by preparative LCMS (pH 2) gave the desired compound (3.1 mg, 20%). LCMS calculated for C₂₃H₂₇ClN₇O₄S (M+H)⁻: m/z=532.1; found: 532.2. ¹H NMR (300 MHz, CD₃OD): δ 8.29 (s, 1H), 7.42 (s, 1H), 6.38 (m, 1H), 4.70 (m, 1H), 4.52 (m, 1H), 4.12 (m, 1H), 3.83 (m, 1H), 3.66 (m, 2H), 2.65 (s, 3H), 2.50 (s, 3H), 2.37 (s, 3H), 2.24 (s, 3H), 1.80 (m, 3H).

Example 18. 1-{1-[7-Chloro-4-(cyclopropylsulfonyl)-6-methyl-2,3,4,5-tetrahydro-1,4-benzoxazepin-9-yl]ethyl}-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine Trifluoroacetate

The desired compound was prepared according to the procedure of Example 17, using cyclopropanesulfonyl chloride instead of methanesulfonyl chloride in 20% yield. LCMS calculated for C₂₁H₂₆ClN₆O₃S (M+H)⁺: m/z=477.1; found: 477.1. ¹H NMR (300 MHz, CD₃OD): δ 8.29 (s, 1H), 7.40 (s, 1H), 6.46 (m, 1H), 4.68 (m, 1H), 4.49 (m, 1H), 4.10 (m, 1H), 3.80 (m, 1H), 3.71 (m, 2H), 2.64 (s, 3H), 2.45 (s, 3H), 2.28 (m, 1H), 1.83 (m, 3H), 0.93 (m, 4H).

Example 19. 1-[1-(4-Acetyl-7-chloro-6-methyl-2,3,4,5-tetrahydro-1,4-benzoxazepin-9-yl)ethyl]-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine Trifluoroacetate

The desired compound was prepared according to the procedure of Example 1, steps 5-8 using acetic anhydride instead of di-tert-butyldicarbonate in 10% yield. LCMS calculated for C₂₀H₂₄ClN₆O₂(M+H)⁺: m/z=415.2; found: 415.0. ¹H NMR (300 MHz, CDCl₃): δ 8.19 (s, 1H), 7.43 (s, 1H), 6.44 (m, 1H), 4.78 (m, 1H), 4.58 (m, 1H), 4.04 (m, 1H), 3.86 (m, 3H), 2.67 (s, 3H), 2.58 (s, 3H), 2.10 (s, 3H), 1.84 (m, 3H).

Example 20. 1-[1-(7-Chloro-6-methyl-4-propionyl-2,3,4,5-tetrahydro-1,4-benzoxazepin-9-yl)ethyl]-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine Trifluoroacetate

The desired compound was prepared according to the procedure of Example 1, steps 5-8 using propanoyl chloride instead of di-tert-butyldicarbonate in 10% yield. LCMS calculated for C₂₁H₂₆ClN₆O₂(M+H)⁺: m/z=429.2; found: 429.0. ¹H NMR (300 MHz, CD₃OD): δ 8.28 (s, 1H), 7.35 (s, 1H), 6.49 (m, 1H), 4.78 (m, 1H), 4.59 (m, 1H), 4.10 (m, 1H), 3.80 (m, 3H), 2.64 (s, 3H), 2.56 (s, 3H), 2.28 (m, 2H), 1.82 (m, 3H), 1.03 (m, 3H).

Example 21. 1-{1-[7-Chloro-4-(methoxyacetyl)-6-methyl-2,3,4,5-tetrahydro-1,4-benzoxazepin-9-yl]ethyl}-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine Trifluoroacetate

The desired compound was prepared according to the procedure of Example 1, steps 5-8 using methoxyacetyl chloride instead of di-tert-butyldicarbonate in 10% yield. LCMS calculated for C₂₁H₂₆ClN₆O₃(M+H)⁺: m/z=445.2; found: 445.0. ¹H NMR (300 MHz, CD₃OD): δ 8.30 (s, 1H), 7.34 (s, 1H), 6.49 (m, 1H), 4.78 (m, 1H), 4.59 (m, 1H), 4.10 (m, 4H), 3.77 (m, 3H), 3.30 (m, 2H), 2.65 (s, 3H), 2.57 (s, 3H), 1.82 (m, 3H).

Example 22. 1-[1-(7-Chloro-4-isobutyryl-6-methyl-2,3,4,5-tetrahydro-1,4-benzoxazepin-9-yl)ethyl]-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine Trifluoroacetate

The desired compound was prepared according to the procedure of Example 1, steps 5-8 using isobutyryl chloride instead of di-tert-butyldicarbonate, 23%. LCMS calculated for C₂₂H₂₈ClN₆O₂(M+H)⁺: m/z=443.2; found: 443.0. ¹H NMR (300 MHz, CD₃OD): δ 8.28 (s, 1H), 7.34 (s, 1H), 6.45 (m, 1H), 4.75 (m, 1H), 4.55 (m, 1H), 4.10 (m, 1H), 3.80 (m, 3H), 2.80 (m, 1H), 2.63 (s, 3H), 2.56 (s, 3H), 1.82 (m, 3H), 1.00 (m, 6H).

Example 23. 2-[9-[1-(4-Amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-6-methyl-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-1,3-thiazole-5-carbonitrile Trifluoroacetate

tert-Butyl 9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-6-methyl-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (10 mg, 0.02 mmol) (treated with 4 N HCl in dioxane, and then the solvent was evaporated) was stirred in NMP and 2-chloro-1,3-thiazole-5-carbonitrile (10 mg, 0.07 mmol) was added. The mixture was heated to 130° C. for 1 hour. Purification by preparative LCMS (pH 10) gave the desired compound (3.2 mg, 30%). LCMS calculated for C₂₂H₂₂ClN₈OS (M+H)⁺: m/z=481.1; found: 481.1. ¹H NMR (300 MHz, CD₃OD): δ 8.14 (s, 1H), 7.74 (s, 1H), 7.31 (s, 1H), 6.31 (m, 1H), 4.99 (m, 1H), 4.78 (m, 1H), 3.98 (m, 3H), 3.75 (m, 1H), 2.58 (m, 6H), 1.77 (m, 3H).

Example 24. 1-[1-(7-Chloro-6-methyl-4-pyrazin-2-yl-2,3,4,5-tetrahydro-1,4-benzoxazepin-9-yl)ethyl]-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine bis(trifluoroacetate)

The desired compound was prepared according to the procedure of Example 23, using 2-chloropyrazine instead of 2-chloro-1,3-thiazole-5-carbonitrile in 10% yield. LCMS calculated for C₂₂H₂₄ClN₈O (M+H)⁺: m/z=451.2; found: 451.1. ¹H NMR (300 MHz, DMSO-d₆): δ 8.28 (s, 1H), 8.23 (s, 1H), 8.05 (s, 1H), 7.76 (s, 1H), 7.24 (s, 1H), 6.31 (m, 1H), 4.89 (m, 1H), 4.75 (m, 1H), 4.05 (m, 3H), 3.75 (m, 1H), 2.58 (m, 6H), 1.68 (m, 3H).

Example 25. 9-[1-(4-Amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-6-methyl-3,4-dihydro-1,4-benzoxazepin-5(2H)-one Trifluoroacetate

Step 1. 3-Acetyl-2-{2-[(tert-butoxycarbonyl)amino]ethoxy}-5-chloro-6-methylbenzoic Acid

tert-Butyl [2-(6-acetyl-4-chloro-2-formyl-3-methylphenoxy)ethyl]carbamate (85 mg, 0.24 mmol) was stirred in methanol (7 mL) and 1.0 M sodium hydroxide in water (2.7 mL) and urea hydrogen peroxide addition compound (200 mg, 2 mmol) was added. Additional urea hydrogen peroxide addition compound (20 mg) and 1.0 M sodium hydroxide in water (0.5 mL) were added and the mixture was stirred for 3 more hours. 1 N HCl was added to pH 5 and the methanol was evaporated. The mixture was extracted with ethyl acetate, washed with brine, dried over sodium sulfate, filtered and evaporated to give the desired compound (75 mg, 84%). LCMS calculated for C₁₇H₂₂ClNO₆Na (M+Na)+: m/z=394.1; found: 393.9.

Step 2. 2-{2-[(tert-Butoxycarbonyl)amino]ethoxy}-5-chloro-3-(1-hydroxyethyl)-6-methylbenzoic

Sodium tetrahydroborate (6.1 mg, 0.16 mmol) was added to a mixture of 3-acetyl-2-{2-[(tert-butoxycarbonyl)amino]ethoxy}-5-chloro-6-methylbenzoic acid (40 mg, 0.1 mmol) in methanol (0.50 mL) at 0° C. and the reaction was stirred at room temperature for 1 hour. The solvent was removed and the residue was diluted with ethyl acetate, washed with saturated sodium bicarbonate, adjusted the pH to 5 with 1 N hydrogen chloride solution, washed with brine, dried over sodium sulfate, filtered and concentrated to give the desired compound (30 mg, 70%). LCMS calculated for C₁₇H₂₄ClNO₆Na (M+Na)+: m/z=396.1; found: 396.0.

Step 3. 7-Chloro-9-(1-hydroxyethyl)-6-methyl-3,4-dihydro-1,4-benzoxazepin-5(2H)-one

2-{2-[(tert-Butoxycarbonyl)amino]ethoxy}-5-chloro-3-(1-hydroxyethyl)-6-methylbenzoic acid (27 mg, 0.072 mmol) was stirred in 4.0 M hydrogen chloride in 1,4-dioxane (3 mL) and evaporated. 1-Hydroxybenzotriazole hydrate (13 mg, 0.087 mmol), N,N-diisopropylethylamine (63 μL, 0.36 mmol) and N,N-dimethylformamide (2.0 mL) were added and the mixture was stirred for ten minutes. Benzotriazol-1-yloxytris(dimethylamino)-phosphonium hexafluorophosphate (38 mg, 0.087 mmol) was added and the mixture was stirred at 30° C. overnight. The mixture was diluted with ethyl acetate, washed with brine, dried over sodium sulfate, filtered and evaporated to give the desired product (14 mg, 76%). LCMS calculated for C₁₂H₁₅ClNO₃ (M+H)⁺: m/z=256.1; found: 256.0.

Step 4. 7-Chloro-9-(1-chloroethyl)-6-methyl-3,4-dihydro-1,4-benzoxazepin-5(2H)-one

A mixture of cyanuric chloride (15 mg, 0.079 mmol), 7-chloro-9-(1-hydroxyethyl)-6-methyl-3,4-dihydro-1,4-benzoxazepin-5(2H)-one (14 mg, 0.053 mmol) and N,N-dimethylformamide (20 μL) in methylene chloride (0.4 mL) was stirred at room temperature overnight. The mixture was diluted with methylene chloride, washed with saturated sodium bicarbonate, water, brine, dried over sodium sulfate, filtered and concentrated to give the desired compound (10 mg, 70%).

Step 5. 9-[1-(4-Amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-6-methyl-3,4-dihydro-1,4-benzoxazepin-5(2H)-one Trifluoroacetate

A mix of 7-chloro-9-(1-chloroethyl)-6-methyl-3,4-dihydro-1,4-benzoxazepin-5(2H)-one (10 mg, 0.04 mmol), 3-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (6.5 mg, 0.044 mmol), cesium carbonate (18 mg, 0.055 mmol) and potassium iodide (0.60 mg, 0.0036 mmol) in N,N-dimethylformamide (0.12 mL) was heated at 140° C. for 1 hour. The mix was diluted with ethyl acetate, washed with water, concentrated and purified by preparative LCMS (pH 2) to give the desired compound (2.7 mg, 10%). LCMS calculated for C₁₈H₂₀ClN₆O₂(M+H)⁺: m/z=387.1; found: 387.0. ¹H NMR (300 MHz, CD₃OD): δ 8.26 (s, 1H), 7.61 (s, 1H), 6.48 (m, 1H), 4.25 (m, 4H), 2.65 (s, 3H), 2.37 (s, 3H), 1.85 (m, 3H).

Examples 26 and 27. tert-Butyl 3-[9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-6-fluoro-2-methyl-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]azetidine-1-carboxylate

Step 1. 1-(5-Chloro-4-fluoro-2-hydroxyphenyl)ethanone

To 4-chloro-3-fluorophenol (from Aldrich, 20 g, 100 mmol) was added acetyl chloride (14.1 mL, 199 mmol) under N₂ with stirring. The resulting mixture turned into a clear solution at room temperature quickly and it was heated at 60° C. for 2 hours. To the resultant mixture was added aluminum trichloride (25.0 g, 187 mmol) in portions and the reaction mixture was heated at 180° C. for 30 minutes. The solids slowly dissolved at high temperature. The reaction mixture was then cooled to room temperature while the flask was swirled carefully in order for the solid to form a thin layer inside the flask and then slowly quenched with 1.0 N HCl (300 mL) while cooling in an ice-bath and stirred overnight. The yellow precipitate was washed with water and dried under vacuum to give the desired product as a yellow solid (23.8 g), which was directly used in the next step without further purification.

Step 2. 1-(5-Chloro-4-fluoro-2-hydroxy-3-iodophenyl)ethanone

A solution of 1-(5-chloro-4-fluoro-2-hydroxyphenyl)ethanone (23.8 g, 126 mmol) in acetic acid (100 mL) was treated with N-iodosuccinimide (34.1 g, 151 mmol) and stirred at 70° C. for 2 hr. The reaction mixture was concentrated, diluted with EtOAc and quenched with sat. NaHCO₃ solution until the bubbling stopped. The organic layers were separated, washed with water, dried over MgSO₄ and stripped to give the desired product which was used in the next step without further purification.

Step 3. tert-Butyl 9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-6-fluoro-2-methyl-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate

The title compound was prepared by methods analogous to Example 1, steps 1-8, but using 1-(5-chloro-4-fluoro-2-hydroxy-3-iodophenyl)ethanone and tert-butyl [(2R)-2-hydroxypropyl]carbamate (Alfa Aesar #H27296) in Step 1. Purification by preparative LCMS (pH 10) gave the desired compound (75 mg, 38%). LCMS calculated for C₂₃H₂₉ClFN₆O₃ (M+H)⁺: m/z=491.2; found: 491.2.

Step 4. tert-Butyl 3-[9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-6-fluoro-2-methyl-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]azetidine-1-carboxylate

tert-Butyl 9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-6-fluoro-2-methyl-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (75 mg, 0.15 mmol) was stirred in 4 NHCl in dioxane (5 mL) and evaporated. The residue was stirred in methanol (4 mL) and tert-butyl 3-oxoazetidine-1-carboxylate (110 mg, 0.61 mmol) was added. Sodium cyanoborohydride (86 mg, 1.4 mmol) was added and the mixture was warmed to 60° C. overnight and evaporated. Water was added and the mixture was extracted with ethyl acetate. The extracts were washed with brine, dried over sodium sulfate, filtered and concentrated. The reactions were purified by prep HPLC on C-18 column eluting water:acetonitrile gradient buffered pH 10 to give two diastereomers (peak #1 and 2): Peak #1 (Example 26): LCMS calculated for C₂₆H₃₄ClFN₇O₃(M+H)⁺: m/z=546.2; found: 546.2 ¹H NMR (300 MHz, CD₃OD): δ 8.14 (s, 1H), 7.38 (m, 1H), 6.32 (m, 1H), 4.11 (m, 1H), 3.95 (m, 2H), 3.78 (m, 2H), 3.50 (m, 2H), 2.92 (m, 2H), 2.65 (m, 1H), 2.60 (s, 3H), 1.80 (m, 3H), 1.42 (s, 9H), 1.38 (m, 3H). Peak #2 (Example 27): LCMS calculated for C₂₆H₃₄ClFN₇O₃(M+H)⁺: m/z=546.2; Found: 546.2.

Examples 28 and 29. 1-{1-[4-(1-Acetylazetidin-3-yl)-7-chloro-6-fluoro-2-methyl-2,3,4,5-tetrahydro-1,4-benzoxazepin-9-yl]ethyl}-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

tert-Butyl 3-[9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-6-fluoro-2-methyl-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]azetidine-1-carboxylate (6 mg, 0.01 mmol) (Example 26, step 4, peak 1) was stirred in 4 NHCl in dioxane for 30 minutes and evaporated to give the hydrochloride salt. The salt was stirred in N,N-dimethylformamide (0.2 mL) with N,N-diisopropylethylamine (6 μL, 0.03 mmol) and acetic anhydride (6 μL, 0.07 mmol) was added. The mixture was stirred for 5 minutes and diluted with methanol (5 mL). Purification by preparative LCMS (pH 10) gave the desired compound 3.3 mg (Example 28): LCMS calculated for C₂₃H₂₈ClFN₇O₂(M+H)⁺: m/z=488.2; found: 488.2 ¹H NMR (300 MHz, CD₃OD): δ 8.14 (s, 1H), 7.38 (m, 1H), 6.32 (m, 1H), 4.20 (m, 2H), 4.00 (m, 2H), 3.80 (m, 1H), 3.50 (m, 2H), 2.98 (m, 2H), 2.67 (m, 1H), 2.59 (s, 3H), 1.85 (s, 3H), 1.80 (m, 3H), 1.39 (m, 3H).

Utilizing the same procedure starting with the material of Example 27 (step 4, peak 2) produced 1.3 mg of product (Example 29): LCMS calculated for C₂₃H₂₈ClFN₇O₂(M+H)⁺: m/z=488.2; found: 488.2 ¹H NMR (300 MHz, CD₃OD): δ 8.14 (s, 1H), 7.38 (m, 1H), 6.32 (m, 1H), 4.20 (m, 1H), 4.00 (m, 3H), 3.79 (m, 1H), 3.60 (m, 1H), 3.48 (m, 1H), 2.95 (m, 2H), 2.71 (m, 1H), 2.60 (s, 3H), 1.85 (s, 3H), 1.77 (m, 3H), 1.31 (m, 3H).

Examples 30, 31, 32, and 33. 1-{1-[4-(1-Acetylazetidin-3-yl)-7-chloro-6-fluoro-2-methyl-2,3,4,5-tetrahydro-1,4-benzoxazepin-9-yl]ethyl}-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

The diasteromers from Example 28 were separated into the respective two enantiomers by chiral prep HPLC using a ChiralPAK IA column 5 μm, 20×250 mm eluting 30% ethanol in hexanes at 18 mL/min, with 20 mg/mL loading to give two peaks: Peak #1 (Example 30), retention time 7.76 min.: LCMS calculated for C₂₃H₂₈ClFN₇O₂ (M+H)⁺: m/z=488.2; found: 488.2; Peak #2 (Example 31), retention time 10.23 min: LCMS calculated for C₂₃H₂₈ClFN₇O₂ (M+H)⁺: m/z=488.2; found: 488.2.

The diasteromers from Example 29 were separated into the respective two enantiomers by chiral prep HPLC using a ChiralPAK AD column 5 μm, 20×250 mm eluting 20% ethanol in hexanes at 16 mL/min, with 20 mg/mL loading to give two peaks: Peak #1 (Example 32), retention time 7.63 min.: LCMS calculated for C₂₃H₂₈ClFN₇O₂(M+H)⁺: m/z=488.2; found: 488.2; Peak #2 (Example 33), retention time 11.36 min.: LCMS calculated for C₂₃H₂₈ClFN₇O₂ (M+H)⁺: m/z=488.2; found: 488.2.

Example 34. 1-{1-[4-(1-Acetylazetidin-3-yl)-7-chloro-6-fluoro-2,3,4,5-tetrahydro-1,4-benzoxazepin-9-yl]ethyl}-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

Step 1. tert-Butyl 9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-6-fluoro-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate

The title compound was prepared by methods analogous to Example 1, steps 1-8, but using 1-(5-chloro-4-fluoro-2-hydroxy-3-iodophenyl)ethanone (from Examples 26-27, step 2) in step 1.

Step 2. tert-Butyl 3-[9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-6-fluoro-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]azetidine-1-carboxylate

The title compound was prepared by methods analogous to Example 26, step 2, but using tert-butyl 9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-6-fluoro-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate.

Step 3. 1-{1-[4-(1-acetylazetidin-3-yl)-7-chloro-6-fluoro-2,3,4,5-tetrahydro-1,4-benzoxazepin-9-yl]ethyl}-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

tert-Butyl 3-[9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-6-fluoro-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]azetidine-1-carboxylate (14 mg, 0.026 mmol) was stirred in 4 N HCl in dioxane for 30 minutes and evaporated to give the hydrochloride salt. The salt was stirred in N,N-dimethylformamide (0.4 mL) with N,N-diisopropylethylamine (10 μL, 0.08 mmol) and acetic anhydride (10 μL, 0.2 mmol) was added. The mixture was stirred for 5 minutes and diluted with methanol. Purification by preparative LCMS (pH 10) gave the desired compound (Example 34). LCMS calculated for C₂₂H₂₆ClN₇O₂ (M+H)⁺: m/z=474.2; found: 474.2.

Examples 35 and 36. 1-{1-[(3S)-7-Chloro-6-fluoro-3-methyl-4-(methylsulfonyl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-9-yl]ethyl}-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

Step 1. tert-Butyl (3S)-9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-6-fluoro-3-methyl-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate

The title compound was prepared by methods analogous to Example 1, steps 1-8, but using 1-(5-chloro-4-fluoro-2-hydroxy-3-iodophenyl)ethanone (from Examples 26-27, step 2) and tert-butyl [(1S)-2-hydroxy-1-methylethyl]carbamate [Ald. #469513] in Step 1. LCMS calculated for C₂₃H₂₉ClFN₆O₃(M+H)⁺: m/z=491.2; found: 491.2.

Step 2. 1-{1-[(3S)-7-chloro-6-fluoro-3-methyl-4-(methylsulfonyl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-9-yl]ethyl}-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

tert-Butyl (3S)-9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-6-fluoro-3-methyl-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (13 mg, 0.026 mmol) was stirred in methylene chloride (100 μL, 2 mmol) with N,N-diisopropylethylamine (14 L, 0.079 mmol) and cooled to 0° C. Methanesulfonyl chloride (2.6 μL, 0.034 mmol) was added, and the mixture was stirred at 0° C. for 1 hr. The mixture was evaporated and diluted with methanol. The reactions were purified by prep HPLC on C-18 column eluting water:acetonitrile gradient buffered pH 10 to give two enantiomers: Peak #1 (Example 35): LCMS calculated for C₁₉H₂₃ClFN₆O₃S (M+H)⁺: m/z=469.1; found: 469.1; Peak #2 (Example 36): LCMS calculated for C₁₉H₂₃ClFN₆O₃S (M+H)⁺: m/z=469.1; found: 469.1.

Examples 37, 38, 39, and 40. 1-{1-[7-Chloro-6-fluoro-2-methyl-4-(methylsulfonyl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-9-yl]ethyl}-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

The title compound was prepared by methods analogous to Example 36, but using tert-butyl 9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-6-fluoro-2-methyl-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate in step 2. The reactions were purified by prep HPLC on C-18 column eluting water:acetonitrile gradient buffered pH 10 to give two diastereomers: Peak #1, which was separated into the respective two enantiomers by chiral prep HPLC using a Phenomenex Lux Cellulose C-4 column 5 μm, 21.2×250 mm eluting 45% ethanol in hexanes at 18 mL/min, with 4 mg/mL loading to give two peaks: Peak #1A (Example 37), retention time 9.80 min: LCMS calculated for C₁₉H₂₃ClFN₆O₃S (M+H)⁺: m/z=469.1; found: 469.1; ¹H NMR (300 MHz, DMSO): δ 8.11 (s, 1H), 7.35 (m, 1H), 6.24 (m, 1H), 4.75 (m, 1H), 4.21 (m, 2H), 3.78 (m, 1H), 3.39 (m, 1H), 2.87 (s, 3H), 2.55 (s, 3H), 1.68 (m, 3H), 1.39 (m, 3H); Peak #1B (Example 38), retention time 11.75 min: LCMS calculated for C₁₉H₂₃ClFN₆O₃S (M+H)⁺: m/z=469.1; found: 469.1.

The second diasteromer peak (Peak #2) was separated into the respective two enantiomers by chiral prep HPLC using a Phenomenex Lux Cellulose C-1 column 5 μm, 21.2×250 mm eluting 20% ethanol in hexanes at 18 mL/min, with 7 mg/mL loading to give two peaks: Peak #2A (Example 39), retention time 12.78 min: LCMS calculated for C₁₉H₂₃ClFN₆O₃S (M+H)⁺: m/z=469.1; found: 469.1; Peak #2B (Example 40), retention time 15.47 min: LCMS calculated for C₁₉H₂₃ClFN₆O₃S (M+H)⁺: m/z=469.1; found: 469.1.

Examples 41 and 42. 3-[9-[1-(4-Amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-6-fluoro-2-methyl-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]cyclobutanecarboxylic Acid Trifluoroacetate

The title compound was prepared by methods analogous to Example 26, but using 3-oxocyclobutanecarboxylic acid in step 2. The reactions were purified by prep HPLC on C-18 column eluting water:acetonitrile gradient buffered pH 2 to give two diastereomers: Peak #1 (Example 41): LCMS calculated for C₂₃H₂₇ClFN₆O₃(M+H)⁺: m/z=489.2; found: 489.2; Peak #2 (Example 42): LCMS calculated for C₂₃H₂₇ClFN₆O₃ (M+H)⁺: m/z=489.2; found: 489.2. ¹H NMR (300 MHz, DMSO-d₆): δ 8.11 (s, 1H), 7.60 (m, 1H), 6.28 (m, 1H), 4.22 (m, 3H), 4.00 (m, 2H), 3.38 (m, 2H), 2.80 (m, 2H), 2.55 (s, 3H), 2.22 (m, 2H), 1.72 (m, 3H), 1.40 (m, 3H).

Examples 43 and 44. 3-[(2S)-9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-6-cyano-2-methyl-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]cyclobutanecarboxamide

N,N-Diisopropylethylamine (78 μl, 0.45 mmol) was added to a mixture of 3-[9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-6-fluoro-2-methyl-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]cyclobutanecarboxylic acid trifluoroacetate (44 mg, 0.09 mmol) and N,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate (34 mg, 0.09 mmol) in N,N-dimethylformamide (2 mL) at room temperature. A solution of ammonia in ethanol (2.0 M, 130 μl) was added and the reaction was stirred at room temperature for 1.5 hrs. The reactions were purified by prep HPLC on C-18 column eluting water:acetonitrile gradient buffered pH 10 to give two diastereomers: Peak #1 (Example 43): LCMS calculated for C₂₃H₂₈ClFN₇O₂(M+H)⁺: m/z=488.2; found: 488.2; Peak #2 (Example 44): LCMS calculated for C₂₃H₂₈ClFN₇O₂(M+H)⁺: m/z=488.2; found: 488.2.

Example 45. 1-{1-[8-Chloro-7-fluoro-5-(methylsulfonyl)-3,4,5,6-tetrahydro-2H-1,5-benzoxazocin-10-yl]ethyl}-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

Step 1. tert-butyl 10-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-8-chloro-7-fluoro-3,4-dihydro-2H-1,5-benzoxazocine-5(6H)-carboxylate

The title compound was prepared by methods analogous to Example 1, steps 1-8, but using 1-(5-chloro-4-fluoro-2-hydroxy-3-iodophenyl)ethanone (from Examples 26-27, step 2) and tert-butyl (3-hydroxypropyl)carbamate [Aldrich #416444] in Step 1. LCMS calculated for C₂₃H₂₉ClFN₆O₃(M+H)⁺: m/z=491.2; found: 491.2.

Step 2. 1-{1-[8-Chloro-7-fluoro-5-(methylsulfonyl)-3,4,5,6-tetrahydro-2H-1,5-benzoxazocin-10-yl]ethyl}-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

tert-Butyl 10-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-8-chloro-7-fluoro-3,4-dihydro-2H-1,5-benzoxazocine-5(6H)-carboxylate (8 mg, 0.02 mmol) was stirred in methylene chloride (80 μL, 1 mmol) with N,N-diisopropylethylamine (8.5 μL, 0.049 mmol) and cooled to 0° C. Methanesulfonyl chloride (1.6 μL, 0.021 mmol) was added and the mixture was stirred at 0° C. for 1 hr. The mixture was evaporated and diluted with methanol and purified by preparative LCMS (pH 10) to give Example 45. LCMS calculated for C₁₉H₂₃ClFN₆O₃S (M+H)⁺: m/z=469.1; found: 469.1. ¹H NMR (300 MHz, CD₃OD): δ 8.14 (s, 1H), 7.65 (m, 1H), 6.36 (m, 1H), 4.58 (m, 2H), 4.21 (m, 2H), 3.52 (m, 2H), 2.87 (s, 3H), 2.60 (s, 3H), 1.91 (m, 2H), 1.80 (m, 3H).

Example 46. 4-(1-Acetylazetidin-3-yl)-9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-2,3,4,5-tetrahydro-1,4-benzoxazepine-6-carbonitrile

Step 1. 1-(4-bromo-5-chloro-2-hydroxyphenyl)ethanone

The 2-bromo-1-chloro-4-methoxybenzene (25.0 g, 113 mmol) [Oakwood cat#035670] was dissolved in carbon disulfide (250 mL), and the acetyl chloride (12 mL, 170 mmol) and aluminum trichloride (37.6 g, 282 mmol) were added. The reaction was heated to reflux and monitored by LC/MS. After heating for 1 h, the reaction became two layers. The reaction allowed to cool to room temperature and poured over ice. The slurry was extracted with ethyl acetate 3×, the combined organic layer was washed with brine, dried over magnesium sulfate and concentrated to give 1-(4-bromo-5-chloro-2-hydroxyphenyl)ethanone as a solid (28.0 g, 99%). ¹H NMR (300 MHz, CDCl₃) δ 12.12 (s, 1H), 7.78 (s, 1H), 7.31 (s, 1H), 2.62 (s, 3H).

Step 2. 4-acetyl-2-chloro-5-hydroxybenzonitrile

1-(4-bromo-5-chloro-2-hydroxyphenyl)ethanone (6.2 g, 25 mmol) was combined with zinc cyanide (4.4 g, 37 mmol) in N,N-dimethylformamide (40 mL) degassed with nitrogen and tris(dibenzylideneacetone)dipalladium(0) (0.38 g, 0.42 mmol) and (9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine) (0.57 g, 0.99 mmol) were added. The reaction was degassed with nitrogen and heated to 120° C. and monitored by LC/MS. After heating for 2 hrs, the reaction was allowed to cool to room temperature, diluted with ethyl acetate, and filtered to remove the solids. The organic layer was washed with water, brine, dried over magnesium sulfate and concentrated in vacuo to give the crude product. The product was purified by FCC on silica gel eluting hexane:ethyl acetate gradient to give 4-acetyl-2-chloro-5-hydroxybenzonitrile as a yellow crystalline solid (3.5 g, 72%).

Step 3. 4-acetyl-6-chloro-3-hydroxy-2-iodobenzonitrile

The 4-acetyl-2-chloro-5-hydroxybenzonitrile (4.9 g, 25 mmol) was dissolved in acetic acid (61.2 mL), and the N-iodosuccinimide (6.8 g, 30 mmol) was added. The reaction was heated to 80° C. and, after heating for 18 hrs, the reaction was concentrated in vacuo to remove the acetic acid. The residue was taken up in ethyl acetate, washed with sodium bicarbonate water, brine, dried over magnesium sulfate and concentrated to give a dark oil. The crude product was purified by FCC on silica gel eluting hexane:ethyl acetate gradient to give 4-acetyl-6-chloro-3-hydroxy-2-iodobenzonitrile as a yellow solid (5.3 g, 66%).

Step 4. tert-butyl [2-(6-acetyl-4-chloro-3-cyano-2-iodophenoxy)ethyl]carbamate

Diethyl azodicarboxylate (2.3 mL, 14 mmol) was added slowly to a solution of triphenylphosphine (3.79 g, 14.5 mmol) and tert-butyl (2-hydroxyethyl)carbamate (2.3 g, 14 mmol) in tetrahydrofuran (93 mL) and cooled in an ice bath. After stirring for 15 minutes, the 4-acetyl-6-chloro-3-hydroxy-2-iodobenzonitrile (3.1 g, 9.6 mmol) was added. The reaction was allowed to warm to room temperature and stirred overnight. The reaction was diluted with ethyl acetate and washed with water, 1 N HCl, and brine, then dried over magnesium sulfate and concentrated to give a dark oil. The product was purified by FCC on silica gel eluting hexane: ethyl acetate gradient to give tert-butyl [2-(6-acetyl-4-chloro-3-cyano-2-iodophenoxy)ethyl]carbamate as a tan solid (3.2 g, 71%). LCMS calculated for C₁₆H₁₈ClIN₂O₄Na (M+Na)⁻: m/z=487.1; found: 486.9.

Step 5. tert-butyl [2-(6-acetyl-4-chloro-3-cyano-2-vinylphenoxy)ethyl]carbamate

A mixture of tert-butyl [2-(6-acetyl-4-chloro-3-cyano-2-iodophenoxy)ethyl]carbamate (3.3 g, 7.1 mmol), 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane (1.81 mL, 10.6 mmol), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (1:1) (0.3 g, 0.4 mmol) and potassium carbonate (2.9 g, 21 mmol) in 1,4-dioxane (40 mL) and water (20 mL) was degassed with nitrogen. The resulting mixture was heated at 80° C. for 1 h. The mixture was poured into water and extracted with ethyl acetate. The extracts were washed with brine, dried over magnesium sulfate, filtered and concentrated. The product was purified by FCC on silica gel using ethyl acetate in hexane (0-40%) to give the desired compound tert-butyl [2-(6-acetyl-4-chloro-3-cyano-2-vinylphenoxy)ethyl]carbamate as a crystalline solid (2.2 g. 85%). LCMS calculated for C₁₈H₂₁ClIN₂O₄Na (M+Na)⁻: m/z=387.1; found: 387.0.

Step 6. tert-butyl {2-[4-chloro-3-cyano-6-(1-hydroxyethyl)-2-vinylphenoxy]ethyl}carbamate

Tert-butyl [2-(6-acetyl-4-chloro-3-cyano-2-vinylphenoxy)ethyl]carbamate (1.6 g, 4.4 mmol) was dissolved in methanol (40 mL) cooled in an ice bath and the sodium tetrahydroborate (0.16 g, 4.4 mmol) was added. The reaction was stirred for 1 h and water was added to quench residual hydride and the reaction was concentrated to remove the methanol. The aqueous was diluted with ethyl acetate washed with brine, dried over magnesium sulfate and concentrated to give tert-butyl {2-[4-chloro-3-cyano-6-(1-hydroxyethyl)-2-vinylphenoxy]ethyl}carbamate as a glass (1.6 g, 100%). LCMS calculated for C₁₈H₂₃ClN₂O₄Na (M+Na)⁺: m/z=389.1; found: 389.1.

Step 7. tert-butyl {2-[4-chloro-3-cyano-2-formyl-6-(1-hydroxyethyl)phenoxy]ethyl}carbamate

Tert-butyl {2-[4-chloro-3-cyano-6-(1-hydroxyethyl)-2-vinylphenoxy]ethyl}carbamate (1.6 g, 4.4 mmol) was dissolved in methylene chloride (1.2 mL) cooled in a dry ice acetone bath and ozone/oxygen was bubbled through the solution until a persistent blue color remained. The reaction was purged with oxygen and nitrogen to remove excess ozone and dimethyl sulfide (0.80 mL, 11 mmol) was added to reduce the ozonide. After stirring for 1 h, the reaction was complete. This was concentrated in vacuo to give a residue give tert-butyl {2-[4-chloro-3-cyano-2-formyl-6-(1-hydroxyethyl)phenoxy]ethyl}carbamate. LCMS calculated for C₁₇H₂₁ClN₂O₅Na (M+Na)⁺: m/z=391.1; found: 391.1.

Step 8. 7-chloro-9-(1-hydroxyethyl)-2,3-dihydro-1,4-benzoxazepine-6-carbonitrile

The crude tert-butyl {2-[4-chloro-3-cyano-2-formyl-6-(1-hydroxyethyl)phenoxy]ethyl}carbamate was dissolved in 1,4-dioxane (16 mL) and was added to an ice cooled 4.0 M hydrogen chloride in dioxane (40 mL) solution. After stirring for 1 h, the reaction was concentrated in vacuo to give 7-chloro-9-(1-hydroxyethyl)-2,3-dihydro-1,4-benzoxazepine-6-carbonitrile as an oil. LCMS calculated for C₁₂H₁₂ClN₂O₂(M+H)⁺: m/z=251.1; found: 251.0. ¹H NMR (300 MHz, DMSO-d₆) δ 8.55 (t, J=2.0 Hz, 1H), 7.75 (s, 1H), 5.53 (d, J=4.6 Hz, 1H), 5.05-4.82 (m, 1H), 4.53-4.24 (m, 2H), 4.20-4.04 (m, 2H), 1.26 (d, J=6.4 Hz, 3H).

Step 9. 7-chloro-9-(1-hydroxyethyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-6-carbonitrile

The crude 7-chloro-9-(1-hydroxyethyl)-2,3-dihydro-1,4-benzoxazepine-6-carbonitrile was taken up in ethanol (30 mL) cooled in an ice bath and the sodium tetrahydroborate (0.16 g, 4.4 mmol) was added. The reaction was allowed to stir for 1 h, and water was added to quench the remaining hydride and the reaction was concentrated to remove most of the ethanol. The residue was dissolved with ethyl acetate, washed with brine, dried over magnesium sulfate, and concentrated to give 7-chloro-9-(1-hydroxyethyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-6-carbonitrile as an oil (0.45 g, 41%). LCMS calculated for C₁₂H₁₄ClN₂O₂(M+H)⁺: m/z=253.1; found: 253.0.

Step 10. tert-butyl 7-chloro-6-cyano-9-(1-hydroxyethyl)-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate

7-Chloro-9-(1-hydroxyethyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-6-carbonitrile (0.140 g, 0.554 mmol) was dissolved in methylene chloride (5.0 mL, 78 mmol) and N,N-diisopropylethylamine (0.29 mL, 1.7 mmol) at room temperature, and the di-tert-butyldicarbonate (0.24 g, 1.1 mmol) was added. The reaction was stirred at room temperature for 1 hr and then diluted with ethyl acetate and washed with 1 N HCl, brine, dried over magnesium sulfate, and concentrated to give a yellow oil. The product was purified by FCC on silica gel eluting a hexane:ethyl acetate gradient to give tert-butyl 7-chloro-6-cyano-9-(1-hydroxyethyl)-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate as an oil (0.12 g, 61%). LCMS calculated for C₁₇H₂₁ClN₂O₄Na (M+Na)⁺: m/z=375.1; found: 375.0.

Step 11. tert-butyl 7-chloro-9-(1-chloroethyl)-6-cyano-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate

The tert-butyl 7-chloro-6-cyano-9-(1-hydroxyethyl)-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (0.090 g, 0.26 mmol) was dissolved in methylene chloride (3 mL) and N,N-dimethylformamide (0.020 mL) and cooled in an ice bath. The thionyl chloride (0.037 mL, 0.51 mmol) was added slowly, and the reaction was stirred for 1 h and then diluted with methylene chloride (30 mL). The reaction mixture was cooled in an ice bath, and water saturated sodium bicarbonate was added. The organic layer was washed with water, brine, dried over magnesium sulfate, and concentrated to give tert-butyl 7-chloro-9-(1-chloroethyl)-6-cyano-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate as an oil. LCMS calculated for C₁₇H₂₀Cl₂N₂O₃Na (M+Na)+: m/z=393.1; found: 393.0.

Step 12. tert-butyl 9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-6-cyano-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate

The crude tert-butyl 7-chloro-9-(1-chloroethyl)-6-cyano-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (0.090 g, 0.26 mmol) was dissolved in N,N-dimethylformamide (3 mL), and 3-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (0.076 g, 0.51 mmol) and cesium carbonate (0.17 g, 0.51 mmol) were added. The reaction was heated to 90° C. for 18 hrs and then allowed to cool to room temperature. The reaction was diluted with ethyl acetate and then decanted from the solids. The organic layer was washed with water, brine, dried over magnesium sulfate, and concentrated to give tert-butyl 9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-6-cyano-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate as an oil. LCMS calculated for C₂₃H₂₇ClN₇O₃(M+H)⁺: m/z=484.1; found: 484.1.

Step 13. 9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-2,3,4,5-tetrahydro-1,4-benzoxazepine-6-carbonitrile bishydrochloride

The crude tert-butyl 9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-6-cyano-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate was dissolved in 4.0 M hydrogen chloride in dioxane (4.0 mL) at room temperature and was stirred for 1 h. The reaction was concentrated in vacuo to give 9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-2,3,4,5-tetrahydro-1,4-benzoxazepine-6-carbonitrile bishydrochloride as an off white solid (0.065 g, 66%). LCMS calculated for C₁₈H₁₉ClN₇O (M+H)⁺: m/z=384.1; found: 384.2.

Step 14. tert-butyl 3-[9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-6-cyano-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]azetidine-1-carboxylate

9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-2,3,4,5-tetrahydro-1,4-benzoxazepine-6-carbonitrile bishydrochloride (0.030 g, 0.078 mmol) was dissolved in methanol (3.0 mL), and the tert-butyl 3-oxoazetidine-1-carboxylate (0.027 g, 0.16 mmol) and then sodium cyanoborohydride (0.0098 g, 0.16 mmol) were added. The reaction was heated to 60° C. for 3 hrs and then allowed to cool to room temperature. The reaction was diluted with ethyl acetate and washed with brine. The organic layer dried over magnesium sulfate and concentrated to give the crude product as an amber oil. The oil was purified by prep HPLC on a C-18 column eluting water:acetonitrile gradient at pH 10 to give tert-butyl 3-[9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-6-cyano-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]azetidine-1-carboxylate (0.015 g, 35%). LCMS calculated for C₂₆H₃₂ClN₈O₃(M+H)⁺: m/z=539.2; found: 539.2.

Step 15. 9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-4-azetidin-3-yl-7-chloro-2,3,4,5-tetrahydro-1,4-benzoxazepine-6-carbonitrile trihydrochloride

Tert-butyl 3-[9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-6-cyano-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]azetidine-1-carboxylate (0.015 g, 0.0278 mmol) was dissolved in 4.0 M hydrogen chloride in dioxane (3.0 mL, 12 mmol) at room temperature and stirred for 1 hr and then concentrated in vacuo to give 9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-4-azetidin-3-yl-7-chloro-2,3,4,5-tetrahydro-1,4-benzoxazepine-6-carbonitrile trihydrochloride as a semi-solid. LCMS calculated for C₂₁H₂₄ClN₈O (M+H)⁺: m/z=439.1; found: 439.1.

Step 16. 4-(1-acetylazetidin-3-yl)-9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-2,3,4,5-tetrahydro-1,4-benzoxazepine-6-carbonitrile

The crude 9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-4-azetidin-3-yl-7-chloro-2,3,4,5-tetrahydro-1,4-benzoxazepine-6-carbonitrile trihydrochloride (0.015 g, 0.0278 mmol) was dissolved in N,N-dimethylformamide (2 mL) and cooled in an ice bath, and then N,N-diisopropylethylamine (0.0142 g, 0.112 mmol) and acetic anhydride (0.0032 mL, 0.033 mmol) were added. After stirring for 1 h, the product was purified without work up, by prep HPLC on a C-18 column eluting water:acetonitrile gradient buffered pH 10 to give 4-(1-acetylazetidin-3-yl)-9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-2,3,4,5-tetrahydro-1,4-benzoxazepine-6-carbonitrile as a white amorphous solid (0.004 g, 33%). LCMS calculated for C₂₃H₂₆ClN₈O₂(M+H)⁺: m/z=481.2; found: 481.2.

Example 47. 9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-4-[1-(2-hydroxyethyl)azetidin-3-yl]-2,3,4,5-tetrahydro-1,4-benzoxazepine-6-carbonitrile

9-[1-(4-Amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-4-azetidin-3-yl-7-chloro-2,3,4,5-tetrahydro-1,4-benzoxazepine-6-carbonitrile (0.015 g, 0.034 mmol) (from Example 46, Step 15) and 2-bromoethanol (0.0097 mL, 0.14 mmol) were combined in N,N-dimethylformamide (1 mL) with triethylamine (0.019 mL, 0.14 mmol) at room temperature. The reaction was heated to 85° C. and after heating for 2 hrs the reaction was concentrated in vacuo and the residue was purified by prep HPLC on a C-18 column eluting water:acetonitrile gradient buffered pH 10 to give the desired compound as a white amorphous solid (0.008 g, 50%). LCMS calculated for C₂₃H₂₈ClN₈O₂ (M+H)⁺: m/z=483.2; found: 483.2.

Examples 48 and 49. 4-(1-Acetylazetidin-3-yl)-9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-2-methyl-2,3,4,5-tetrahydro-1,4-benzoxazepine-6-carbonitrile

Step 1. tert-butyl [2-(6-acetyl-4-chloro-3-cyano-2-iodophenoxy)propyl]carbamate

Using methods analogous to Example 46, but using tert-butyl (2-hydroxypropyl)carbamate in step 4, tert-butyl [2-(6-acetyl-4-chloro-3-cyano-2-iodophenoxy)propyl]carbamate was prepared as a pale yellow oil (1.3 g, 58%). LCMS calculated for C₁₇H₂₀ClN₂O₄Na (M+Na)⁺: m/z=501.0; found: 501.0.

Step 2. 4-(1-acetylazetidin-3-yl)-9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-2-methyl-2,3,4,5-tetrahydro-1,4-benzoxazepine-6-carbonitrile

Using methods analogous to Example 46, but using the intermediate tert-butyl [2-(6-acetyl-4-chloro-3-cyano-2-iodophenoxy)propyl]carbamate, the desired compound was prepared as a mixture of diastereomers. The isomers were separated and purified by prep HPLC on a C-18 column eluting water:acetonitrile gradient buffered pH 10, to obtain: Peak #1 (Example 48): LCMS calculated for C₂₄H₂₈ClN₈O₂ (M+H)⁺: m/z=495.1; found: 495.2.

and Peak #2 (Example 49): LCMS calculated for C₂₄H₂₈ClN₈O₂(M+H)⁺: m/z=495.1; found: 495.2.

Examples 50 and 51. 2-{3-[9-[1-(4-Amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-6-cyano-2-methyl-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]azetidin-1-yl}acetamide

Step 1. 9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-4-azetidin-3-yl-7-chloro-2-methyl-2,3,4,5-tetrahydro-1,4-benzoxazepine-6-carbonitrile Trishydrochloride

Using methods analogous to Example 46, steps 1-15, but using tert-butyl (2-hydroxypropyl)carbamate in step 4, the 9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-4-azetidin-3-yl-7-chloro-2-methyl-2,3,4,5-tetrahydro-1,4-benzoxazepine-6-carbonitrile trishydrochloride was prepared as a solid. LCMS calculated for C₂₂H₂₆ClN₈O (M+H)⁺: m/z=453.2; found: 453.2.

Step 2. 2-{3-[9-[1-(4-amino-3-methyl-H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-6-cyano-2-methyl-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]azetidin-1-yl}acetamide

2-Bromoacetamide (0.01 g, 0.09 mmol) was added to a mixture of 9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-4-azetidin-3-yl-7-chloro-2-methyl-2,3,4,5-tetrahydro-1,4-benzoxazepine-6-carbonitrile trishydrochloride (20 mg, 0.04 mmol) and triethylamine (20 μL, 0.18 mmol) in N,N-dimethylformamide (2 mL) and then heated to 80° C. for 2 h. The reaction was allowed to cool and was purified without work up by prep HPLC on a C-18 column eluting water:acetonitrile gradient buffered pH 10 to give the title compounds as two separated diastereomers: Peak #1 (Example 50): LCMS calculated for C₂₄H₂₉ClN₉O₂(M+H)⁺: m/z=510.2; found: 510.2; Peak #2 (Example 51): LCMS calculated for C₂₄H₂₉ClN₉O₂(M+H)⁺: m/z=510.2; found: 510.2.

Examples 52 and 53. 2-{3-[9-[1-(4-Amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-6-cyano-2-methyl-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]azetidin-1-yl}acetamide

Peak #2 (from Example 51) was separated into the respective enantiomers by chiral prep HPLC using a Phenomenex Lux Cellulose C-4 column 5 m, 21.2×250 mm eluting with 60% ethanol in hexanes at 18 mL/min, with 5 mg/mL loading to give two peaks: Peak #1 (Example 52), retention time 9.48 min: LCMS calculated for C₂₄H₂₉ClN₉O₂(M+H)⁺: m/z=510.2; found: 510.2; Peak #2 (Example 53), retention time 12.42 min: LCMS calculated for C₂₄H₂₉ClN₉O₂ (M+H)⁺: m/z=510.2; found: 510.2.

Examples 54 and 55. 9-[1-(4-Amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-4-[1-(2-hydroxy-2-methylpropyl)azetidin-3-yl]-2-methyl-2,3,4,5-tetrahydro-1,4-benzoxazepine-6-carbonitrile

9-[1-(4-Amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-4-azetidin-3-yl-7-chloro-2-methyl-2,3,4,5-tetrahydro-1,4-benzoxazepine-6-carbonitrile trishydrochloride (0.015 g, 0.034 mmol) was dissolved in N,N-dimethylformamide (1.0 mL) and triethylamine (0.025 mL, 0.18 mmol), and 2,2-dimethyloxirane (0.050 g) was added. The reaction was heated to 85° C. stirred for 4 h. The reaction was concentrated in vacuo, and the product was purified without workup by prep HPLC on a C-18 column eluting water:acetonitrile gradient buffered pH 10 to give the title compound as two diastereomers: Peak #1 (Example 54) (0.002 g, 13%): LCMS calculated for C₂₆H₃₄ClN₈O₂ (M+H)⁺: m/z=525.2; found: 525.2; Peak #2 (Example 55) (0.002 g 13%): LCMS calculated for C₂₆H₃₄ClN₈O₂(M+H)⁺: m/z=525.2; found: 525.2.

Examples 56 and 57. (2S)-9-[1-(4-Amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-4-[1-(2-hydroxyethyl)azetidin-3-yl]-2-methyl-2,3,4,5-tetrahydro-1,4-benzoxazepine-6-carbonitrile

Using methods analogous to Example 47, but using tert-butyl [(2R)-2-hydroxypropyl]carbamate (from Example 46, step 4), the desired products were prepared as a mixture of single diastereomers. The reaction products were purified by prep HPLC on a C-18 column eluting water:acetonitrile gradient buffered pH 10 to give two diastereomers: Peak #1 (Example 56), as a white amorphous solid: LCMS calculated for C₂₄H₃₀ClN₈O₂(M+H)⁺: m/z=497.2; Found: 497.2; Peak #2 (Example 57), as a white amorphous solid: LCMS calculated for C₂₄H₃₀ClN₈O₂ (M+H)⁺: m/z=497.2; found: 497.2.

Example 58. 9-[1-(4-Amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-4-(2-hydroxyethyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-6-carbonitrile

2-Bromoethanol (4.7 μL, 0.066 mmol) was added to a mixture of 9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-2,3,4,5-tetrahydro-1,4-benzoxazepine-6-carbonitrile bishydrochloride (15 mg, 0.039 mmol) (from Example 46, step 13) and triethylamine (10 μL, 0.09 mmol) in N,N-dimethylformamide (2 mL). The reaction was heated at 80° C. for 3 h and then allowed to cool. The product was purified without workup by prep HPLC on a C-18 column eluting water:acetonitrile gradient buffered pH 10 to give the desired compound as white amorphous solid (0.08 g, 50%). LCMS calculated for C₂₀H₂₃ClN₇O₂ (M+H)⁺: m/z=428.1; found: 428.2.

Examples 59 and 60. 9-[1-(4-Amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-2-methyl-4-(pyridin-3-ylmethyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-6-carbonitrile

Step 1. 9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-2-methyl-2,3,4,5-tetrahydro-1,4-benzoxazepine-6-carbonitrile Bishydrochloride

Using methods analogous to Example 46, steps 1-13, but using tert-butyl (2-hydroxypropyl)carbamate in step 4, the 9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-2-methyl-2,3,4,5-tetrahydro-1,4-benzoxazepine-6-carbonitrile bishydrochloride was prepared as a mixture of diastereomers. LCMS calculated for C₁₉H₂₁ClN₇O (M+H)⁺: m/z=398.1; found: 398.2.

Step 2. 9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-2-methyl-4-(pyridin-3-ylmethyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-6-carbonitrile

9-[1-(4-Amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-2-methyl-2,3,4,5-tetrahydro-1,4-benzoxazepine-6-carbonitrile bishydrochloride (0.020 g, 0.05 mmol) was taken up in N,N-dimethylformamide (2.0 mL) and triethylamine (0.034 mL, 0.24 mmol), and the 3-(bromomethyl)pyridine hydrobromide was added. The reaction was heated to 85° C. for 2 h and was allowed to cool. The product was purified by prep HPLC on C-18 column eluting water:acetonitrile gradient buffered pH 10 to give two diastereomers: Peak #1 (Example 59): LCMS calculated for C₂₅H₂₆ClN₈O (M+H)⁺: m/z=489.2; found: 489.2; Peak #2 (Example 60): LCMS calculated for C₂₅H₂₆ClN₈O (M+H)⁺: m/z=489.2; found: 489.2.

Examples 61, 62, 63, and 64. 9-[1-(4-Amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-4-(2-hydroxyethyl)-2-methyl-2,3,4,5-tetrahydro-1,4-benzoxazepine-6-carbonitrile

Using methods analogous to Example 59, but using 2-bromoethanol in step 2, a mixture of diastereomers of the desired compound was prepared. The isomers were separated into the respective four enantiomers by chiral prep HPLC using a Phenomenex Lux Cellulose C-4 column 5 μm, 21.2×250 mm eluting 20% ethanol in hexanes at 22 mL/min, with 7 mg/mL loading to give four peaks retention time: Peak #1 (Example 61), retention time 15.47 min: LCMS calculated for C₂₁H₂₅ClN₇O₂ (M+H)⁺: m/z=442.2; found: 442.1; Peak #2 (Example 62), retention time 18.18 min: LCMS calculated for C₂₁H₂₅ClN₇O₂ (M+H)⁺: m/z=442.2; found: 442.1; Peak #3 (Example 63), retention time 26.86 min: LCMS calculated for C₂₁H₂₅ClN₇O₂ (M+H)⁺: m/z=442.2; found: 442.1; Peak #4 (Example 64), retention time 29.28 min: LCMS calculated for C₂₁H₂₅ClN₇O₂ (M+H)⁺: m/z=442.2; found: 442.1.

Examples 65 and 66. 9-[1-(4-Amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-4-(2-hydroxy-2-methylpropyl)-2-methyl-2,3,4,5-tetrahydro-1,4-benzoxazepine-6-carbonitrile

Oxirane, 2,2-dimethyl-(5.5 μL, 0.066 mmol) was added to a mixture of 9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-2-methyl-2,3,4,5-tetrahydro-1,4-benzoxazepine-6-carbonitrile bishydrochloride (16 mg, 0.039 mmol) and triethylamine (10 μL, 0.09 mmol) in N,N-dimethylformamide (2 mL). The reaction was heated at 80° C. for 3 hrs and was allowed to cool to room temperature. The reaction was purified without workup by prep HPLC on C-18 column eluting water:acetonitrile gradient buffered pH 10 to give two diastereomers: Peak #1 (Example 65): LCMS calculated for C₂₃H₂₉ClN₇O₂(M+H)⁺: m/z=470.2; found: 470.2; Peak #2 (Example 66): LCMS calculated for C₂₃H₂₉ClN₇O₂(M+H)⁺: m/z=470.2; found: 470.2.

Examples 67 and 68. N-{3-[9-[1-(4-Amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-6-cyano-2-methyl-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]cyclobutyl}acetamide

Step 1: tert-Butyl {3-[9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-6-cyano-2-methyl-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]cyclobutyl}carbamate

9-[1-(4-Amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-2-methyl-2,3,4,5-tetrahydro-1,4-benzoxazepine-6-carbonitrile bishydrochloride (20 mg, 0.05 mmol) from Example 59, step 1, was dissolved in methanol (1.1 mL), and the tert-butyl (3-oxocyclobutyl)carbamate (0.019 g, 0.10 mmol) was added, followed by the sodium cyanoborohydride (0.0063 g, 0.10 mmol). The reaction was heated to 60° C. for 2 h, allowed to cool, diluted with water, and extracted with ethyl acetate. The combined organic layer was washed with brine, dried over magnesium sulfate, filtered, and concentrated to give tert-butyl {3-[9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-6-cyano-2-methyl-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]cyclobutyl}carbamate. LCMS calculated for C₂₈H₃₆ClN₈O₃(M+H)⁺: m/z=567.2; found: 567.3.

Step 2. 4-(3-Aminocyclobutyl)-9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-2-methyl-2,3,4,5-tetrahydro-1,4-benzoxazepine-6-carbonitrile Tris Hydrochloride

Tert-butyl {(3-[9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-6-cyano-2-methyl-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]cyclobutyl}carbamate was taken up in 4.0 M hydrogen chloride in dioxane (1 mL, 4 mmol) and was stirred for 1 h. The reaction was concentrated in vacuo to give crude 4-(3-aminocyclobutyl)-9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-2-methyl-2,3,4,5-tetrahydro-1,4-benzoxazepine-6-carbonitrile trishydrochloride as a solid. LCMS calculated for C₂₃H₂₈ClN₈O (M+H)⁺: m/z=467.2; found: 467.2.

Step 3. N-{3-[9-[1-(4-Amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-6-cyano-2-methyl-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]cyclobutyl}acetamide

The crude 4-(3-aminocyclobutyl)-9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-2-methyl-2,3,4,5-tetrahydro-1,4-benzoxazepine-6-carbonitrile trishydrochloride was dissolved in N,N-dimethylformamide (2 mL) and triethylamine (10 μL, 0.1 mmol). To this mixture was added acetic anhydride (7.7 mg, 0.075 mmol). The reaction was stirred for 1 h at room temperature, and the reaction was purified without workup by prep HPLC on C-18 column eluting water:acetonitrile gradient buffered pH 10 to give two diastereomers: Peak #1 (Example 67): LCMS calculated for C₂₅H₃₀ClN₈O₂ (M+H)⁺: m/z=509.2; found: 509.2; Peak #2 (Example 68): LCMS calculated for C₂₅H₃₀ClN₈O₂ (M+H)⁺: m/z=509.2; found: 509.2.

Examples 69 and 70. 9-[1-(4-Amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-2-ethyl-4-(2-hydroxyethyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-6-carbonitrile

Step 1. tert-Butyl (2-hydroxybutyl)carbamate

Di-tert-butyldicarbonate (3.7 g, 17 mmol) was added to a solution of 1-amino-2-butanol (1 g, 10 mmol) and N,N-diisopropylethylamine (3 g, 20 mmol) in methylene chloride (20 mL). The reaction was stirred for 3 h at room temperature and was partitioned between methylene chloride and water. The combined organic layer was washed with 1 N HCl, brine, dried over MgSO₄, filtered and concentrated to give crude tert-butyl (2-hydroxybutyl)carbamate (2.0 g, 90%).

Step 2., 9-[1-(4-Amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-2-ethyl-4-(2-hydroxyethyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-6-carbonitrile

Using methods analogous to Example 61, but using tert-butyl (2-hydroxybutyl)carbamate, the title compound was prepared as a mixture of diastereomers. The reaction was purified by prep HPLC on C-18 column eluting water:acetonitrile gradient buffered pH 10 to give two diastereomers. Peak #1 (Example 69): LCMS calculated for C₂₂H₂₇ClN₇O₂(M+H)⁺: m/z=456.2; Found: 456.2; Peak #2 (Example 70): LCMS calculated for C₂₂H₂₇ClN₇O₂(M+H)⁺: m/z=456.2; Found: 456.2.

Examples 71 and 72. 4-(1-Acetylazetidin-3-yl)-9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-6-fluoro-2-methyl-4,5-dihydro-1,4-benzoxazepin-3(2H)-one

Step 1. Ethyl 2-(6-acetyl-4-chloro-3-fluoro-2-iodophenoxy)propanoate

A solution of 1-(5-chloro-4-fluoro-2-hydroxy-3-iodophenyl)ethanone (5.00 g, 15.9 mmol) in N,N-dimethylformamide (80.0 mL) was treated with potassium carbonate (4.39 g, 31.8 mmol), followed by ethyl 2-bromopropanoate (2.48 mL, 19.1 mmol), and then stirred at 60° C. for 3 h. The reaction was stirred overnight at 60° C., and then worked up per the procedure below. The reaction was then re-submitted to the reaction conditions and stirred at 90° C. for 4 h. The reaction mixture was diluted with water and ethyl acetate. The organic layer was separated and washed with brine, dried over magnesium sulfate, filtered, and concentrated to give a crude residue. Purification by flash column chromatography (100% hexanes to 10% EtOAc/hexanes) gave the desired product (3.66 g, 56%) as a mixture of enantiomers. LCMS calculated for C₁₃H₁₄ClFIO₄ (M+H)⁺: m/z=415.0; found: 414.9.

Step 2. Ethyl 2-[4-chloro-3-fluoro-2-iodo-6-(2-methyl-1,3-dioxolan-2-yl)phenoxy]propanoate

A solution of ethyl 2-(6-acetyl-4-chloro-3-fluoro-2-iodophenoxy)propanoate (3.58 g, 8.63 mmol) and 1,2-ethanediol (1.20 mL, 21.6 mmol) in toluene (16.3 mL) was treated with p-toluenesulfonic acid monohydrate (246 mg, 1.30 mmol) and heated at reflux in a flask fitted with a Dean-Stark trap filled with sieves. The reaction mixture was cooled and poured into saturated sodium bicarbonate (150 mL) and extracted with ethyl acetate (2×200 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated to give a crude residue. Purification by flash column chromatography (100% hexanes to 10% EtOAc/hexanes) gave the desired product (2.25 g, 57%) as a mixture of enantiomers. LCMS calculated for C₁₅H₁₈ClFIO₅ (M+H)⁺: m/z=459.0; found: 459.0.

Step 3. Ethyl 2-[4-chloro-3-fluoro-6-(2-methyl-1,3-dioxolan-2-yl)-2-vinylphenoxy]propanoate

A mixture of ethyl 2-[4-chloro-3-fluoro-2-iodo-6-(2-methyl-1,3-dioxolan-2-yl)phenoxy]propanoate (1.83 g, 3.99 mmol), 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane (0.880 mL, 5.19 mmol), and potassium carbonate (1.65 g, 12.0 mmol) in 1,4-dioxane (15.6 mL) and water (7.8 mL) was degassed with nitrogen for 10 min. The reaction mixture was treated with [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (1:1) (163 mg, 0.199 mmol), degassed with nitrogen for another 10 min, and heated at 80° C. for 2 h. The reaction mixture was filtered through Celite and washed with ethyl acetate. The filtrate was poured into water. The aqueous layer was separated and re-extracted with ethyl acetate. The combined organic extracts were washed with brine, dried over sodium sulfate, filtered, and concentrated give a crude residue. Purification by flash column chromatography (100% hexanes to 15% EtOAc/hexanes) gave the desired product (2.25 g, 57%) as a mixture of enantiomers. LCMS calculated for C₁₇H₂₁ClFO₅ (M+H)⁺: m/z=359.1; found: 359.1.

Step 4. Ethyl 2-[4-chloro-3-fluoro-2-formyl-6-(2-methyl-1,3-dioxolan-2-yl)phenoxy]propanoate

A solution of ethyl 2-[4-chloro-3-fluoro-6-(2-methyl-1,3-dioxolan-2-yl)-2-vinylphenoxy]propanoate (400 mg, 1.11 mmol) in methylene chloride (40 mL) at −78° C. was treated with ozone until a purple color persisted. The reaction mixture was purged with oxygen, treated with dimethyl sulfide (1 mL) and warmed to room temperature. The reaction mixture was concentrated to give the crude product (392 mg, 98%) as a mixture of enantiomers that was used without further purification. LCMS calculated for C₁₆H₁₉ClFO₆ (M+H)⁺: m/z=361.1; found: 361.1.

Step 5. 1-Acetylazetidin-3-amine Hydrochloride

A solution of tert-butyl azetidin-3-ylcarbamate (1.00 g, 5.81 mmol) [Ark Pharma, AK26432] in tetrahydrofuran (50 mL) was treated with triethylamine (1.6 mL, 11.6 mmol) followed by N,N-dimethylformamide (15 mL) and cooled to 0° C. The reaction mixture was treated with acetyl chloride (495 μL, 6.97 mmol) and stirred overnight at room temperature. The reaction mixture was diluted with ether and washed with water and brine, dried over magnesium sulfate, filtered, and concentrated give a crude residue that was used immediately without purification. The intermediate azetidine was diluted with methylene chloride (30 mL), treated with 4.0 M hydrogen chloride in dioxane (22.0 mL, 88.0 mmol), and stirred at rt for 30 min. The reaction mixture was diluted with ether and the precipitated solid was collected by filtration in order to give the desired product (550 mg, 63%) as a HCl salt. LCMS calculated for C₅H₁₁N₂O (M+H)⁺: m/z=115.1; found: 115.2.

Step 6. 4-(1-Acetylazetidin-3-yl)-7-chloro-6-fluoro-2-methyl-9-(2-methyl-1,3-dioxolan-2-yl)-4,5-dihydro-1,4-benzoxazepin-3(2H)-one

A solution of ethyl 2-[4-chloro-3-fluoro-2-formyl-6-(2-methyl-1,3-dioxolan-2-yl)phenoxy]propanoate (392 mg, 1.09 mmol) in methanol (21 mL) was treated with sodium cyanoborohydride (171 mg, 2.72 mmol) followed by 1-acetylazetidin-3-amine hydrochloride (360 mg, 2.39 mmol) and stirred at room temperature overnight. The reaction mixture was quenched with acetic acid (200 μL) and concentrated in vacuo. The residue was diluted with toluene (60 mL) and heated at 110° C. for 2 h. The solvent was concentrated in vacuo, and the residue was purified via preparative LCMS (XBridge C18 column, eluting with a gradient of acetonitrile/water containing 0.1% ammonium hydroxide, at flow rate of 60 mL/min) to give the desired product (142 mg, 32%) as a mixture of enantiomers. LCMS calculated for C₁₉H₂₃ClFN₂O₅(M+H)⁺: m/z=413.1; found: 413.1.

Step 7. 9-Acetyl-4-(1-acetylazetidin-3-yl)-7-chloro-6-fluoro-2-methyl-4,5-dihydro-1,4-benzoxazepin-3 (2H)-one

A solution of 4-(1-acetylazetidin-3-yl)-7-chloro-6-fluoro-2-methyl-9-(2-methyl-1,3-dioxolan-2-yl)-4,5-dihydro-1,4-benzoxazepin-3(2H)-one (190 mg, 0.460 mmol) in methanol (20 mL) and was treated with 6.0 M hydrogen chloride in water (1.15 mL, 6.90 mmol) and stirred at room temperature for 3 h. The reaction mixture was diluted with ethyl acetate and water. The organic layer was separated, washed with brine, dried over sodium sulfate, filtered, and concentrated to give the desired product (132 mg, 78%) as a mixture of enantiomers that was used without further purification. LCMS calculated for C₁₇H₁₉ClFN₂O₄(M+H)⁺: m/z=369.1; found: 369.1.

Step 8. 4-(1-Acetylazetidin-3-yl)-7-chloro-6-fluoro-9-(1-hydroxyethyl)-2-methyl-4,5-dihydro-1,4-benzoxazepin-3(2H)-one

A solution of 9-acetyl-4-(1-acetylazetidin-3-yl)-7-chloro-6-fluoro-2-methyl-4,5-dihydro-1,4-benzoxazepin-3(2H)-one (112 mg, 0.304 mmol) in methanol (5.6 mL) at −10° C. was treated with sodium tetrahydroborate (17 mg, 0.456 mmol) and stirred for 30 min at 0° C. The reaction mixture was quenched with acetic acid (86 μL, 1.52 mmol) at 0° C. and then diluted with ethyl acetate and water. The organic layer was separated, washed with brine, dried over sodium sulfate, filtered, and concentrated to give a crude residue. Purification via preparative LCMS (XBridge C18 column, eluting with a gradient of acetonitrile/water containing 0.1% ammonium hydroxide, at flow rate of 60 mL/min) gave two fractions. Each fraction contained a pair of enantiomers: peak 1 (30 mg, 27%) and peak 2 (50 mg, 44%). Peak 1: LCMS calculated for C₁₇H₂₁ClFN₂O₄(M+H)⁺: m/z=371.1; found: 371.1. Peak 2: LCMS calculated for C₁₇H₂₁ClFN₂O₄ (M+H)⁺: m/z=371.1; found: 371.1.

Step 9. 4-(1-Acetylazetidin-3-yl)-9-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-7-chloro-6-fluoro-2-methyl-4,5-dihydro-1,4-benzoxazepin-3(2H)-one

The two fractions from step 8 were processed individually and identically. A suspension of 4-(1-acetylazetidin-3-yl)-7-chloro-6-fluoro-9-(1-hydroxyethyl)-2-methyl-4,5-dihydro-1,4-benzoxazepin-3(2H)-one (49.0 mg, 0.132 mmol) (step 8, peak 2) and N,N-dimethylformamide (1.0 μL, 0.013 mmol) in methylene chloride (1.1 mL) was treated with thionyl chloride (24 μL, 0.330 mmol) and stirred for 2 h. The reaction mixture was added to ice cooled saturated sodium bicarbonate and diluted with dichloromethane. The organic layer was separated, washed with brine, dried over sodium sulfate, filtered, and concentrated to give the intermediate chloride that was used immediately. A solution of the chloro intermediate in N,N-dimethylformamide (2.0 mL) and was treated with 3-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (30 mg, 0.198 mmol) and cesium carbonate (86.1 mg, 0.264 mmol) and heated in a sealed tube at 80° C. for 2 h. The reaction mixture was purified via preparative LCMS (XBridge C18 column, eluting with a gradient of acetonitrile/water containing 0.1% ammonium hydroxide, at flow rate of 60 mL/min) to give the desired product (19 mg, 29%) as a mixture of enantiomers. Product produced starting from the product of step 8, peak 1 (Example 71): LCMS calculated for C₂₃H₂₆ClFN₇O₃(M+H)⁺: m/z=502.2; found: 502.1; ¹H NMR (400 MHz, DMSO-d₆) δ 8.20 (s, 0.4H), 8.16 (s, 0.6H), 7.74 (br s, 2H), 7.43 (d, J=8.2 Hz, 0.4H), 7.20 (d, J=8.3 Hz, 0.6H), 6.31-6.01 (m, 1H), 5.67-5.55 (m, 0.6H), 5.38-5.25 (m, 0.4H), 5.22-5.04 (m, 2H), 4.65-4.48 (m, 1H), 4.38-4.26 (m, 0.6H), 4.22-4.13 (m, 0.4H), 4.12-3.97 (m, 1H), 3.94-3.79 (m, 1H), 3.74-3.21 (m, 1H), 2.56 (s, 1.8H), 2.53 (s, 1.2H), 1.81-1.62 (m, 6H), 1.40 (d, J=6.2 Hz, 1.8H), 1.23-1.13 (m, 1.2H); Product produced starting from the product of step 8, peak 2 (Example 72): LCMS calculated for C₂₃H₂₆ClFN₇O₃(M+H)⁺: m/z=502.2; found: 502.1; ¹H NMR (300 MHz, DMSO-d₆) δ 8.15 (s, 0.9H), 8.12 (s, 0.1H), 7.47 (br s, 2H), 7.41 (d, J=8.5 Hz, 0.9H), 7.17 (d, J=8.5 Hz, 0.1H), 6.25-6.06 (m, 1H), 5.71-5.52 (m, 0.1H), 5.39-5.23 (m, 0.9H), 5.22-5.01 (m, 2H), 4.66-4.47 (m, 1H), 4.41-4.25 (m, 0.9H), 4.23-4.12 (m, 0.1H), 4.11-3.96 (m, 1H), 3.94-3.77 (m, 1H), 3.67-3.54 (m, 1H), 2.55 (s, 0.3H), 2.52 (s, 2.7H), 1.82-1.61 (m, 6H), 1.40 (d, J=6.2 Hz, 0.3H), 1.27-1.16 (m, 2.7H).

Compounds Synthesized

Experimental procedures for compounds below are summarized in Table 1 below. Mass spectrometry data and ¹H NMR data for the compounds are summarized in Table 2.

TABLE 1

Ex. No. Name R^(x) R^(w) R^(3b) R⁴ R⁵ Proc.^(a) 73 3-[9-[1-(4-amino-3-methyl- 1H-pyrazolo[3,4- d]pyrimidin-1-yl)ethyl]-7- chloro-6-fluoro-2,3- dihydro-1,4-benzoxazepin- 4(5H)-yl]-N,N- dimethylazetidine-1- carboxamide H H

F Cl 34 74 3-[9-[1-(4-amino-3-methyl- 1H-pyrazolo[3,4- d]pyrimidin-1-yl)ethyl]-7- chloro-6-fluoro-2,3- dihydro-1,4-benzoxazepin- 4(5H)-yl]-N,N- dimethylazetidine-1- sulfonamide H H

F Cl 34 75 1-(1-{7-chloro-6-fluoro-2- methyl-4-[1- (methylsulfonyl)azetidin-3- yl]-2,3,4,5-tetrahydro-1,4- benzoxazepin-9-yl}ethyl)- 3-methyl-1H-pyrazolo[3,4- d]pyrimidin-4-amine Me H

F Cl 28 76 1-{1-[7-chloro-6-fluoro-2- methyl-4-(1- propionylazetidin-3-yl)- 2,3,4,5-tetrahydro-1,4- benzoxazepin-9-yl]ethyl}- 3-methyl-1H-pyrazolo[3,4- d]pyrimidin-4-amine Me H

F Cl 28 77, 78 (2R)-1-[9-[1-(4-amino-3- methyl-1H-pyrazolo[3,4- d]pyrimidin-1-yl)ethyl]-7- chloro-6-fluoro-2-methyl- 2,3-dihydro-1,4- benzoxazepin-4(5H)- yl]propan-2-ol Me H

F Cl 50 Peak 1 (Ex. 77) Peak 2 (Ex. 78) 79, 80 methyl 3-[9-[1-(4-amino-3- methyl-1H-pyrazolo[3,4- d]pyrimidin-1-yl)ethyl]-7- chloro-6-fluoro-2-methyl- 2,3-dihydro-1,4- benzoxazepin-4(5H)- yl]azetidine-1-carboxylate Me H

F Cl 28 Peak 1 (Ex. 79) Peak 2 (Ex. 80) 81, 82 3-[9-[1-(4-amino-3-methyl- 1H-pyrazolo[3,4- d]pyrimidin-1-yl)ethyl]-7- chloro-6-fluoro-2-methyl- 2,3-dihydro-1,4- benzoxazepin-4(5H)- yl]azetidine-1-sulfonamide Me

F Cl 28 Peak 1 (Ex. 81) Peak 2 (Ex. 82) 83, 84 3-[9-[1-(4-amino-3-methyl- 1H-pyrazolo[3,4- d]pyrimidin-1-yl)ethyl]-7- chloro-6-fluoro-2-methyl- 2,3-dihydro-1,4- benzoxazepin-4(5H)- yl]azetidine-1-carboxamide Me H

F Cl 28 Peak 1 (Ex. 83) Peak 2 (Ex. 84) 85 (2S)-1-{3-[(2S)-9-[(1S)-1- (4-amino-3-methyl-1H- pyrazolo[3,4-d]pyrimidin- 1-yl)ethyl]-7-chloro-6- fluoro-2-methyl-2,3- dihydro-1,4-benzoxazepin- 4(5H)-yl]azetidin-1- yl}propan-2-ol Me H

F Cl 50 86 (2R)-1-{3-[(2S)-9-[(1S)-1- (4-amino-3-methyl-1H- pyrazolo[3,4-d]pyrimidin- 1-yl)ethyl]-7-chloro-6- fluoro-2-methyl-2,3- dihydro-1,4-benzoxazepin- 4(5H)-yl]azetidin-1- yl}propan-2-ol Me H

F Cl 50 87, 88 2-{3-[(2S)-9-[1-(4-amino- 3-methyl-1H-pyrazolo[3,4- d]pyrimidin-1-yl)ethyl]-7- chloro-6-fluoro-2-methyl- 2,3-dihydro-1,4- benzoxazepin-4(5H)- yl]azetidin-1-yl}acetamide Me H

F Cl 28 Peak 1 (Ex. 87) Peak 2 (Ex. 88) 89 9-[1-(4-amino-3-methyl- 1H-pyrazolo[3,4- d]pyrimidin-1-yl)ethyl]-7- chloro-4-(1- propionylazetidin-3-yl)-2,3, 4,5-tetrahydro-1,4- benzoxazepine-6- carbonitrile H H

CN Cl 46 90 9-[1-(4-amino-3-methyl- 1H-pyrazolo[3,4- d]pyrimidin-1-yl)ethyl]-7- chloro-4-[1- (methylsulfonyl)azetidin-3- yl]-2,3,4,5-tetrahydro-1,4- benzoxazepine-6- carbonitrile H H

CN Cl 46 91 3-[9-[1-(4-amino-3-methyl- 1H-pyrazolo[3,4- d]pyrimidin-1-yl)ethyl]-7- chloro-6-cyano-2,3- dihydro-1,4-benzoxazepin- 4(5H)-yl]-N- isopropylazetidine-1- carboxamide H H

CN Cl 46 92 ethyl 3-[9-[1-(4-amino-3- methyl-1H-pyrazolo[3,4- d]pyrimidin-1-yl)ethyl]-7- chloro-6-cyano-2,3- dihydro-1,4-benzoxazepin- 4(5H)-yl]azetidine-1- carboxylate H H

CN Cl 46 93, 94 9-[1-(4-amino-3-methyl- 1H-pyrazolo[3,4- d]pyrimidin-1-yl)ethyl]-7- chloro-2-methyl-4-[1- (methylsulfonyl)azetidin-3- yl]-2,3,4,5-tetrahydro-1,4- benzoxazepine-6- carbonitrile Me H

CN Cl 48 Peak 1 (Ex. 93) Peak 2 (Ex. 94) 95, 96 9-[1-(4-amino-3-methyl- 1H-pyrazolo[3,4- d]pyrimidin-1-yl)ethyl]-7- chloro-2-methyl-4-(1- propionylazetidin-3-yl)-2,3, 4,5-tetrahydro-1,4- benzoxazepine-6- carbonitrile Me H

CN Cl 48 Peak 1 (Ex. 95) Peak 2 (Ex. 96) 97 ,98 3-[9-[1-(4-amino-3-methyl- 1H-pyrazolo[3,4- d]pyrimidin-1-yl)ethyl]-7- chloro-6-cyano-2-methyl-2, 3-dihydro-1,4- benzoxazepin-4(5H)-yl]-N- ethylazetidine-1- carboxamide Me H

CN Cl 48 Peak 1 (Ex. 97) Peak 2 (Ex. 98) 99, 100 ethyl 3-[9-[1-(4-amino-3- mcthyl-1H-pyrazolo[3,4- d]pyrimidin-1-yl)ethyl]-7- chloro-6-cyano-2-methyl-2, 3-dihvdro-1,4- benzoxazepin-4(5H)- yl]azetidine-1-carboxylate Me H

CN Cl 48 Peak 1 (Ex. 99) Peak 2 (Ex. 100) 101, 102 3-[9-[1-(4-amino-3-methyl- 1H-pyrazolo[3,4- d]pyrimidin-1-yl)ethyl]-7- chloro-6-cyano-2-methyl-2, 3-dihydro-1,4- benzoxazepin-4(5H)-yl]-N- isopropylazetidine-1- carboxamide Me H

CN Cl 48 Peak 1 (Ex. 101) Peak 2 (Ex. 102) 103, 104 9-[1-(4-amino-3-methyl- 1H-pyrazolo[3,4- d]pyrimidin-1-yl)ethyl]-7- chloro-4-[1-(2- hydroxyethyl)azetidin-3- yl]-2-methyl-2,3,4,5- tetrahydro-1,4- benzoxazepine-6- carbonitrile Me H

CN Cl 50 Peak 1 (Ex. 103) Peak 2 (Ex. 104) 105, 106 3-[9-[1-(4-amino-3-methyl- 1H-pyrazolo[3,4- d]pyrimidin-1-yl)ethyl]-7- chloro-6-cyano-2-methyl-2, 3-dihydro-1,4- benzoxazepin-4(5H)-yl]-N, N-dimethylazetidine-1- sulfonamide Me H

CN Cl 48 Peak 1 (Ex. 105) Peak 2 (Ex. 106) 107, 108 9-[1-(4-amino-3-methyl- 1H-pyrazolo[3,4- d]pyrimidin-1-yl)ethyl]-7- chloro-4-(cyanomethyl)-2- methyl-2,3,4,5-tetrahydro- 1,4-benzoxazepine-6- carbonitrile Me H

CN Cl 59 Peak 1 (Ex. 107) Peak 2 (Ex. 108) 109, 110 2-[9-[1-(4-amino-3-methyl- 1H-pyrazolo[3,4- d]pyrimidin-1-yl)ethyl]-7- chloro-6-cyano-2-methyl-2, 3-dihydro-1,4- benzoxazepin-4(5H)- yl]acetamide Me H

CN Cl 59 Peak 1 (Ex. 109) Peak 2 (Ex. 110) 111, 112 9-[1-(4-amino-3-methyl- 1H-pyrazolo[3,4- d]pyrimidin-1-yl)ethyl]-7- chloro-4-(2-methoxyethyl)- 2-methyl-2,3,4,5- tetrahydro-1,4- benzoxazepine-6- carbonitrile Me H

CN Cl 59 Peak 1 (Ex. 111) Peak 2 (Ex. 112) 113, 114, 115 3-[9-[1-(4-amino-3-methyl- 1H-pyrazolo[3,4- d]pyrimidin-1-yl)ethyl]-7- chloro-6-cyano-2-methyl- 2,3-dihydro-1,4- benzoxazepin-4(5H)-yl]-N- methylcyclobutane- carboxamide Me H

CN Cl 67 Peak 1 (Ex. 113) Peak 2 (Ex. 114) Peak 3 (Ex. 115) ^(a)Compound made by an analogous procedure to the indicated Example procedure. Peak information indicates the order in which the diasteromers eluted under the analogous column conditions.

TABLE 2 Ex. MS No. [M + H]⁺ ¹H NMR Spectra 73 503.1 ¹H NMR (300 MHz, DMSO-d₆): δ 8.14 (s, 1 H), 7.31 (m, 1 H), 6.22 (m, 1 H), 4.20 (m, 1 H), 3.87 (m, 3 H), 3.60 (m, 6 H), 2.80 (m, 2 H), 2.71 (s, 6 H), 2.54 (s, 3 H), 1.69 (m, 3 H) 74 539.2 ¹H NMR (300 MHz, DMSO-d₆): δ 8.12 (s, 1 H), 7.35 (m, 1 H), 6.22 (m, 1 H), 3.95 (m, 1 H), 3.77 (m, 2 H), 3.61 (m, 4 H), 2.80 (m, 2 H), 2.69 (s, 6 H), 2.55 (s, 3 H), 1.69 (m, 3 H) 75 524.1 ¹H NMR (300 MHz, CD₃OD): δ 8.12 (s, 1 H), 7.32 (m, 1 H), 6.38 (m, 1 H), 3.93 (m, 3 H), 3.80 (m, 3 H), 3.52 (m, 2 H), 2.91 (s, 3 H), 2.61 (s, 3 H), 1.79 (m, 3 H), 1.31 (m, 3 H) 76 502.2 ¹H NMR (300 MHz, CD₃OD): δ 8.14 (s, 1 H), 7.33 (m, 1 H), 6.39 (m, 1 H), 4.20 (m, 1 H), 3.99 (m, 3 H), 3.79 (m, 2 H), 3.60 (m, 1 H), 3.49 (m, 1 H), 2.12 (m, 2 H), 1.78 (m, 3 H), 1.31 (m, 3 H), 1.05 (m, 3 H) 77 449.2 78 449.2 79 504.1 80 504.1 ¹H NMR (300 MHz, DMSO-d₆): δ 8.11 (s, 1 H), 7.39 (m, 1 H), 6.28 (m, 1 H), 3.82 (m, 5 H), 3.65 (m, 3 H), 3.50 (s, 3 H), 2.85 (m, 1 H), 2.63 (m, 1 H), 2.55 (s, 3 H), 1.66 (m, 3 H), 1.29 (m, 3 H) 81 525.1 82 525.1 ¹H NMR (300 MHz, DMSO-d₆): δ 8.11 (s, 1 H), 7.40 (m, 1 H), 6.85 (s, 2 H), 6.28 (m, 1 H) 3.82 (m, 3 H) 3.69 (m, 2 H) 3.52 (m, 3 H) 2.80 (m, 1 H) 2.62 (m, 1 H), 2.55 (s, 3 H), 1.67 (m, 3 H), 1.28 (m, 3 H) 83 489.2 84 489.2 85 504.2 86 504.2 87 503.2 88 503.2 89 495.1 90 517.1^(b) 91 524.2 92 511.1 93 531.1 94 531.1 95 509.3 96 509.2 97 524.3 98 524.2 99 525.2 100 525.3 101 538.2 102 538.2 103 497.2 104 497.1 105 560.1 106 560.1 107 437.1 108 437.2 109 455.2 110 455.1 111 456.2 112 456.1 113 509.1 114 509.1 115 509.2 ^(b) [M + Na]

Example A1: P13K Enzyme Assay

PI3-Kinase luminescent assay kit including lipid kinase substrate, D-myo-phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2)D (+)-sn-1,2-di-O-octanoylglyceryl, 3-O-phospho linked (PIP2), biotinylated I(1,3,4,5)P4, PI(3,4,5)P3 Detector Protein is purchased from Echelon Biosciences (Salt Lake City, Utah). AlphaScreen™ GST Detection Kit including donor and acceptor beads is purchased from PerkinElmer Life Sciences (Waltham, Mass.). PI3Kδ (p110δ/p85α) is purchased from Millipore (Bedford, Mass.). ATP, MgCl₂, DTT, EDTA, HEPES and CHAPS are purchased from Sigma-Aldrich (St. Louis, Mo.).

AlphaScreen™ Assay for PI3Kδ

The kinase reaction are conducted in 384-well REMP plate from Thermo Fisher Scientific in a final volume of 40 μL. Inhibitors are first diluted serially in DMSO and added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay is 2%. The PI3K assays are carried out at room temperature in 50 mM HEPES, pH 7.4, 5 mM MgCl₂, 50 mM NaCl, 5 mM DTT and CHAPS 0.04%. Reactions are initiated by the addition of ATP, the final reaction mixture consisted of 20 μM PIP2, 20 μM ATP, 1.2 nM PI3Kδ are incubated for 20 minutes. 10 μL of reaction mixture are then transferred to 5 μL 50 nM biotinylated I(1,3,4,5)P4 in quench buffer: 50 mM HEPES pH 7.4, 150 mM NaCl, 10 mM EDTA, 5 mM DTT, 0.1% Tween-20, followed with the addition of 10 μL AlphaScreen™ donor and acceptor beads suspended in quench buffer containing 25 nM PI(3,4,5)P3 detector protein. The final concentration of both donor and acceptor beads is 20 mg/ml. After plate sealing, the plates are incubated in a dark location at room temperature for 2 hours. The activity of the product is determined on Fusion-alpha microplate reader (Perkin-Elmer). IC₅₀ determination is performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 3.0 software. Compounds with an IC₅₀ of less than 10 μM in in the assay of Example A1 are considered to be active.

Example A2: PI3K Enzyme Assay

Materials: Lipid kinase substrate, phosphoinositol-4,5-bisphosphate (PIP2), are purchased from Echelon Biosciences (Salt Lake City, Utah). PI3K isoforms α, β, δ and γ are purchased from Millipore (Bedford, Mass.). ATP, MgCl₂, DTT, EDTA, MOPS and CHAPS are purchased from Sigma-Aldrich (St. Louis, Mo.).

The kinase reaction are conducted in clear-bottom 96-well plate from Thermo Fisher Scientific in a final volume of 24 μL. Inhibitors are first diluted serially in DMSO and added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay is 0.5%. The PI3K assays are carried out at room temperature in 20 mM MOPS, pH 6.7, 10 mM MgCl₂, 5 mM DTT and CHAPS 0.03%. The reaction mixture is prepared containing 50 μM PIP2, kinase and varying concentration of inhibitors. Reactions are initiated by the addition of ATP containing 2.2 μCi [γ-³³P]ATP to a final concentration of 1000 μM. The final concentration of PI3K isoforms α, β, δ and γ in the assay were 1.3, 9.4, 2.9 and 10.8 nM, respectively. Reactions are incubated for 180 minutes and terminated by the addition of 100 μL of 1 M potassium phosphate pH 8.0, 30 mM EDTA quench buffer. A 100 μL aliquot of the reaction solution are then transferred to 96-well Millipore MultiScreen IP 0.45 m PVDF filter plate (The filter plate is prewetted with 200 μL 100% ethanol, distilled water, and 1 M potassium phosphate pH 8.0, respectively). The filter plate is aspirated on a Millipore Manifold under vacuum and washed with 18×200 μL wash buffer containing 1 M potassium phosphate pH 8.0 and 1 mM ATP. After drying by aspiration and blotting, the plate is air dried in an incubator at 37° C. overnight. Packard TopCount adapter (Millipore) is then attached to the plate followed with addition of 120 μL Microscint 20 scintillation cocktail (Perkin Elmer) in each well. After the plate sealing, the radioactivity of the product is determined by scintillation counting on Topcount (Perkin-Elmer). IC₅₀ determination is performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 3.0 software. Compounds with an IC₅₀ of less than 10 μM in in the assay of Example A2 are considered to be active.

Example A3: PI3Kδ Scintillation Proximity Assay Materials

[γ-³³P]ATP (10 mCi/mL) was purchased from Perkin-Elmer (Waltham, Mass.). Lipid kinase substrate, D-myo-Phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2)D (+)-sn-1,2-di-O-octanoylglyceryl, 3-O-phospho linked (PIP2), CAS 204858-53-7, was purchased from Echelon Biosciences (Salt Lake City, Utah). PI3Kδ (p110δ/p85α) was purchased from Millipore (Bedford, Mass.). ATP, MgCl₂, DTT, EDTA, MOPS and CHAPS were purchased from Sigma-Aldrich (St. Louis, Mo.). Wheat Germ Agglutinin (WGA) YSi SPA Scintillation Beads was purchased from GE healthcare life sciences (Piscataway, N.J.).

The kinase reaction was conducted in polystyrene 384-well matrix white plate from Thermo Fisher Scientific in a final volume of 25 μL. Inhibitors were first diluted serially in DMSO and added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 0.5%. The PI3K assays were carried out at room temperature in 20 mM MOPS, pH 6.7, 10 mM MgCl₂, 5 mM DTT and CHAPS 0.03%. Reactions were initiated by the addition of ATP, the final reaction mixture consisted of 20 μM PIP2, 20 μM ATP, 0.2 Ci [γ-³³P] ATP, 4 nM PI3Kδ. Reactions were incubated for 210 min and terminated by the addition of 40 μL SPA beads suspended in quench buffer: 150 mM potassium phosphate pH 8.0, 20% glycerol. 25 mM EDTA, 400 μM ATP. The final concentration of SPA beads was 1.0 mg/mL. After the plate sealing, plates were shaken overnight at room temperature and centrifuged at 1800 rpm for 10 minutes, the radioactivity of the product was determined by scintillation counting on Topcount (Perkin-Elmer). IC₅₀ determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 3.0 software. Compounds with an IC₅₀ of less than 10 μM in in the assay of Example A3 are considered to be active. IC₅₀ data for Examples 1-25 is presented in Table 3 for PI3Kδ as determined by the assay of Example A2 or A3 as indicated

TABLE 3 Example # PI3Kδ IC₅₀ (nM)* Assay 1 ++ A3 2 + A3 3 + A3 4 + A3 5 + A3 6 + A3 7 + A3 8 + A3 9 + A3 10 + A3 11 + A3 12 + A3 13 + A3 14 + A3 15 + A3 16 + A3 17 + A3 18 + A3 19 + A3 20 + A3 21 + A3 22 + A3 23 + A3 24 + A3 25 + A3 26 + A2 27 + A2 28 + A2 29 + A2 30 + A2 31 +++++ A2 32 + A2 33 ++ A2 34 + A2 35 + A2 36 +++ A2 37 + A2 38 +++++ A2 39 +++++ A2 40 + A2 41 + A2 42 + A2 43 + A2 44 + A2 45 + A2 46 + A2 47 + A2 48 ++ A2 49 + A2 50 + A2 51 + A2 52 + A2 53 + A2 54 + A2 55 + A2 56 + A2 57 + A2 58 + A2 59 + A2 60 + A2 61 +++++ A2 62 + A2 63 + A2 64 ++ A2 65 + A2 66 + A2 67 + A2 68 + A2 69 + A2 70 + A2 72 ++ A2 73 + A2 74 + A2 75 + A2 76 + A2 77 + A2 78 + A2 79 + A2 80 + A2 81 + A2 82 + A2 83 + A2 84 + A2 85 + A2 86 + A2 87 ++ A2 88 + A2 89 + A2 90 + A2 91 + A2 92 + A2 93 + A2 94 + A2 95 + A2 96 + A2 97 + A2 98 + A2 99 + A2 100 + A2 101 + A2 102 + A2 103 + A2 104 + A2 105 + A2 106 + A2 107 + A2 108 + A2 109 + A2 110 + A2 111 + A2 112 + A2 113 + A2 114 + A2 115 + A2 *column symbols: + refers to ≤ 100 nM, ++ refers to >100 nM to 500 nM, +++ refers to >500 nM to 1000 nM, ++++ refers to >1000 nM to 10,000 nM, +++++ refers to >800 nM

Example B1: B Cell Proliferation Assay

To acquire B cells, human PBMC are isolated from the peripheral blood of normal, drug free donors by standard density gradient centrifugation on Ficoll-Hypague (GE Healthcare, Piscataway, N.J.) and incubated with anti-CD19 microbeads (Miltenyi Biotech, Auburn, Calif.). The B cells are then purified by positive immunosorting using an autoMacs (Miltenyi Biotech) according to the manufacture's instruction.

The purified B cells (2×10⁵/well/200 μL) are cultured in 96-well ultra-low binding plates (Corning, Corning, N.Y.) in RPMI1640, 10% FBS and goat F(ab′)2 anti-human IgM (10 μg/ml) (Invitrogen, Carlsbad, Calif.) in the presence of different amount of test compounds for three days. [³H]-thymidine (1 Ci/well) (PerkinElmer, Boston, Mass.) in PBS is then added to the B cell cultures for an additional 12 hours before the incorporated radioactivity is separated by filtration with water through GF/B filters (Packard Bioscience, Meriden, Conn.) and measured by liquid scintillation counting with a TopCount (Packard Bioscience). Compounds with an IC₅₀ of less than 10 μM in in the assay of Example B1 are considered to be active.

Example B2: Pfeiffer Cell Proliferation Assay

Pfeiffer cell line (diffuse large B cell lymphoma) are purchased from ATCC (Manassas, Va.) and maintained in the culture medium recommended (RPMI and 10% FBS). To measure the anti-proliferation activity of the compounds, the Pfeiffer cells are plated with the culture medium (2×10³ cells/well/per 200 μl) into 96-well ultra-low binding plates (Corning, Corning, N.Y.), in the presence or absence of a concentration range of test compounds. After 3-4 days, [³H]-thymidine (1 μCi/well) (PerkinElmer, Boston, Mass.) in PBS is then added to the cell culture for an additional 12 hours before the incorporated radioactivity is separated by filtration with water through GF/B filters (Packard Bioscience, Meridenj, Conn.) and measured by liquid scintillation counting with a TopCount (Packard Bioscience). Compounds with an IC₅₀ of less than 10 μM in in the assay of Example B2 are considered to be active.

Example B3: SUDHL-6 Cell Proliferation Assay

SUDHL-6 cell line (diffuse large B cell lymphoma) was purchased from ATCC (Manassas, Va.) and maintained in the culture medium recommended (RPMI and 10% FBS). To measure the anti-proliferation activity of the compounds through ATP quantitation, the SUDHL-6 cells was plated with the culture medium (5000 cells/well/per 200 μl) into 96-well polystyrene clear black tissue culture plate (Greiner-bio-one through VWR, NJ) in the presence or absence of a concentration range of test compounds. After 3 days, Cell Titer-GLO Luminescent (Promega, Madison, Wis.) cell culture agent was added to each well for 10 minutes at room temperature to stabilize the luminescent signal. This determines the number of viable cells in culture based on quantitation of the ATP present, which signals the presence of metabolically active cells. Luminescence was measured with the TopCount 384 (Packard Bioscience through Perkin Elmer, Boston, Mass.). Compounds with an IC₅₀ of less than 10 μM in in the assay of Example B3 are considered to be active. IC₅₀ data for the Examples is presented in Table 4 determined by the assay of Example B3.

TABLE 4 Example # SUDHL IC₅₀ (nM)* 3 + 4 + 5 + 6 + 10 + 12 + 13 + 18 ++ 20 + 21 + 23 + 24 ++ 26 + 27 + 28 + 29 + 30 + 32 + 34 + 35 + 37 + 40 + 41 + 42 + 44 + 45 + 46 + 47 + 48 ++ 49 + 50 + 51 + 53 + 54 + 55 + 56 + 57 + 58 + 60 + 62 + 63 + 65 + 66 + 67 + 68 + 69 + 70 + 71 ++ 73 + 74 ++ 75 + 76 + 78 + 80 + 82 + 83 + 84 + 85 + 86 + 88 + 89 + 90 + 91 + 92 + 93 + 94 + 95 + 96 + 97 + 98 + 99 + 100 + 101 + 102 + 104 + 105 + 106 + 108 + 110 + 112 + 114 + 115 + *column symbols: + refers to ≤500 nM, ++ refers to >500 nM to 1000 nM, +++ refers to >1000 nM to 2000 nM, ++++ refers to >2000 nM to 10,000 nM

Example C: Akt Phosphorylation Assay

Ramos cells (B lymphocyte from Burkitts lymphoma) are obtained from ATCC (Manassas, Va.) and maintained in RPMI1640 and 10% FBS. The cells (3×10⁷ cells/tube/3 mL in RPMI) are incubated with different amounts of test compounds for 2 hrs at 37° C. and then stimulated with goat F(ab′)₂ anti-human IgM (5 μg/mL) (Invitrogen) for 17 minutes in a 37° C. water bath. The stimulated cells are spun down at 4° C. with centrifugation and whole cell extracts are prepared using 300 μL lysis buffer (Cell Signaling Technology, Danvers, Mass.). The resulting lysates are sonicated and supernatants are collected. The phosphorylation level of Akt in the supernatants are analyzed by using PathScan phospho-Akt1 (Ser473) sandwich ELISA kits (Cell Signaling Technology) according to the manufacturer's instruction.

Various modifications of the invention, in addition to those described herein, will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims. Each reference, including all patent, patent applications, and publications, cited in the present application is incorporated herein by reference in its entirety. 

1-39. (canceled)
 40. A compound of Formula XXIII:

or a pharmaceutically acceptable salt thereof, wherein: R¹ is methyl; R⁴ is methyl, F or CN; R⁵ is Cl; R⁶ is H; R^(3b) is H, Cy, —(C₁₋₃ alkylene)-Cy, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C(═O)R^(b), C(═O)NR^(c)R^(d), C(═O)OR^(a), or S(═O)₂R^(b), wherein said C₁₋₆ alkyl is optionally substituted by 1, 2, 3, or 4 independently selected R^(13b) groups; each R^(a), R^(b), R^(c), and R^(d) is independently selected from C₁₋₆ alkyl and Cy; wherein said C₁₋₆ alkyl is optionally substituted with 1, 2, or 3 independently selected R^(13b) groups; each Cy is independently selected from monocyclic C₃₋₇ cycloalkyl, monocyclic 4-7 membered heterocycloalkyl, phenyl, and monocyclic 5-6 membered heteroaryl, wherein said monocyclic C₃₋₇ cycloalkyl, monocyclic 4-7 membered heterocycloalkyl, phenyl, and monocyclic 5-6 membered heteroaryl are optionally substituted with 1, 2, 3, or 4 independently selected R^(13b) groups; each R^(13b) is independently selected from CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl, OR^(a1), C(═O)R^(b1), C(═O)NR^(c1)R^(d1), C(═O)OR^(a1), NR^(c1)C(═O)R^(b1), S(═O)₂R^(b1), and S(═O)₂NR^(c1)R^(d1), wherein said C₁₋₆ alkyl is optionally substituted with 1 or 2 independently selected R¹¹ groups; each R¹¹ is independently selected from OH and carbamyl; each R^(a1), R^(c1), and R^(d1) is independently selected from H, C₁₋₆ alkyl, and C₁₋₆ haloalkyl; and each R^(b1) is independently selected from C₁₋₆ alkyl and C₁₋₆ haloalkyl. 41-42. (canceled)
 43. The compound of claim 40, which is: 1-{1-[8-Chloro-7-fluoro-5-(methylsulfonyl)-3,4,5,6-tetrahydro-2H-1,5-benzoxazocin-10-yl]ethyl}-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine; or a pharmaceutically acceptable salt thereof.
 44. A pharmaceutical composition comprising a compound of claim 40, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier. 45-58. (canceled)
 59. The compound of claim 40, or a pharmaceutically acceptable salt thereof, wherein R⁴ is methyl.
 60. The compound of claim 40, or a pharmaceutically acceptable salt thereof, wherein R^(3b) is S(═O)₂R^(b).
 61. The compound of claim 40, or a pharmaceutically acceptable salt thereof, wherein R^(b) is C₁₋₆ alkyl.
 62. The compound of claim 40, or a pharmaceutically acceptable salt thereof, wherein R^(3b) is S(═O)₂R^(b) and R^(b) is C₁₋₆ alkyl.
 63. The compound of claim 40, or a pharmaceutically acceptable salt thereof, wherein R^(3b) is S(═O)₂CH₃.
 64. The compound of claim 40, or a pharmaceutically acceptable salt thereof, wherein: R⁴ is methyl; R^(3b) is S(═O)₂R^(b); and R^(b) is C₁₋₆ alkyl.
 65. A method of treating B cell lymphoma in a patient, comprising administering to said patient a therapeutically effective amount of a compound of claim 40, or a pharmaceutically acceptable salt thereof.
 66. A method of treating diffuse large B cell lymphoma in a patient, comprising administering to said patient a therapeutically effective amount of a compound of claim 40, or a pharmaceutically acceptable salt thereof.
 67. A method of treating chronic lymphocytic leukemia in a patient, comprising administering to said patient a therapeutically effective amount of a compound of claim 40, or a pharmaceutically acceptable salt thereof.
 68. A method of treating follicular B-cell Non-Hodgkin lymphoma in a patient, comprising administering to said patient a therapeutically effective amount of a compound of claim 40, or a pharmaceutically acceptable salt thereof.
 69. A method of treating small lymphocytic lymphoma in a patient, comprising administering to said patient a therapeutically effective amount of a compound of claim 40, or a pharmaceutically acceptable salt thereof.
 70. A method of treating Non-Hodgkin lymphoma in a patient, comprising administering to said patient a therapeutically effective amount of a compound of claim 40, or a pharmaceutically acceptable salt thereof. 